30th Annual Meeting and Scientific Sessions
April 13 – 16, 2011

ISHLT Academy: Core Competencies in Lung Transplantation
April 12 – 13, 2011

Contents:

Directors • Committees • Reviewers 1
Award Recipients 18
Meeting Highlights • Gala • CME Information 24
Daily Schedule Foldouts between 18-35
Floorplan Diagrams 36
ISHLT Academy Program 38
Schedule at a Glance 44
Scientific Program 56
General Poster Session 143
Exhibitor Floorplan and List of Exhibitors 184
Independent Medical Education Activity 210

OFFICERS

John Dark, MB, FRCS, President,
Freeman Hospital, Newcastle, United Kingdom
Lori J. West, MD, DPhil, President-Elect,
University of Alberta, Edmonton, Canada
James K. Kirklin, MD, Past-President,
University of Alabama at Birmingham, AL, USA
Duane Davis, MD, Secretary-Treasurer,
Duke University Medical Center, Durham, NC, USA

DIRECTORS

Raymond L. Benza, MD,
Allegheny General Hospital, Pittsburgh, PA, USA
Susan M. Chernenko, RN, MN, NP,
Toronto General Hospital, Toronto, Canada
Maria G. Crespo-Leiro, MD,
Hospital Universitario A Coruna, La Coruna, Spain
James F. George, PhD,
University of Alabama at Birmingham, AL, USA
Allan R. Glanville, MD, FRACP,
St. Vincent’s Hospital, Sydney, Australia
Jayan Parameshwar, FRCP,
Papworth Hospital, Cambridge, United Kingdom
Patricia A. Uber, PharmD,
University of Alabama at Birmingham, AL, USA
J. David Vega, MD, Emory Clinic, Atlanta, GA, USA
Geert M. Verleden, MD, PhD,
University Hospital Gasthuisberg, Leuven, Belgium
Florian M. Wagner, MD,
University Heart Center Hamburg, Eppendorf, Germany
Andreas O. Zuckermann, MD, University of Vienna, Austria

EX OFFICIO BOARD MEMBERS

Mandeep R. Mehra, MBBS, FACC, FACP, Editor, Journal of Heart and Lung Transplantation, University of Maryland School of Medicine, Baltimore, MD, USA
Marshall I. Hertz, MD, Transplant Registry Medical Director, University of Minnesota, MN, USA
Richard N. Pierson, III, MD, 2011 Scientific Program Chair, University of Maryland-Baltimore, USA
Heather J. Ross, MD, MHSc, FRCP(C), Development Committee Chair, Toronto General Hospital, Canada
Amanda W. Rowe, ISHLT Executive Director

STAFF

Amanda W. Rowe, Executive Director
Phyllis Glenn, Director of Membership Services
Lisa A. Edwards, Director of Meetings
Lee Ann Mills, Director of Operations
Susie Newton, Administrative Assistant
2011 Annual Meeting
Scientific Program Committee

PROGRAM CHAIR: Richard N. Pierson, III, MD,
University of Maryland-Baltimore, MD, USA
PRESIDENT: John Dark, MB, FRCS,
Freeman Hospital, Newcastle Upon Tyne, United Kingdom
Annalisa Angelini, MD, University of Padua, Padova, Italy
Selim M. Arcasoy, MD, Columbia University, New York, NY, USA
Christian Benden, MD,
University Hospital Zurich, Zurich, Switzerland
Raymond L. Benza, MD,
Allegheny General Hospital, Pittsburgh, PA, USA
Marion Delcroix, MD, Marion Delcroix, Leuven, Belgium
Juan F. Delgado Jimenez, MD,
Hospital Doce de Octubre, Madrid, Spain
Daniel F. Dilling, MD,
Loyola University Medical Center, Maywood, IL, USA
James F. George, PhD,
University of Alabama at Birmingham, USA
Bronwyn J. Levvey, RN,
Grad Dip Clin Ep, Alfred Hospital, Melbourne, Australia
Mandeep R. Mehra, MBBS, FACC, FACP, University of Maryland School of Medicine, Baltimore, MD, USA
Francis D. Pagani, MD, PhD,
University of Michigan Health System, Ann Arbor, MI, USA
Michael G. Petty, PhD (c), RN, CCNS, CNS, University of Minnesota Medical Center, Minneapolis, MN, USA
Exgenij V. Potapov, MD, PhD,
German Heart Institute, Berlin, Germany
Hermann Reichenspurner, MD, PhD,
University Heart Centre Hamburg Eppendorf, Germany
Marlene Rose, PhD,
Harefield Hospital, Harefield, United Kingdom
Bruce R. Rosengard, MD, FRCS,
Massachusetts General Hospital, Boston, MA, USA
Heather J. Ross, MD, MHSc, FRCP(c),
Toronto General Hospital, Toronto, Canada
Fernanda P. Silveira, MD,
University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Lynne W. Stevenson, MD,
Brigham & Women’s Hospital, Boston, MA, USA
Stuart C. Sweet, MD, PhD,
St. Louis Children’s Hospital, St. Louis, MO, USA
Jeffrey J. Teuteberg, MD,
University of Pittsburgh/Presbyterian, Pittsburgh, PA, USA
Vincent G. Valentine, MD,
University of Texas Medical Branch, Galveston, TX, USA
Dirk Van Raemdonck, MD, PhD,
University Hospital Gasthuisberg, Leuven, Belgium
Lori J. West, MD, DPhil,
University of Alberta, Edmonton, Canada
Glen P. Westall, FRACP, PhD,
Alfred Hospital, Melbourne, Australia
ABSTRACT REVIEWERS

Lara Danziger-Isakov, MD, MPH, The Cleveland Clinic Foundation, Cleveland, OH, USA
Hiroshi Date, MD, Kyoto University, Kyoto, Japan
Sabina M. De Geest, RN, PhD, University of Basel, Basel, Switzerland
Roelof A. de Weger, PhD, University Medical Center Utrecht, Utrecht, The Netherlands
Mario C. Deng, MD, Columbia University Medical Center, New York, NY, USA
Tobias Deuse, MD, PhD, University Heart Center Hamburg, Hamburg, Germany
Gundeeep S. Dhillon, MD, Stanford University Medical Center, Stanford, CA, USA
Lieven J. Dupont, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium
Thomas M. Egan, MD, MSC, UNC, University of North Carolina School of Medicine, Chapel Hill, NC, USA
Stephan M. Ensminger, MD, PhD, University of Erlangen-Nurnberg, Erlangen, Germany
Michiel E. Erasmus, MD, PhD, University Medical Center Groningen, Groningen, The Netherlands
Melanie D. Everitt, MD, Primary Children’s Medical Center, Salt Lake City, UT, USA
Giuseppe Faggian, MD, University of Verona, Verona, Italy
James C. Fang, MD, Case Western University Hospital, Shaker Heights, OH, USA
Albert Faro, MD, St. Louis Children’s Hospital, Washington University School of Medicine, St. Louis, MO, USA
Erika D. Feller, MD, University of Maryland, Baltimore, MD, USA
Michael C. Fishbein, MD, UCLA School of Medicine, Los Angeles, CA, USA
Andrew J. Fisher, FRCP, PhD, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
Veronica Franco, MD, Ohio State University Medical Center, Columbus, OH, USA
Robert P. Frantz, MD, Mayo Clinic, Rochester, MN, USA
Michael M. Givertz, MD, Brigham & Women’s Hospital, Boston, MA, USA
Allan R. Glanville, MD, FRACP, St. Vincent’s Hospital, Sydney, Australia
Mardi Gomberg-Maitland, MD, MSc, University of Chicago, Chicago, IL, USA
Julian H. Gooi, MD, Alfred Hospital, Melbourne, Victoria, Australia
Cynthia J. Gries, MD, MSc, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Finn Gustafsson, MD, PhD, Rigshospitalet, Copenhagen, Denmark
Marc K. Halushka, MD, PhD, Johns Hopkins Hospital, Baltimore, MD, USA
Margaret M. Hannan, MD, Mater Hospital, Dublin, Ireland
Nicola E. Hiemann, MD, DHZB, Deutsches Herzcenter Berlin, Berlin, Germany

Peter M. Hopkins, FRACP, Prince Charles Hospital, Brisbane, Australia
Martin P. Iversen, MD, PhD, Rigshospitalet, Copenhagen, Denmark
Valluvan Jeevanandam, MD, University of Chicago Medical Center, Chicago, IL, USA
Beth D. Kaufman, MD, University of Pennsylvania, Philadelphia, PA, USA
Cassie C. Kennedy, MD, Mayo Clinic, Rochester, MN, USA
Shaf Keshavjee, MD, FRCS, Toronto General Hospital, Toronto, Ontario, Canada
Daniel H. Kim, MD, Mazankowski Alberta Heart Institute, Edmonton, Alberta, Canada
Richard Kirk, MA FRCP FRCPCH, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
James K. Kirklin, MD, University of Alabama at Birmingham, Birmingham, AL, USA
Michelle M. Kittleson, MD, PhD, Cedars Sinai Heart Institute, Beverly Hills, CA, USA
Walter Klepetko, MD, Medical University of Vienna, Vienna, Austria
Jon Kobashigawa, MD, Cedars-Sinai Heart Institute, Beverly Hills, CA, USA
Daniel Kreisel, MD, PhD, Washington University School of Medicine, St. Louis, MO, USA
Bernard M. Kubak, MD, PhD, UCLA Medical Center, Los Angeles, CA, USA
Michael A. Kuhn, MD, Loma Linda University, Loma Linda, CA, USA
Renee L. Lassinger, RN, MSN, ANP, Mid-State Cardiology, Brentwood, TN, USA
Lorriana E. Leard, MD, UCSF, University of California-San Francisco, San Francisco, CA, USA
David J. Lederer, MD, Columbia University, New York, NY, USA
Karl B. Lemstrom, MD, PhD, Helsinki University, Helsinki, Finland
Deborah J. Levine, MD, University of Texas Health Science Center, San Antonio, TX, USA
Matthias Loebe, MD, PhD, University of California-San Francisco, San Francisco, CA, USA
Guy A. MacGowan, MD, Freeman Hospital, Newcastle upon Tyne, United Kingdom
Jane MacIver, RN, MSc, Toronto General Hospital, Toronto, Ontario, Canada
Abeel A. Mangi, MD, Temple University Hospital, Philadelphia, PA, USA
Luigi Martinelli, MD, Ospedale Niguarda, Milano, Italy
David P. Mason, MD, Cleveland Clinic Foundation, Cleveland, OH, USA
Michael A. McDonald, MD, University of Toronto General Hospital, Toronto, Ontario, Canada
John F. McDyer, MD, Johns Hopkins, Baltimore, MD, USA
Christopher G. A. McGregor, MD, University College London, The Heart Hospital, London, United Kingdom
Javier Segovia, MD, PhD, Puerta de Hierro Hosp, Madrid, Spain  
Pali D. Shah, MD,  
Vanderbilt University Medical Center, Nashville, TN, USA  
Michael Shullo, PharmD,  
University of Pittsburgh, Pittsburgh, PA, USA  
Jacqueline M. Smits, MD, PhD, Eurotransplant International Foundation, Leiden, The Netherlands  
Gregory I. Snell, FRACP, MBB,  
Alfred Hospital, Melbourne, Australia  
Heike Spaderna, PhD,  
Johannes Gutenberg University, Mainz, Germany  
Randall C. Starling, MD, MPH,  
Cleveland Clinic, Cleveland, OH, USA  
Josef Stehlik, MD, MPH,  
University of Utah, Salt Lake City, UT, USA  
Martin Strueber, MD,  
Hannover Medical School, Hannover, Germany  
Jose A. Tallaj, MD,  
University of Alabama at Birmingham, Birmingham, AL, USA  
Daniel G. Tang, MD,  
Medical School of Virginia, Richmond, VA, USA  
Jeffrey A. Towbin, MD, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA  
Simon Urschel, MD,  
University of Alberta, Edmonton, Alberta, Canada  
Florian M. Wagner, MD, University Heart Center Hamburg  
Eppendorf, Hamburg, Germany  
Robert G. Weintraub, MB, BS, FRACP, FACC,  
Royal Children’s Hospital, Parkville, Victoria, Australia  
Lori J. West, MD, DPhil, University of Alberta, Alberta Diabetes Institute, Edmonton, Alberta, Canada  
Birgit Weynand, MD,  
Cliniques Universitaires St Luc, Brussels, Belgium  
Christopher H. Wigfield, MD, FRCS,  
Loyola University Medical Center, Maywood, IL, USA  
David S. Wilkes, MD,  
Indiana University School of Medicine, Indianapolis, IN, USA  
Gayle L. Winters, MD,  
Brigham & Women’s Hospital, Boston, MA, USA  
Jackson Y. Wong, MBBS, FRPCH, Stollery Children’s, University of Alberta, Edmonton, Alberta, Canada  
Samuel A. Yousem, MD,  
University of Pittsburgh Medical Center, Pittsburgh, PA, USA  
Andreas O. Zuckermann, MD,  
University of Vienna, Vienna, Austria
About ISHLT

The International Society for Heart and Lung Transplantation (ISHLT) is a not-for-profit, multidisciplinary, professional organization dedicated to improving the care of patients with advanced heart or lung disease through transplantation, mechanical support and innovative therapies via research, education and advocacy.

ISHLT was created in 1981 at a small gathering of about 15 cardiologists and cardiac surgeons. Today we have over 2700 members from over 45 countries, representing over 15 different professional disciplines involved in the management and treatment of end-stage heart and lung disease. This multinational, multidisciplinary mix is one of the biggest strengths of the Society. It brings greater breadth and depth to our educational offerings and provides an exceptional environment for networking and exchanging information on an informal basis.

Our members include anesthesiologists, basic scientists, cardiologists, cardiothoracic surgeons, ethicists, immunologists, nurses, pathologists, perfusionists, pharmacists, pulmonologists, tissue engineers, transplant coordinators, and infectious disease specialists. Despite their differing specializations, all ISHLT members share a common dedication to the advancement of the science and treatment of end-stage heart and lung disease.

The Purposes of the Society are:

To associate persons interested in the fields of heart and lung transplantation, end-stage heart and lung disease, and related sciences.

To encourage and stimulate basic and clinical research in these disciplines and to promote new therapeutic strategies.

To hold scientific meetings featuring presentations and discussions relevant to these disciplines.

To sponsor a scientific journal for the publication of manuscripts related to these disciplines.

To establish and maintain an international registry for heart and lung transplantation.

To award research grants and establish endowments for the study of these disciplines.
ISHLT COMMITTEES

Education Committee
Allen S. Anderson, MD, FACC,
Chair and Heart Failure Council Workforce Leader
Martha L. Mooney, MD,
Infectious Diseases Council Workforce Leader
Matthew Morrell, MD,
Junior Faculty & Trainee Council Workforce Leader
Robert C. Bogaev, MD, FACC,
Mechanical Circulatory Support Council Workforce Leader
Sharon A. Beer, RN, MSc, Nursing, Health Sciences & Allied Health Council Workforce Leader
E. Rene Rodriguez, MD, Pathology Council Workforce Leader
Daphne Hsu, MD,
Pediatric Transplantation Council Workforce Leader
Dana McPhothlin, MD,
Pulmonary Hypertension Council Workforce Leader
Christopher H. Wigfield, MD, FRCS,
Pulmonary Transplantation Council Workforce Leader
Beatriz Diaz Molina, MD, At Large Member
Keith McNeil, FRACP, At Large Member
Andreas O. Zuckermann, MD, At Large Member

Communications Committee
Maryl R. Johnson, MD, Chair
David P. Nelson, MD, Heart Failure Council Workforce Leader
Vincent G. Valentine, MD,
Infectious Diseases Council Workforce Leader
Pali D. Shah, MD,
Junior Faculty & Trainee Council Workforce Leader
Evgenij V. Potapov, MD,
Mechanical Circulatory Support Council Workforce Leader
Bronwyn J. Levvey, RN, Nursing, Health Sciences and Allied Health Council Workforce Leader
James B. Atkinson, MD, PhD,
Pathology Council Workforce Leader
Anne L. Dipchand, MD,
Pediatric Transplantation Council Workforce Leader
Deborah J. Levine, MD,
Pulmonary Hypertension Council Workforce Leader
Christine L. Lau, MD,
Pulmonary Transplantation Council Workforce Leader
Allen S. Anderson, MD,
FACC Education Committee Representative
David Weill, MD,
Standards & Guidelines Committee Representative
David S. Feldman, MD ISHLT Links Newsletter Editor
Mandeep R. Mehra, MD JHLT Editor
Cynthia S. Herrington, MD, At Large Member
Cedric D. Sheffield, MD, At Large Member
Cynthia J. Gries, MD, MSc, At Large Member

Grants And Awards Committee
Duane Davis, MD, Chair
Mark Barr, MD, Past Chair
Lori J. West, MD, DPhil, Reviewer
Carla C. Baan, PhD, Reviewer
Marshall I. Hertz, MD, Reviewer
Bernice L. Coleman, RN, PhD, Reviewer

JHLT Editorial Board
Mandeep R. Mehra, MBBS, FACC, FACP, Editor-in-Chief
Patricia A. Uber, PharmD, Executive Editor
Millie Bileck, Journal Office Coordinator
Cathy Winks, Journal Office Coordinator
Tanya Johnson, Journal Office Coordinator
Maria Rosa Costanzo, MD (Editor Emeritus 1995-1999), Consulting Editor
James K. Kirklin, MD (Editor Emeritus 2000-2009), Consulting Editor
Jonathan B. Orens, MD (USA), Editorial Office Consultant
Jayan Parameshwar, FRCP (UK), Editorial Office Consultant
Richard N. Pierson, III, MD (USA), Editorial Office Consultant
Claus B. Andersen, MD, D.M.Sc (Denmark), Editorial Board Consultant
Marcelo Cantarovich, MD (Canada), Editorial Board Consultant
Charles E. Canter, MD (USA), Editorial Board Consultant
Pablo F. Castro, MD, (Chile), Editorial Board Consultant
Richard E. Chinnock, MD (USA), Editorial Board Consultant
John V. Conte, MD (USA), Editorial Board Consultant
Paul A. Corris, MB FRCP (UK), Editorial Board Consultant
Duane Davis, MD (USA), Editorial Board Consultant
Fabienne Dobbels, MSc, PhD (Belgium), Editorial Board Consultant
Howard J. Eisen, MD (USA), Editorial Board Consultant
Roger W. Evans, PhD (USA), Editorial Board Consultant
Michael C. Fishbein, MD (USA), Editorial Board Consultant
Edward R. Garrity, Jr., MD (USA), Editorial Board Consultant
James F. George, PhD (USA), Editorial Board Consultant
Christine L. Lau, MD,
Pulmonary Transplantation Council Workforce Leader
Allen S. Anderson, MD,
FACC Education Committee Representative
David Weill, MD,
Standards & Guidelines Committee Representative
David S. Feldman, MD ISHLT Links Newsletter Editor
Mandeep R. Mehra, MD JHLT Editor
Cynthia S. Herrington, MD, At Large Member
Cedric D. Sheffield, MD, At Large Member
Cynthia J. Gries, MD, MSc, At Large Member
ISHLT COMMITTEES

Professional Standards and Guidelines Committee
Maria Rosa Costanzo, MD, Chair
Naveen Pereira, MD,
Heart Failure Council Workforce Leader
Lara Danziger-Isakov, MD, MPH,
Infectious Diseases Council Workforce Leader
Susan D. Moffatt-Bruce, MD, PhD,
Junior Faculty & Trainee Council Workforce Leader
Stephanie A. Moore, MD,
Mechanical Circulatory Support Council Workforce Leader
Michael G. Petty, PhD(c), RN, CCNS, CNS, Nursing, Health Sciences & Allied Health Council Workforce Leader
Carmela D. Tan, MD, Pathology Council Workforce Leader
Robert J. Boucek, Jr. MD,
Pediatric Transplantation Council Workforce Leader
Evelyn Horn, MD,
Pulmonary Hypertension Council Workforce Leader
David Weill, MD,
Pulmonary Transplantation Council Workforce Leader
Diego H. Delgado, MD, At Large Member
Maria G. Crespo-Leiro, MD, At Large Member
Daniela Pini, MD, At Large Member

Registries and Databases Committee
Marshall I. Hertz, MD, Chair
Josef Stehlik, MD, Heart Failure
Frauke Mattner, MD,
Infectious Diseases Council Workforce Leader
Jennifer C. Matthews, MD,
Junior Faculty & Trainee Council Workforce Leader
Jaap Lahpor, MD, PhD,
Mechanical Circulatory Support Council Workforce Leader
Fabienne Dobbels, PhD, Nursing, Health Sciences & Allied Health Council Workforce Leader
Robert F. Padera, MD, PhD,
Pathology Council Workforce Leader
Richard E. Chinnock, MD,
Pediatric Transplantation Council Workforce Leader
Mardi Gomberg-Maitland, MD, MSc,
Pulmonary Hypertension Council Workforce Leader
Fernando Torres, MD, PA,
Pulmonary Hypertension Council Workforce Leader
Shaf Keshavjee, MD,
Pulmonary Transplantation Council Workforce Leader
Roger D. Yusen, MD, MPH, Outcomes Specialist
Maria G. Crespo-Leiro, MD, Outcomes Specialist
Kathryn A. Philibin, RN, TII Liaison
Anna Kucheryavaya, Biostatistician

Thoracic Registry Steering Committee
Marshall I. Hertz, MD, Medical Director
Josef Stehlik, MD, MPH, Associate Medical Director, Heart
Jason D. Christie, MD,
Associate Medical Director, Lung/Heart-Lung
Richard Kirk, MA, FRCP, FRCPCH,
Associate Medical Director, Pediatric Heart
Paul Aurora, MRCP, PhD,
Associate Medical Director, Pediatric Lung/Heart-Lung
Christian Benden, MD,
Associate Medical Director, OEO Relations
Leah Edwards, PhD, Biostatistician
Jaime Williamson, SAS Analyst
Kathryn A. Philibin, RN, TII Liaison
Anna Kucheryavaya, Assistant Biostatistician

Scientific Council Operating Boards
MECHANICAL CIRCULATORY SUPPORT
Francis D. Pagani, MD, Chair
Emma Birks, MRCP, PhD, Past Chair
Stephanie A. Moore, MD,
Standards & Guidelines Workforce Leader
Roberta C. Bogaev, MD, FACC, Education Workforce Leader
Jaap Lahpor, MD, PhD,
Registries & Databases Workforce Leader
Evgenij V. Potapov, MD, Communications Workforce Leader
Mario C. Deng, MD, Development Liaison
HEART FAILURE AND TRANSPLANT MEDICINE
David A. Baran, MD, Chair
Lee R. Goldberg, MD, MPH, Vice Chair
Maria G. Crespo-Leiro, MD, Past Chair
Naveen Pereira, MD,
Standards & Guidelines Workforce Leader
Allen S. Anderson, MD, Education Workforce Leader
Josef Stehlik, MD, Registries & Databases Workforce Leader
David P. Nelson, MD, Communications Workforce Leader
Robert C. Bourge, MD, Development Liaison

INFECTIONIOUS DISEASES
Martha L. Mooney, MD, Chair
Frauke Mattner, MD, Vice Chair
Margaret M. Hannan, MD, Past Chair
Lara Danziger-Isakov, MD, MPH,
Standards & Guidelines Workforce Leader
Martha L. Mooney, MD, Education Workforce Leader
Frauke Mattner, MD, Registries & Databases Workforce Leader
Vincent G. Valentine, MD, Communications Workforce Leader
Eric A. M. Verschuuren, MD, PhD, Development Liaison

NURSING, HEALTH SCIENCES AND ALLIED HEALTH
Bernice L. Coleman, RN, PhD, Chair
Nancy P. Blumenthal, CRNP, Vice Chair
Connie White-Williams, MSN, Past Chair
Michael G. Petty, PhD(c), RN, CCNS, CNS,
Standards & Guidelines Workforce Leader
Sharon A. Beer, RN, MSn Education Workforce Leader
Fabienne Dobbels, PhD,
Registries & Databases Workforce Leader
Bronwyn J. Levvey, RN,
Grad Dip Clin Ep, Communications Workforce Leader
Judy A. Currey, PhD, Grants and Awards Workforce Leader
Kevin Carney, RN, CCTC, Development Liaison
Annette Devito Dabbs, RN, PhD,
Research Mentorship Workforce Leader

PATHOLOGY
Annalisa Angelini, MD, Chair
To Be Elected, Vice Chair
Stephan M. Ensminger, MD, PhD, Past Chair
Carmela D. Tan, MD, Standards & Guidelines Workforce Leader
E. Rene Rodriguez, MD, Education Workforce Leader
Robert F. Padera, MD, PhD,
Registries & Databases Workforce Leader
James B. Atkinson, MD, PhD,
Communications Workforce Leader

PEDIATRIC TRANSPLANTATION
Elfriede Pahl Schuette, MD, Chair
Beth Kaufman, MD, Vice Chair
Christian Benden, MD, Past Chair
Robert J. Boucek, Jr., MD,
Standards & Guidelines Workforce Leader
Daphne Hsu, MD, Education Workforce Leader
Richard E. Chinnoch, MD,
Registries & Databases Workforce Leader
Anne L. Dipchand, MD, Communications Workforce Leader

PULMONARY HYPERTENSION
Myung Park, MD, Chair
Robert P. Frantz, MD, Vice Chair
Raymond L. Benza, MD, Past Chair
Evelyn Horn, MD, Standards & Guidelines Workforce Leader
Dana P. McGlathlin, MD, Education Workforce Leader
Mardi Gomberg-Maitland, MD, MSc,
Registries & Databases Workforce Leader
Fernando Torres, MD, PA,
Registries & Databases Workforce Leader
Deborah J. Levine, MD, Communications Workforce Leader
Srinivas Murali, MD, Development Liaison

PULMONARY TRANSPLANTATION
Lianne G. Singer, MD, FRCP, Chair
David Weill, MD, Vice Chair
Michael Mulligan, MD, Vice Chair-Elect/Secretary
Geert M. Verleden, MD, PhD, Past Chair
David Weill, MD, Standards & Guidelines Workforce Leader
Christopher H. Wigfield, MD, FRCS,
Education Workforce Leader
Shaf Keshavjee, MD, Registries & Databases Workforce Leader
Christine L. Lau, MD, Communications Workforce Leader
Roger D. Yusen, MD, MPH, Quality of Life Workforce Leader
Patrick Evrard, MD, Development Liaison

JUNIOR FACULTY AND TRAINEES
David W. Markham, MD, Chair
Daniel Dilling, MD, Vice Chair
Lorriana E. Leard, MD, Past Chair
Susan D. Moffatt-Bruce, MD, PhD,
Standards & Guidelines Workforce Leader
Matthew Morrell, MD, Education Workforce Leader
Jennifer C. Matthews-Cowger, MD,
Registries & Databases Workforce Leader
Pali D. Shah, MD, Communications Workforce Leader
Arezu, Z. Aliabadi, MD, Development Liaison

NURSING, HEALTH SCIENCES AND ALLIED HEALTH
Bernice L. Coleman, RN, PhD, Chair
Nancy P. Blumenthal, CRNP, Vice Chair
Connie White-Williams, MSN, Past Chair
Michael G. Petty, PhD(c), RN, CCNS, CNS,
Standards & Guidelines Workforce Leader
Sharon A. Beer, RN, MSn Education Workforce Leader
Fabienne Dobbels, PhD,
Registries & Databases Workforce Leader
Bronwyn J. Levvey, RN,
Grad Dip Clin Ep, Communications Workforce Leader
Judy A. Currey, PhD, Grants and Awards Workforce Leader
Kevin Carney, RN, CCTC, Development Liaison
Annette Devito Dabbs, RN, PhD,
Research Mentorship Workforce Leader

PATHOLOGY
Annalisa Angelini, MD, Chair
To Be Elected, Vice Chair
Stephan M. Ensminger, MD, PhD, Past Chair
Carmela D. Tan, MD, Standards & Guidelines Workforce Leader
E. Rene Rodriguez, MD, Education Workforce Leader
Robert F. Padera, MD, PhD,
Registries & Databases Workforce Leader
James B. Atkinson, MD, PhD,
Communications Workforce Leader

PEDIATRIC TRANSPLANTATION
Elfriede Pahl Schuette, MD, Chair
Beth Kaufman, MD, Vice Chair
Christian Benden, MD, Past Chair
Robert J. Boucek, Jr., MD,
Standards & Guidelines Workforce Leader
Daphne Hsu, MD, Education Workforce Leader
Richard E. Chinnoch, MD,
Registries & Databases Workforce Leader
Anne L. Dipchand, MD, Communications Workforce Leader

PULMONARY HYPERTENSION
Myung Park, MD, Chair
Robert P. Frantz, MD, Vice Chair
Raymond L. Benza, MD, Past Chair
Evelyn Horn, MD, Standards & Guidelines Workforce Leader
Dana P. McGlathlin, MD, Education Workforce Leader
Mardi Gomberg-Maitland, MD, MSc,
Registries & Databases Workforce Leader
Fernando Torres, MD, PA,
Registries & Databases Workforce Leader
Deborah J. Levine, MD, Communications Workforce Leader
Srinivas Murali, MD, Development Liaison

PULMONARY TRANSPLANTATION
Lianne G. Singer, MD, FRCP, Chair
David Weill, MD, Vice Chair
Michael Mulligan, MD, Vice Chair-Elect/Secretary
Geert M. Verleden, MD, PhD, Past Chair
David Weill, MD, Standards & Guidelines Workforce Leader
Christopher H. Wigfield, MD, FRCS,
Education Workforce Leader
Shaf Keshavjee, MD, Registries & Databases Workforce Leader
Christine L. Lau, MD, Communications Workforce Leader
Roger D. Yusen, MD, MPH, Quality of Life Workforce Leader
Patrick Evrard, MD, Development Liaison

JUNIOR FACULTY AND TRAINEES
David W. Markham, MD, Chair
Daniel Dilling, MD, Vice Chair
Lorriana E. Leard, MD, Past Chair
Susan D. Moffatt-Bruce, MD, PhD,
Standards & Guidelines Workforce Leader
Matthew Morrell, MD, Education Workforce Leader
Jennifer C. Matthews-Cowger, MD,
Registries & Databases Workforce Leader
Pali D. Shah, MD, Communications Workforce Leader
Arezu, Z. Aliabadi, MD, Development Liaison
PAST SCIENTIFIC PROGRAM CHAIRS

<table>
<thead>
<tr>
<th>Year</th>
<th>Location</th>
<th>Co-Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>1981</td>
<td>San Francisco, CA</td>
<td>Edward B. Stinson, MD and Michael L. Hess, MD</td>
</tr>
<tr>
<td>1982</td>
<td>Phoenix, AZ</td>
<td>Michael Kaye and Bernard Gersh</td>
</tr>
<tr>
<td>1983</td>
<td>New Orleans, LA</td>
<td>Stuart W. Jamieson, MD &amp; Mark E. Thompson, MD</td>
</tr>
<tr>
<td>1984</td>
<td>New York, NY</td>
<td>Randall B. Griep, MD</td>
</tr>
<tr>
<td>1985</td>
<td>Anaheim, CA</td>
<td>Terence A. H. English, FRCS and Hillel Laks, MD</td>
</tr>
<tr>
<td>1986</td>
<td>New York, NY</td>
<td>John C. Baldwin, MD</td>
</tr>
<tr>
<td>1987</td>
<td>New Orleans, LA</td>
<td>Bruno Reichart, MD</td>
</tr>
<tr>
<td>1988</td>
<td>Munich, Germany</td>
<td>D. Glenn Pennington, MD</td>
</tr>
<tr>
<td>1989</td>
<td>San Diego, CA</td>
<td>John B. O’Connell, MD</td>
</tr>
<tr>
<td>1990</td>
<td>Paris, France</td>
<td>Eric A. Rose, MD</td>
</tr>
<tr>
<td>1991</td>
<td>San Diego, CA</td>
<td>Maria Rosa Costanzo, MD</td>
</tr>
<tr>
<td>1992</td>
<td>Boca Raton, FL</td>
<td>John Wallwork, MBCchB, FRCS</td>
</tr>
<tr>
<td>1993</td>
<td>Venice, Italy</td>
<td>Leslie W. Miller, MD</td>
</tr>
<tr>
<td>1994</td>
<td>San Francisco, CA</td>
<td>William A. Baumgartner, MD</td>
</tr>
<tr>
<td>1995</td>
<td>New York, NY</td>
<td>Stephan Schueler, MD</td>
</tr>
<tr>
<td>1996</td>
<td>Chicago, IL</td>
<td>James B. Young, MD</td>
</tr>
<tr>
<td>1997</td>
<td>San Francisco, CA</td>
<td>Mark L. Barr, MD</td>
</tr>
<tr>
<td>1998</td>
<td>Osaka, Japan</td>
<td>John Kobashigawa, MD</td>
</tr>
<tr>
<td>1999</td>
<td>Vancouver, Canada</td>
<td>David O. Taylor, MD</td>
</tr>
<tr>
<td>2000</td>
<td>Washington, DC</td>
<td>Robert C. Robbins, MD</td>
</tr>
<tr>
<td>2001</td>
<td>Vienna, Austria</td>
<td>Bruce R. Rosengard, MD</td>
</tr>
<tr>
<td>2002</td>
<td>San Francisco, CA</td>
<td>Mandeep R. Mehra, MD</td>
</tr>
<tr>
<td>2003</td>
<td>Philadelphia, PA</td>
<td>Shaf Keshavjee, MD</td>
</tr>
<tr>
<td>2004</td>
<td>Madrid, Spain</td>
<td>John Dark, MB, FRCS</td>
</tr>
<tr>
<td>2005</td>
<td>San Francisco, CA</td>
<td>Duane Davis, MD</td>
</tr>
<tr>
<td>2006</td>
<td>Boston, MA</td>
<td>Lori J. West, MD, DPhil</td>
</tr>
<tr>
<td>2007</td>
<td>Paris, France</td>
<td>Randall C. Starling, MD, MPH</td>
</tr>
<tr>
<td>2008</td>
<td>Chicago, IL</td>
<td>Hermann Rechenspurner, MD</td>
</tr>
</tbody>
</table>

PAST EDITORS, JOURNAL OF HEART AND LUNG TRANSPLANTATION

- 1981-1985: Jacques G. Losman, MD
- 1986-1994: Michael P. Kaye, MD
- 1995-1999: Maria Rosa Costanzo, MD
- 2000-2009: James K. Kirklin, MD
- 2010-Present: Mandeep R. Mehra, MBBS, FACC, FACP

LIFETIME ACHIEVEMENT AWARD

- 1996: Norman Shumway, MD
- 1999: Keith Reemtsma, MD
- 2004: Sir Magdi Yacoub, MD
- 2010: Margaret Billingham, MD

LIFETIME SERVICE AWARD

- 1996: Michael P. Kaye, MD
- 1997: Jacques G. Losman, MD

PIONEERS IN TRANSPLANTATION LECTURE

- 2000: Christiaan Barnard, MD
- 2002: Michael DeBakey, MD
- 2006: Leonard L. Bailey, MD
- 2008: Richard E. Lower, MD
- 2009: Christian E. A. Cabrol, MD

NORMAN E. SHUMWAY ISHLT CAREER DEVELOPMENT AWARD

- 2000: Gordon D. Wu, MD (supported by Roche)
- 2002: Anthony Azakie, MD (supported by Roche)
- 2004: Allan M. Ramirez, MD (supported by Novartis Pharma)
- 2006: Dennis W. Wigle, MD, PhD (supported by Astellas Pharma)
- 2008: Glen Westall, MD, PhD (supported by Roche)
- 2010: Sonja Schrepfer, MD, PhD (supported by Astellas)
## ISHLT Tuesday

<table>
<thead>
<tr>
<th>TIME</th>
<th>SAPPHIRE BC</th>
<th>SAPPHIRE D</th>
<th>SAPPHIRE AE</th>
<th>SAPPHIRE IM</th>
<th>AQUA 306</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **ISHLT Academy**
  - 2:00 – 6:00 pm

- **Dinner Break**
  - 6:00 – 7:00 pm

### ISHLT Board Meeting
- 8:00 am – 10:00 am

### Exhibit Hall
- 9:00 am – 10:00 am

### Thoracic Registry Executive Committee Mtg.
- 2:00 – 4:00 pm

### Basic Science 
- 2:00 – 4:00 pm

### Exhibits & Databases
- 4:00 – 6:00 pm

### Academy Faculty Dinner
- 4:00 – 6:00 pm
AWARD RECIPIENTS

Kendra N. Taylor, PhD (supported by Roche)
Monica Zwierzchowiakusa, MD
(supported by XDx) 2005
Ryan C. Fields, MD (supported by Chimerix)
Arne Neystnick, MD (supported by Astellas)
Ahmad Saad, MD (supported by Roche)
(supported by Roche) 2006
Rachel L. Anderson, MRRS
Zhaozhui Li, PhD (supported by Transmedics)
Heather E. Merry, MD (supported by EnCyte)
Edward N. Seung, PhD (supported by XDx)
Matthew J. Weiss, MD (supported by Novartis)
J. Raymond Fitzpatrick, III, MD
(supported by EnCyte) 2007
Howard F. Huang, MD (supported by Transmedics)
Mythnam Jayakanthan, MD
(supported by XDx) 2008
Timothy M. Millington, MD
(supported by Novartis)
Satish N. Nadig, MD (supported by Roche)
Takeshi Oyari, MD, PhD
(supported by Actelion) 2009
Sonja Schrepler, MD (supported by Astellas)
Jonathan Chow, PhD (supported by XDx)
Satoshi Itou, MD (supported by Transmedics)
Teresa Marinini, MD (supported by Novartis)
Deepthi Saini, PhD (supported by Gilead)
Amushi Shirouzu, MD, PhD
(supported by Astellas) 2010
Seiichiro Sugimoto, MD, PhD
(supported by Roche)
Hua Shen, MD, PhD (supported by Astellas)
Tobias Deuse, MD, PhD (supported by Novartis)
Masahiro Miyajima, MD, PhD (supported by XDx)
Shin Hirayama, MD, PhD (supported by Gilead)
Esme Diike, PhD (supported by Novartis)
Smita Sihag, MD (supported by XDx)
Nina Patil, MSc, PhD (supported by XDx)

ISHLT TRANSPLANT RESEARCH FELLOWSHIP GRANTS
1995 Frances L. Johnson, MD (supported by Ortho-Biotech)
1996 Tuja S. Bomen, MD (supported by Roche)
Andrew F. Pierre, MD (supported by Ortho-Biotech)
Jonathan Chen, MD (supported by Roche)
Alzina M. Kraminskan, MD (supported by Astellas)
Owen T. Lawrence, MD (supported by Ortho-Biotech)
Anne K. Raisanen-Sokolowski, MD (supported by Roche)
Kelly S.A. Blair, MD (supported by Roche)
A.M. El Gamel, MD (supported by Ortho-Biotech)
Christine L. Lau, MD (supported by Wyeth-Ayerst)
Scott D. Ross, MD
Margaret L. Schwarze, MD (supported by Novartis)
Sivasai Krovvidi, PhD (supported by Roche)
Satoshi Saito, MD (supported by Novartis)
Satoshi Sihag, MD (supported by Astellas)
Shin Hirayama, MD, PhD (supported by Genentech)
Smita Sihag, MD (supported by Astellas)
Masahiro Miyajima, MD, PhD (supported by XDx)
Tobias Deuse, MD, PhD (supported by Astellas)
Donald Wong, PhD (supported by Roche)
Sarah S. Lee, MD (supported by Novartis)
Christopher H. Wignfield, FRCS
(supported by Roche)
Arnae Gertison, MD (supported by Roche)
Matteo Vatta, PhD (supported by Roche)
Ruediger Hoechelt, MD (supported by Roche)
Eswot J. van den Bos, MD (supported by Astellas)
Felix Fernandez, MD (supported by Roche)
Christian A. Glasgow, MD (supported by Astellas)
Toryoshi Shoji, MD, PhD (supported by Astellas)

AWARD RECIPIENTS

ISHLT TRANSPLANT REGISTRY JUNIOR FACULTY AWARD
2007 Beth D. Kaufman, MD
2008 Cynthia Gries, MD, MSc
Scott Halpern, MD, PhD
Josef Stehlik, MD, MPH
2010 Jennifer Comway, MD, FRCPC
Kirah K. Khush, MD, MAS

PHILIP K. CAVES AWARD
1983 Robin G. Cohen, MD
1984 Hermann Reichenbuerger, MD
1985 Michael A. Breda, MD
1986 Stuart J. Knechtle, MD
1987 Wim Van Der Bij, MD
1988 Charles D. Fraser, Jr., MD
1989 A.M. Wood, MD
1990 Andrea J. Duncan, MD
1991 A. Juninere, MD
1992 David P. Kappelanski, MD
1993 David Marshman, MD
1994 John Wnter, MD
1995 Elizabeth A. Davies, MD
1996 Moninder S. Bhabra, MD
1997 Simon D. Eiref, MD
1998 Carla G. Baan, MD
1999 Joerg Koglin, MD
2000 Michael Fischbein, MD
2001 Alexander S. Krosnick, MD
2002 Peter Blaha, MD
2003 Sigrid Sandner, MD
2004 M.D. Peterson, MD
2005 Sigrid Sandner, MD
2006 Frank D’Ovidio, MD
2007 Gregor Warmecke, MD
2008 Yeaherry Troosters, PhD
2009 Mi-Young Song, PhD
2010 Stacey M. Pollock-BarZiv, PhD

AWARD RECIPIENTS

ISHLT NURSING AND SOCIAL SCIENCES RESEARCH GRANT
1997 Eileen Collins, RN, PhD
1999 Joanne Salyer, PhD
2000 Nancy M. Albert, MSN, RN
2001 Lynn Doering, RN, DNSc
2002 Annette J. de Vita Babbs, RN, MN, PhD
2003 Diane H. Lelouidis, RN, MSN
2004 Janet F. Madill, PhD
2005 Desider E. Logan, PhD
2006 Annemarie F. Kaan, MCM
2008 Thierry Troosters, PhD
2010 Mylvganam Jeyakanthan, MD
(supported by Transmedics)

AWARD RECIPIENTS

Philip K. CavES AWARD
1998 Katherine S. Blair, RN, MSN
1999 Jeanne Salyer, PhD
2000 Nancy M. Albert, MSN, RN
2001 Lynn Doering, RN, DNSc
2002 Annette J. de Vita Babbs, RN, MN, PhD
2003 Diane H. Lelouidis, RN, MSN
2004 Janet F. Madill, PhD
2005 Desider E. Logan, PhD
2006 Annemarie F. Kaan, MCM
2008 Thierry Troosters, PhD
2010 Mylvganam Jeyakanthan, MD
(supported by Transmedics)
**ISHLT Wednesday**

<table>
<thead>
<tr>
<th>TIME</th>
<th>SAPPHIRE BC</th>
<th>SAPPHIRE D</th>
<th>SAPPHIRE AE</th>
<th>SAPPHIRE IM</th>
<th>AQUA 306</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td>SATELLITE 1</td>
<td>SATELLITE 2</td>
<td>SATELLITE 3</td>
<td>ISHLT ACADEMY</td>
<td>SATELLITE 4</td>
</tr>
<tr>
<td></td>
<td>HEART – Risk Scores</td>
<td>Lung Allocation</td>
<td>Lung Microvascular</td>
<td></td>
<td>PH</td>
</tr>
<tr>
<td>9:00 AM</td>
<td>BREAK</td>
<td>BREAK</td>
<td>BREAK</td>
<td>BREAK</td>
<td></td>
</tr>
<tr>
<td>10:00 AM</td>
<td>SATELLITE 6</td>
<td>SATELLITE 7</td>
<td>SATELLITE 8</td>
<td>ISHLT ACADEMY</td>
<td>SATELLITE 9</td>
</tr>
<tr>
<td></td>
<td>PH &amp; LTX</td>
<td>CAV</td>
<td>AMR 1: Antibodies</td>
<td>10:30 am – 12:30 pm</td>
<td>Kids on Waitlist</td>
</tr>
<tr>
<td>11:00 AM</td>
<td>BREAK</td>
<td>BREAK</td>
<td>BREAK</td>
<td>BREAK</td>
<td></td>
</tr>
<tr>
<td>12:00 PM</td>
<td>BOX LUNCH PICK-UP (ticket required)</td>
<td>SAPPHIRE FOYER</td>
<td>12:45 pm – 1:15 pm</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:00 PM</td>
<td>LUNCH BREAK, 12:30 – 1:30 pm</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td>SATELLITE 11</td>
<td>SATELLITE 12</td>
<td>SATELLITE 13</td>
<td>SATELLITE 14</td>
<td>SATELLITE 15</td>
</tr>
<tr>
<td></td>
<td>Sick Enough for MCS</td>
<td>CTEPH</td>
<td>AMR 2: Lung</td>
<td>Lung Tx ECMO</td>
<td>AMR 2: What’s Festering</td>
</tr>
<tr>
<td>3:00 PM</td>
<td>BREAK</td>
<td>BREAK</td>
<td>BREAK</td>
<td>BREAK</td>
<td></td>
</tr>
<tr>
<td>4:00 PM</td>
<td>SATELLITE 17</td>
<td>SATELLITE 18</td>
<td>SATELLITE 19</td>
<td>SATELLITE 20</td>
<td>SATELLITE 21</td>
</tr>
<tr>
<td></td>
<td>MCS RV Failure</td>
<td>Donor Organ Optim.</td>
<td>AMR 3: Heart</td>
<td>OB</td>
<td>PEDS Consensus</td>
</tr>
<tr>
<td>5:00 PM</td>
<td>BREAK</td>
<td>BREAK</td>
<td>BREAK</td>
<td>BREAK</td>
<td></td>
</tr>
<tr>
<td>6:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**INDIGO 202**

<table>
<thead>
<tr>
<th>TIME</th>
<th>INDIGO 202</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM</td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td></td>
</tr>
<tr>
<td>9:00 AM</td>
<td></td>
</tr>
<tr>
<td>10:00 AM</td>
<td></td>
</tr>
<tr>
<td>11:00 AM</td>
<td></td>
</tr>
<tr>
<td>12:00 PM</td>
<td></td>
</tr>
<tr>
<td>1:00 PM</td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td></td>
</tr>
<tr>
<td>3:00 PM</td>
<td></td>
</tr>
<tr>
<td>4:00 PM</td>
<td></td>
</tr>
<tr>
<td>5:00 PM</td>
<td></td>
</tr>
<tr>
<td>6:00 PM</td>
<td></td>
</tr>
<tr>
<td>7:00 PM</td>
<td></td>
</tr>
<tr>
<td>8:00 PM</td>
<td></td>
</tr>
<tr>
<td>9:00 PM</td>
<td></td>
</tr>
<tr>
<td>10:00 PM</td>
<td></td>
</tr>
</tbody>
</table>

**INDIGO 204A**

<table>
<thead>
<tr>
<th>TIME</th>
<th>INDIGO 204A</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM</td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td></td>
</tr>
<tr>
<td>9:00 AM</td>
<td></td>
</tr>
<tr>
<td>10:00 AM</td>
<td></td>
</tr>
<tr>
<td>11:00 AM</td>
<td></td>
</tr>
<tr>
<td>12:00 PM</td>
<td></td>
</tr>
<tr>
<td>1:00 PM</td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td></td>
</tr>
<tr>
<td>3:00 PM</td>
<td></td>
</tr>
<tr>
<td>4:00 PM</td>
<td></td>
</tr>
<tr>
<td>5:00 PM</td>
<td></td>
</tr>
<tr>
<td>6:00 PM</td>
<td></td>
</tr>
<tr>
<td>7:00 PM</td>
<td></td>
</tr>
<tr>
<td>8:00 PM</td>
<td></td>
</tr>
<tr>
<td>9:00 PM</td>
<td></td>
</tr>
<tr>
<td>10:00 PM</td>
<td></td>
</tr>
</tbody>
</table>

**INDIGO 204B**

<table>
<thead>
<tr>
<th>TIME</th>
<th>INDIGO 204B</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM</td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td></td>
</tr>
<tr>
<td>9:00 AM</td>
<td></td>
</tr>
<tr>
<td>10:00 AM</td>
<td></td>
</tr>
<tr>
<td>11:00 AM</td>
<td></td>
</tr>
<tr>
<td>12:00 PM</td>
<td></td>
</tr>
<tr>
<td>1:00 PM</td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td></td>
</tr>
<tr>
<td>3:00 PM</td>
<td></td>
</tr>
<tr>
<td>4:00 PM</td>
<td></td>
</tr>
<tr>
<td>5:00 PM</td>
<td></td>
</tr>
<tr>
<td>6:00 PM</td>
<td></td>
</tr>
<tr>
<td>7:00 PM</td>
<td></td>
</tr>
<tr>
<td>8:00 PM</td>
<td></td>
</tr>
<tr>
<td>9:00 PM</td>
<td></td>
</tr>
<tr>
<td>10:00 PM</td>
<td></td>
</tr>
</tbody>
</table>

**INDIGO 400**

<table>
<thead>
<tr>
<th>TIME</th>
<th>INDIGO 400</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM</td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td></td>
</tr>
<tr>
<td>9:00 AM</td>
<td></td>
</tr>
<tr>
<td>10:00 AM</td>
<td></td>
</tr>
<tr>
<td>11:00 AM</td>
<td></td>
</tr>
<tr>
<td>12:00 PM</td>
<td></td>
</tr>
<tr>
<td>1:00 PM</td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td></td>
</tr>
<tr>
<td>3:00 PM</td>
<td></td>
</tr>
<tr>
<td>4:00 PM</td>
<td></td>
</tr>
<tr>
<td>5:00 PM</td>
<td></td>
</tr>
<tr>
<td>6:00 PM</td>
<td></td>
</tr>
<tr>
<td>7:00 PM</td>
<td></td>
</tr>
<tr>
<td>8:00 PM</td>
<td></td>
</tr>
<tr>
<td>9:00 PM</td>
<td></td>
</tr>
<tr>
<td>10:00 PM</td>
<td></td>
</tr>
</tbody>
</table>

**INDIGO 206**

<table>
<thead>
<tr>
<th>TIME</th>
<th>INDIGO 206</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM</td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td></td>
</tr>
<tr>
<td>9:00 AM</td>
<td></td>
</tr>
<tr>
<td>10:00 AM</td>
<td></td>
</tr>
<tr>
<td>11:00 AM</td>
<td></td>
</tr>
<tr>
<td>12:00 PM</td>
<td></td>
</tr>
<tr>
<td>1:00 PM</td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td></td>
</tr>
<tr>
<td>3:00 PM</td>
<td></td>
</tr>
<tr>
<td>4:00 PM</td>
<td></td>
</tr>
<tr>
<td>5:00 PM</td>
<td></td>
</tr>
<tr>
<td>6:00 PM</td>
<td></td>
</tr>
<tr>
<td>7:00 PM</td>
<td></td>
</tr>
<tr>
<td>8:00 PM</td>
<td></td>
</tr>
<tr>
<td>9:00 PM</td>
<td></td>
</tr>
<tr>
<td>10:00 PM</td>
<td></td>
</tr>
</tbody>
</table>
NURSING AND SOCIAL SCIENCES EXCELLENCE IN RESEARCH AWARD

2005  Mary Amanda Dew, PhD
2006  Kathleen L. Grady, PhD, RN
2007  Christianne Kugler, PhD
2008  Annette DeVito Dabbs, RN, PhD
2009  Connie White-Williams, MSN
2010  Heike Spaderna, PhD
       Gerdi Weidner, PhD

ISHLT BRANISLAV RADOVANCEVIC MEMORIAL BEST MCSD PAPER AWARD (supported by Thoratec)

2009  Nishant Shah, MD
2010  Jose N. Nativi, MD

ISHLT BRANISLAV RADOVANCEVIC MEMORIAL FELLOWSHIP GRANT (supported by Thoratec)

2009  Sasa D. Borovic, MD
2010  Iki Adachi, MD

Plenary Sessions

Plenary Sessions will feature presentations by leaders in our Society as well as invited speakers whose contributions in related fields offer fresh perspectives that we may be able to apply to the care of our patients. The Opening Plenary Session on Thursday will feature Registry Reports from Marshall Hertz and Jim Kirklin. These are traditionally a high-point of the meeting. The ISHLT Registry will provide us with contemporary information regarding activity and outcome trends in international thoracic transplantation, and the INTERMACS will update us on evolving application of mechanical circulatory support in the United States. The session winds up with the Pioneer Lecture from Elizabeth Hammond of Utah School of Medicine, Salt Lake City, Utah. Dr. Hammond participated in groundbreaking clinical trials of induction T-Cell depletion in heart allograft recipients during the 1980’s and 90’s. She pioneered the diagnosis of humoral cardiac allograft injury, and significantly contributed to our understanding of its pathogenesis. She is being honored for these important contributions to clinical and translational investigation in our field.

On Friday, “Gazing Into the Crystal Ball – Emerging Therapy in Thoracic Transplantation” will highlight clinical immune modulation (David Wilkes), alternatives for survivors of CHD, (Michael Hubler), cell-based alternatives to MCS (Eduardo Marban), repairing and re-engineering lungs for transplant (Shaf Keshavjee), and expected progress with lung assist devices (Joseph Zwischenberger). Saturday morning will feature Walter Dembitsky, talking about “MCS Evolution And Counter-Evolution: Can We Fool Mother Nature?” and Lynne Stevenson will moderate an expert panel (Roland Hetzer, Nicholas Smedira, Heather Ross) discussing “Choices After Age 70: MCSD, Heart Transplant, or Palliative Care.” On Saturday afternoon, the Closing Plenary Session will feature a Keynote Lecture, “Proteomics/Novel Diagnostics In Transplantation” by Daniel Salomon,
<table>
<thead>
<tr>
<th>TIME</th>
<th>SAPPHIRE BC</th>
<th>SAPPHIRE D</th>
<th>SAPPHIRE AE</th>
<th>SAPPHIRE IM</th>
<th>AQUA 306</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM</td>
<td>Sunrise 1</td>
<td>Sunrise 1</td>
<td>Sunrise 2</td>
<td>Sunrise 3</td>
<td>Collagen Vascular</td>
</tr>
<tr>
<td>8:00 AM</td>
<td>OPENING PLENARY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 AM</td>
<td>BREAK</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 AM</td>
<td>CONCURRENT 1</td>
<td>MCS: Landscape</td>
<td>CONCURRENT 2</td>
<td>CHT Prediction Myocard Complications</td>
<td>CONCURRENT 3</td>
</tr>
<tr>
<td>12:00 PM</td>
<td>Mid-Day 1</td>
<td>Thoracic Organ Pushing Limits</td>
<td>Mid-Day 2</td>
<td>RV Failure</td>
<td>Mid-Day 3</td>
</tr>
<tr>
<td>1:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td></td>
<td></td>
<td>CONCURRENT 6</td>
<td>Cardiac Antibodies</td>
<td>CONCURRENT 7</td>
</tr>
<tr>
<td>3:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:00 PM</td>
<td>BREAK</td>
<td>BREAK</td>
<td>BREAK</td>
<td>BREAK</td>
<td>BREAK</td>
</tr>
<tr>
<td>5:00 PM</td>
<td></td>
<td></td>
<td>CONCURRENT 12</td>
<td>MCS: Paradigm Shift</td>
<td>CONCURRENT 13</td>
</tr>
<tr>
<td>6:00 PM</td>
<td>Mini Orals 1</td>
<td>MHC</td>
<td>Mini Orals 2</td>
<td>CHT</td>
<td>Mini Orals 3</td>
</tr>
<tr>
<td>7:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**SATELLITE SYMPOSIUM**

- Pulmonary Hypertension: 7:00 - 9:00 pm
an address by Frank Delmonico on the topic of “Emerging Public Policy Initiatives for Promoting Organ Donation,” a “What’s Hot / What’s Cool” summary of the meeting and the field for heart failure and transplant (Mandeep Mehra), lung failure and transplant (Allan Glanville), MCS (Francis Pagani), and basic science/immunobiology (Stephan Ensminger) followed by a spirited “Supersize Me” debate between Marshall Hertz and John Wallwork regarding the proposition: “Obesity IS NOT a Contraindication to Thoracic Replacement Therapy.”

Mechanical Circulatory Support
This 31st Annual Meeting and Scientific Sessions of ISHLT will have a record number of presentations addressing the challenges of patient selection for mechanical circulatory support (MCS), clinical management of the MCS patient and recommendations to reduce adverse events. A Mid-Day Symposium on Pediatric VADs will include: special anatomic and physiologic considerations complicating MCS implant in CHD (Eric Devaney); current device options for the single ventricle (Michael Hubler); an update on the North American experience with pediatric VADs (Holger Buchholz); and an update on the NIH PumpKin trial (Bartley Griffith). Among the other offerings are popular staples from prior years (VADs Gone Bad; RV support during and after LVAD implantation). MCS case presentation sessions have been particularly popular at prior meetings, and the San Diego program will offer added opportunities for members to participate actively in these sessions.

Pulmonary Hypertension
This year, the PH members of the Program Committee have put together a diverse and exciting series of pre-meeting and mid-day symposia to discuss emerging options for the management of advanced PH. The Program Committee and the PH Council will take advantage of the meeting’s location to highlight important contributions by local members of our society, complemented by presentations from some of the leading authorities in the world. An important theme throughout the meeting will be a focus on right ventricular (dys)function, its assessment through imaging and other modalities, and its management in the context of heart and lung transplant, and in conjunction with MCS and ECMO support. For example, don’t miss the Friday Sunrise Symposium on “Pulmonary Hypertension Complicating Left Ventricular Failure: Problems and Progress.” To round things out, Pre-Meeting Symposium 4 on Wednesday morning will address new concepts, therapies and innovations in PAH. On the whole, the San Diego meeting offers a great opportunity to learn more about primary and secondary pulmonary hypertension and their management.

Infectious Disease
San Diego will feature cutting edge developments in the diagnosis and management of infectious diseases in thoracic transplant and MCSD patients. In addition to Pre-Meeting Symposium updates on CMV (“The Gathering Storm”), we will be entertained (“What’s Fester ing?”) and enlightened (“Microbe Hunters - Munitions, Germs and Steel”) by leaders in the field during other Mid-Day and Sunrise Symposium sessions throughout the meeting. Additional talks highly relevant to infectious disease specialists working with thoracic transplant and MCSD patients, and specifically useful to guide difficult clinical treatment decisions, will be found throughout the Symposium and Concurrent Oral Abstract sessions.

Pediatric Transplantation
There are many sessions that are tailored to the particular interest to the pediatric heart and lung transplant community. Of particular note are a Wednesday Pre-Meeting Symposium in conjunction with IPTA to ask “Do we have a consensus?” with respect to donor and recipient selection criteria and post-transplant management approaches, and a Thursday Mid-Day Symposium on pediatric VAD and ECMO technology.

Basic Science
The “Caves Award” competition session will continue to highlight original research by our young academic scientists, who present their “hottest” experimental and clinical research to a jury of senior scientists and interested members. Translational science will be particularly highlighted in Plenary and Mid-Day Symposium sessions. Most notably, Dan Salomon’s Saturday Keynote Plenary lecture will discuss proteomics and other evolving diagnostic tools that are likely to find their way to our patients’ bedside during the next decade. Another session not to be missed is Thursday’s “Immunological Aspects of Engineered Heart Tissue and Cellular Replacement Therapies,” discussing how immunity influences progress related to engineered heart tissue (Lenard Conradi), augmenting cardiomyocyte proliferation in the failing heart (Loren Field) and emerging stem cell-based therapies (Stefan Janssens).

Pathology and Basic Science
This year’s Annual Meeting will emphasize features of AMR in clinical heart and lung transplantation, including the latest guidance regarding detection and management of antidonor antibodies. Significant advances in the use of molecular tools to detect rejection, anticipate graft acceptance (tolerance) and diagnose rejection will be highlighted in Daniel Salomon’s Keynote Plenary talk and in multiple other areas of the program. In addition, the latest data will be presented in oral abstract sessions regarding cellular mechanisms of chronic heart and lung rejection (CAV, OBS), PTLD and other malignancies, pathobiology of AMR, and the role of innate and adaptive immunity in the pathogenesis of early and late thoracic organ failure.

Nursing, Health Science and Allied Health
Our 2011 Annual Meeting program has been constructed and designed based on extensive feedback and helpful program evaluations from our nursing science, social science and allied health colleagues. Thanks to the enthusiastic engagement of their Council, the nursing and social science content of this year’s meeting will be enriched by discussion of “new solutions to old problems,” of palliative care’s role in the management of difficult patient scenarios, and of activities and strategies that are associated with improved quality of life.
### ISHLT Friday

<table>
<thead>
<tr>
<th>TIME</th>
<th>SAPPHIRE BC</th>
<th>SAPPHIRE D</th>
<th>SAPPHIRE AE</th>
<th>SAPPHIRE IM</th>
<th>AQUA 306</th>
<th>TIME</th>
<th>SAPPHIRE BC</th>
<th>SAPPHIRE D</th>
<th>SAPPHIRE AE</th>
<th>SAPPHIRE IM</th>
<th>AQUA 306</th>
<th>TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM</td>
<td>Sunrise 5</td>
<td>Sunrise 6</td>
<td>Sunrise 7</td>
<td>Recovery VADS</td>
<td>LTx Experiment</td>
<td>PH LV Failure</td>
<td>Sunrise 8</td>
<td>Kids Immunology</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td>PLENARY SESSION</td>
<td>Crystal Ball</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CONCURRENT 18</td>
<td>Cardiac Donor Selection</td>
<td>CONCURRENT 19</td>
<td>Cardiac Future Therapies</td>
<td>12:15 – 1:45 pm</td>
<td>CONCURRENT 20</td>
</tr>
<tr>
<td>9:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CONCURRENT 22</td>
<td>Cardiac MCS: Lifelong Challenges</td>
<td>CONCURRENT 23</td>
<td>Cardiac Mid-Day 5</td>
<td>12:15 – 1:45 pm</td>
<td>CONCURRENT 24</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Annual Business Meeting</td>
<td>CONCURRENT 18</td>
<td>CONCURRENT 19</td>
<td>CONCURRENT 20</td>
<td>CONCURRENT 21</td>
<td></td>
<td>Mid-Day 5</td>
<td>Long Future Therapies</td>
<td>Mid-Day 6</td>
<td>Sharing Hearts Around World</td>
<td>12:15 – 1:45 pm</td>
<td>Mid-Day 7</td>
</tr>
<tr>
<td>11:00 AM</td>
<td>CONCURRENT 18</td>
<td>CONCURRENT 19</td>
<td>CONCURRENT 20</td>
<td>CONCURRENT 21</td>
<td></td>
<td></td>
<td>CONCURRENT 22</td>
<td>Cardiac MCS: Lifelong Challenges</td>
<td>CONCURRENT 23</td>
<td>Cardiac Mid-Day 5</td>
<td>12:15 – 1:45 pm</td>
<td>CONCURRENT 24</td>
</tr>
<tr>
<td>12:00 PM</td>
<td>CONCURRENT 18</td>
<td>CONCURRENT 19</td>
<td>CONCURRENT 20</td>
<td>CONCURRENT 21</td>
<td></td>
<td></td>
<td>CONCURRENT 22</td>
<td>Cardiac MCS: Lifelong Challenges</td>
<td>CONCURRENT 23</td>
<td>Cardiac Mid-Day 5</td>
<td>12:15 – 1:45 pm</td>
<td>CONCURRENT 24</td>
</tr>
<tr>
<td>1:00 PM</td>
<td>CONCURRENT 18</td>
<td>CONCURRENT 19</td>
<td>CONCURRENT 20</td>
<td>CONCURRENT 21</td>
<td></td>
<td></td>
<td>CONCURRENT 22</td>
<td>Cardiac MCS: Lifelong Challenges</td>
<td>CONCURRENT 23</td>
<td>Cardiac Mid-Day 5</td>
<td>12:15 – 1:45 pm</td>
<td>CONCURRENT 24</td>
</tr>
<tr>
<td>2:00 PM</td>
<td>CONCURRENT 18</td>
<td>CONCURRENT 19</td>
<td>CONCURRENT 20</td>
<td>CONCURRENT 21</td>
<td></td>
<td></td>
<td>CONCURRENT 22</td>
<td>Cardiac MCS: Lifelong Challenges</td>
<td>CONCURRENT 23</td>
<td>Cardiac Mid-Day 5</td>
<td>12:15 – 1:45 pm</td>
<td>CONCURRENT 24</td>
</tr>
<tr>
<td>3:00 PM</td>
<td>CONCURRENT 18</td>
<td>CONCURRENT 19</td>
<td>CONCURRENT 20</td>
<td>CONCURRENT 21</td>
<td></td>
<td></td>
<td>CONCURRENT 22</td>
<td>Cardiac MCS: Lifelong Challenges</td>
<td>CONCURRENT 23</td>
<td>Cardiac Mid-Day 5</td>
<td>12:15 – 1:45 pm</td>
<td>CONCURRENT 24</td>
</tr>
<tr>
<td>4:00 PM</td>
<td>CONCURRENT 18</td>
<td>CONCURRENT 19</td>
<td>CONCURRENT 20</td>
<td>CONCURRENT 21</td>
<td></td>
<td></td>
<td>CONCURRENT 22</td>
<td>Cardiac MCS: Lifelong Challenges</td>
<td>CONCURRENT 23</td>
<td>Cardiac Mid-Day 5</td>
<td>12:15 – 1:45 pm</td>
<td>CONCURRENT 24</td>
</tr>
<tr>
<td>5:00 PM</td>
<td>CONCURRENT 18</td>
<td>CONCURRENT 19</td>
<td>CONCURRENT 20</td>
<td>CONCURRENT 21</td>
<td></td>
<td></td>
<td>CONCURRENT 22</td>
<td>Cardiac MCS: Lifelong Challenges</td>
<td>CONCURRENT 23</td>
<td>Cardiac Mid-Day 5</td>
<td>12:15 – 1:45 pm</td>
<td>CONCURRENT 24</td>
</tr>
<tr>
<td>6:00 PM</td>
<td>CONCURRENT 18</td>
<td>CONCURRENT 19</td>
<td>CONCURRENT 20</td>
<td>CONCURRENT 21</td>
<td></td>
<td></td>
<td>CONCURRENT 22</td>
<td>Cardiac MCS: Lifelong Challenges</td>
<td>CONCURRENT 23</td>
<td>Cardiac Mid-Day 5</td>
<td>12:15 – 1:45 pm</td>
<td>CONCURRENT 24</td>
</tr>
<tr>
<td>7:00 PM</td>
<td>CONCURRENT 18</td>
<td>CONCURRENT 19</td>
<td>CONCURRENT 20</td>
<td>CONCURRENT 21</td>
<td></td>
<td></td>
<td>CONCURRENT 22</td>
<td>Cardiac MCS: Lifelong Challenges</td>
<td>CONCURRENT 23</td>
<td>Cardiac Mid-Day 5</td>
<td>12:15 – 1:45 pm</td>
<td>CONCURRENT 24</td>
</tr>
<tr>
<td>8:00 PM</td>
<td>Gala Reception</td>
<td>Mini Orals 7</td>
<td>Mini Orals 8</td>
<td>Mini Orals 9</td>
<td>Mini Orals 10</td>
<td></td>
<td>CONCURRENT 32</td>
<td>PED Much Ado</td>
<td>Mini Orals 11</td>
<td>EM0/FED</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CONCURRENT 32</td>
<td>PED Much Ado</td>
<td>Mini Orals 11</td>
<td>EM0/FED</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CONCURRENT 32</td>
<td>PED Much Ado</td>
<td>Mini Orals 11</td>
<td>EM0/FED</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Pulmonary Transplantation

As one of the core disciplines at the foundation of our society, lung failure management and pulmonary replacement therapy will be prominent topics in multiple sessions. In addition to “Crystal Ball” Plenary session talks highlighting emerging new treatment approaches and technologies (repairing and re-engineering lungs for transplant by Shaf Keshavjee, and expected progress with lung assist devices by Joseph Zwischenberger), multiple Mid-Day, Pre-Meeting and Sunrise Symposia will focus on new evidence and remaining controversies important to clinicians working with cardiac transplant and heart failure patients. Thursday’s “Immunological Aspects of Engineered Heart Tissue and Cellular Replacement Therapies in Heart Failure” will feature cutting-edge talks by Lenard Conradi, Loren Field and Stefan Janssens, and will be moderated by Sonja Schreper and Doris Taylor, whose own work will be highlighted on Friday. On Friday, international transplant practices will be compared in a Saturday Mid-Day Symposium on “Sharing Hearts Around the World: What Works and What Fails in International transplant practices” will be compared in a Saturday Mid-Day Symposium on “Sharing Hearts Around the World: What Works and What Fails in International transplant practices.” Multiple Mid-Day and Sunrise Symposia will focus on new evidence and remaining controversies important to clinicians working with lung transplant patients. These presentations, and the eight concurrent oral abstract sessions devoted to lung failure and lung transplantation, as well as extensive additional offerings related to pulmonary hypertension, right heart failure and ECMO, should prove to be of particular interest to those engaged in these fields.

Heart Failure and Transplant Medicine

As another of the core disciplines at the foundation of our society, heart failure management and cardiac replacement and repair therapies will be prominent topics in multiple sessions. In addition to Pre-Meeting Symposium sessions highlighting emerging new treatment approaches and technologies (donor organ selection and rejuvenation; diagnosis and treatment of cardiac AMR; CAV consensus and controversy), multiple Mid-Day and Sunrise Symposia will focus on new evidence and remaining controversies important to clinicians working with cardiac transplant and heart failure patients. Thursday’s “Immunological Aspects of Engineered Heart Tissue and Cellular Replacement Therapies in Heart Failure" will feature cutting-edge talks by Lenard Conradi, Loren Field and Stefan Janssens, and will be moderated by Sonja Schreper and Doris Taylor, whose own work will be highlighted on Friday. On Friday, international transplant practices will be compared in a Saturday Mid-Day Symposium on “Sharing Hearts Around the World: What Works and What Fails in International Systems.” A Saturday Mid-Day Symposium on “Sharing Hearts Around the World: What Works and What Fails in International transplant practices” will be compared in a Saturday Mid-Day Symposium on “Sharing Hearts Around the World: What Works and What Fails in International transplant practices.” Multiple Mid-Day and Sunrise Symposia will focus on new evidence and remaining controversies important to clinicians working with lung transplant patients. These presentations, and the eight concurrent oral abstract sessions devoted to lung failure and lung transplantation, as well as extensive additional offerings related to pulmonary hypertension, right heart failure and ECMO, should prove to be of particular interest to those engaged in these fields.
<table>
<thead>
<tr>
<th>TIME</th>
<th>SAPPHIRE FOYER</th>
<th>SAPPHIRE D</th>
<th>SAPPHIRE AE</th>
<th>SAPPHIRE IM</th>
<th>AQUA 306</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM</td>
<td>Sunrise 10</td>
<td>Sunrise 9</td>
<td>Sunrise 14</td>
<td>Sunrise 13</td>
<td>Break</td>
</tr>
<tr>
<td>8:00 AM</td>
<td>CONCURRENT 33</td>
<td>CONCURRENT 34</td>
<td>CONCURRENT 35</td>
<td>CONCURRENT 36</td>
<td>Break</td>
</tr>
<tr>
<td>9:00 AM</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
</tr>
<tr>
<td>11:00 AM</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
</tr>
<tr>
<td>12:00 PM</td>
<td>Mid-Day 5</td>
<td>Mid-Day 10</td>
<td>Mid-Day 13</td>
<td>Mid-Day 12</td>
<td>Break</td>
</tr>
<tr>
<td>1:00 PM</td>
<td>CONCURRENT 39</td>
<td>CONCURRENT 40</td>
<td>CONCURRENT 41</td>
<td>CONCURRENT 42</td>
<td>Break</td>
</tr>
<tr>
<td>2:00 PM</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
</tr>
<tr>
<td>3:00 PM</td>
<td>CLOSING PLENARY SESSION</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
</tr>
<tr>
<td>4:00 PM</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
</tr>
<tr>
<td>5:00 PM</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
</tr>
<tr>
<td>6:00 PM</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
</tr>
<tr>
<td>7:00 PM</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
</tr>
<tr>
<td>8:00 PM</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
</tr>
<tr>
<td>9:00 PM</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
</tr>
<tr>
<td>10:00 PM</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
</tr>
</tbody>
</table>

**ISHLT Saturday**

<table>
<thead>
<tr>
<th>TIME</th>
<th>INDIGO 202</th>
<th>INDIGO 204</th>
<th>INDIGO 206</th>
<th>SAPPHIRE 400</th>
<th>INDIGO BALLROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM</td>
<td>Sunrise 12</td>
<td>Sunrise 11</td>
<td>Sunrise 12</td>
<td>Sunrise 12</td>
<td>Council Reports to BdD</td>
</tr>
<tr>
<td>8:00 AM</td>
<td>CONCURRENT 37</td>
<td>CONCURRENT 38</td>
<td>CONCURRENT 43</td>
<td>CONCURRENT 43</td>
<td>Break</td>
</tr>
<tr>
<td>9:00 AM</td>
<td>Broken Heart</td>
<td>ID Viral</td>
<td>Jr Faculty Cases</td>
<td>Jr Faculty Cases</td>
<td>Break</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
<td>Board Meeting 5:00 – 10:00 pm</td>
</tr>
</tbody>
</table>
Target Audience
The audience for this program includes physicians, surgeons, scientists, nurses and transplant coordinators engaged in the practice of heart and lung transplantation, the management and treatment of heart and lung transplant recipients, the management and treatment of patients with end-stage heart or lung disease, basic science or clinical research related to these fields or specialties which cause them to become involved in the treatment of transplant recipients or patients with end-stage heart or lung disease.

Learning Objectives
Please refer to the disclosure documents distributed at the registration desk for the learning objectives for this educational activity.

Conflict of Interest Disclosure
Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker’s presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner.

These disclosures have been distributed from the registration desk. Additionally, all speakers have been asked to verbally disclose at the start of their presentation any financial interest or affiliations and to indicate if a product they are discussing is not labeled for the use under discussion or is still investigational. ISHLT will ensure that all conflicts of interest have been resolved in accordance with ACCME requirements for the purpose of eliminating bias in the presentation of educational and scientific content.
The day prior to the 2011 Annual Meeting, we are conducting the second ishlt academy: Core Competencies in Lung Transplantation. The complete program is below. If you were unable to attend the ishlt academy this year, you can order a DVD of the activity. Order forms are available at the ISHLT Registration Desk. A substantial discount is available to those who purchase the DVD while at the 2011 Annual Meeting.

The ishlt academy: Core Competencies in Lung Transplantation will provide a concise review of clinical knowledge and essential professional skills to facilitate best practice of surgical and medical aspects involved in the care of patients during assessment as candidates and as recipients of lung transplantation. The course consists of focused presentations with an emphasis on clinical practice. All lectures will be delivered by internationally recognized experts in the field. Related topics will be discussed in Question and Answer sessions following each lecture. The course will be interactive and assist participants with more detailed individual review. This course is designed to be of benefit for both seasoned clinicians and allied professionals practicing in the field, but is primarily arranged for current trainee physicians, Fellows, and attending providers in the early stages of their careers.

The faculty for this course consists of internationally recognized leaders in each subspecialty, and the educational workforce of the Pulmonary Council is confident this course will be most comprehensive and valuable for practitioners in the field of lung transplantation.
CONTINUING MEDICAL EDUCATION INFORMATION

Accreditation Statement
The ishlt academy: Core Competencies in Lung Transplantation has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education. The International Society for Heart & Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The ISHLT designates this live activity for a maximum of 9.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure
Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker’s presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation any financial interest or affiliations and to indicate if a product they are discussing is not labeled for the use under discussion or is still investigational.

Learning Objectives
Please refer to the disclosure documents distributed at the registration desk for the learning objectives for this educational activity.

Educational Goals
The educational goals of this activity are to provide a concise review of clinical knowledge and essential professional skills to facilitate best practice of surgical and medical aspects involved in the care of patients during assessment as candidates and as recipients of lung transplantation. The course consists of focused presentations with an emphasis on clinical practice.

Target Audience
This course is designed to be of benefit for both seasoned clinicians and allied professionals practicing in the field, but is primarily arranged for current trainee physicians, Fellows and attending providers in the early stages of their careers.
Part II: Martha L. Mooney, MD, Sentara Norfolk Transplant Center, EVMS, Virginia Beach, VA, USA
5. Diagnosis, Prophylaxis & Management of Early Post-Transplant Infections
6. Diagnosis, Prophylaxis & Management of Later Infections
7. Non-Infectious Allograft Sequelae of Infectious Pathogens
8. Immune Monitoring and Infection

9:45 AM Question and Answer Session

10:00 AM BREAK

10:15 AM Lung Transplantation Pathology

Part I: Susan Stewart, FRCPath, Papworth Hospital, Cambridge, United Kingdom
1. Specimen Adequacy and Handling
2. Preservation Injury and Other Causes of Early Graft Failure
3. Pathology of Acute Cellular Rejection (ACR)
4. Histopathological Mimics of ACR Including Infection

Part II: Gerald J. Berry, MD, Stanford University, Stanford, CA, USA
5. Lymphocytic Bronchiolitis/ Bronchitis
6. Chronic Airway Rejection
7. Acute Antibody Mediated Rejection (AMR)
8. Recurrence of Primary Pathology

11:00 AM Question and Answer Session

11:15 AM Case Discussions (and Panel Discussions – All faculty)
Andrew Fisher, FRCP, PhD – Cases 1 & 3
Christopher Wigfield, MD, FRCS – Cases 2 & 4
1. Case Discussion: Candidate for Lung Transplantation Evaluation & Wait List Considerations
2. Case Discussion: Donor Decision Process and Procurement Strategies
3. Case Discussion: ACR Differential Diagnosis & Management
4. Case Discussion: Late Infection Work-Up and PTLD Diagnosis

NOON Course Summary and Evaluation

12:30 PM ADJOURN
TUESDAY, APRIL 12, 2011

8:00 AM – 5:00 PM
Exhibit Booth Installation/Set-up (Indigo Ballroom)

8:00 AM – 2:00 PM
ISHLT BOARD OF DIRECTORS MEETING (Sapphire 400)

NOON – 2:00 PM
ISHLT Academy Registration Open (Sapphire IM Foyer)

NOON – 8:00 PM
Speaker Ready Room Open (Sapphire 410)

2:00 PM – 4:00 PM
THORACIC REGISTRY EXECUTIVE COMMITTEE MEETING (Indigo 204A)
BASIC SCIENCE AND TRANSLATIONAL RESEARCH COUNCIL STEERING COMMITTEE MEETING (204B)

2:00 PM – 9:00 PM
ISHLT ACADEMY: CORE COMPETENCIES IN LUNG TRANSPLANTATION (Sapphire IM)

4:00 PM – 6:00 PM
EDUCATION COMMITTEE MEETING (Indigo 206)

4:30 PM – 6:30 PM
REGISTRIES AND DATABASES COMMITTEE MEETING (Indigo 204A)

5:00 PM – 7:00 PM
Registration Open (Sapphire Foyer)

6:00 PM – 7:00 PM
ACADEMY FACULTY DINNER (Indigo 204B)
WEDNESDAY, APRIL 13, 2011

6:30 AM – 6:30 PM
Speaker Ready Room Open (Sapphire 410)

7:00 AM – 6:30 PM
Registration Open (Sapphire Foyer)

7:30 AM – 12:30 PM
ISHLT ACADEMY: CORE COMPETENCIES IN LUNG TRANSPLANTATION (Sapphire IM)

8:00 AM – 6:30 PM
Exhibit Booth Set-up (Indigo Ballroom)

8:00 AM – 10:00 AM
Pre-Meeting Symposium 1: “Risky Business!” Heart Failure, Transplant, and Mechanical Circulatory Support (Sapphire BC)
Pre-Meeting Symposium 2: Optimizing Lung Allocation. Square Pegs in Round Holes? (Sapphire D)
Pre-Meeting Symposium 3: Preserving Microvascular Function in Lung Transplantation (Sapphire AE)
Pre-Meeting Symposium 5: Old Problems, New Solutions: Clinical Exemplars for Nursing, Health Sciences & Allied Health (Indigo 202)

9:00 AM – 6:00 PM
Press Office (Sapphire 411)

10:00 AM – 10:30 AM
COFFEE BREAK (Sapphire Foyer)

10:30 AM – 12:30 PM
Pre-Meeting Symposium 6: Challenges in Lung Transplantation for Pulmonary Arterial Hypertension (Sapphire BC)
Pre-Meeting Symposium 7: Coronary Artery Vasculopathy: From Consensus to Controversy (Sapphire D)
Pre-Meeting Symposium 8: AMR 1 – Role of Antibody Detection in the Diagnosis of AMR (Sapphire AE)
Pre-Meeting Symposium 9: Preventable Death: Kids on the Waitlist (Aqua 306)
Pre-Meeting Symposium 10: CMV – The Gathering Storm (Indigo 202)

NOON – 6:00 PM
Poster Mounting (Indigo Ballroom and Indigo Foyer)

12:45 PM – 1:15 PM
BOX LUNCH PICK-UP (Sapphire Foyer)

2:00 PM – 4:00 PM
Pre-Meeting Symposium 11: When Does “Less Sick” = “Sick Enough” for MCS? (Sapphire BC)
Pre-Meeting Symposium 12: Clinical Challenges in Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (Sapphire D)
Pre-Meeting Symposium 13: AMR 2: AMR in the Lung: Controversies in Clinical Treatment and Diagnosis (Sapphire AE)
Pre-Meeting Symposium 14: Extracorporeal Support in Lung Transplantation (Sapphire IM)
Pre-Meeting Symposium 15: What’s Festering? (Aqua 306)
Pre-Meeting Symposium 16: Quality of Life in the Interventions for End-Stage Thoracic Organ Disease (Indigo 202)

4:00 PM – 4:30 PM
COFFEE BREAK (Sapphire Foyer)

4:30 PM – 6:30 PM
Pre-Meeting Symposium 17: Management of the Failing Right Ventricle at the Time of MCS Implant (Sapphire BC)
Pre-Meeting Symposium 18: Donor Organ Optimization (Sapphire D)
Pre-Meeting Symposium 19: AMR3 – The Role of Pathology in Diagnosis of AMR In the Heart (Sapphire AE)
Pre-Meeting Symposium 20: Obliterative Bronchiolitis: Translation of Cells to Patients (Sapphire IM)
Pre-Meeting Symposium 21: Joint ISHLT/IPTA Session: Pediatric Cardiothoracic Transplant: Do We Have Consensus? (Aqua 306)
Pre-Meeting Symposium 22: Regulation in the Immune System (Indigo 202)

6:30 PM – 7:30 PM
BASIC SCIENCE AND TRANSLATIONAL RESEARCH COUNCIL MEETING (Indigo 206)
INFECTIOUS DISEASES COUNCIL MEETING (Sapphire 400)
STANDARDS AND GUIDELINES COMMITTEE MEETING (Indigo 204B)

6:30 PM – 8:00 PM
EXHIBIT HALL WELCOME RECEPTION (Indigo Ballroom)
THURSDAY, APRIL 14, 2011

6:30 AM – 6:30 PM
Speaker Ready Room Open (Sapphire 410)

7:00 AM – 5:30 PM
Registration Desk Open (Sapphire Foyer)

7:00 AM – 8:00 AM
Sunrise Symposium 1: The Role of IL17 in Lung Transplantation (Sapphire AE)

Sunrise Symposium 2: VADS Gone Bad (Sapphire IM)


Sunrise Symposium 4: Microbe Hunters – Munitions, Germs and Steel: A Case-Based Discussion (Indigo 202)

8:00 AM – 10:00 AM
OPENING PLENARY SESSION (Sapphire BCD)

9:00 AM – 6:00 PM
Press Office Open (Sapphire 411)

10:00 AM – 10:30 AM
COFFEE BREAK (Indigo Ballroom)

10:00 AM – 4:00 PM
Exhibit Hall Open (Indigo Ballroom)
Poster Viewing (Indigo Ballroom and Indigo Foyer)

10:30 AM – NOON
Concurrent Session 1: The Landscape of VAD Complications – Work to be Done (Sapphire BCD)

Concurrent Session 2: Prediction and Management of Complications After Heart Transplantation (Sapphire AE)

Concurrent Session 3: Risk Assessment in Pulmonary Hypertension (Sapphire IM)

Concurrent Session 4: Breathless? We Can Offer an Alternative Lung (Aqua 306)

Concurrent Session 5: Update on Pathological Diagnosis of AMR in Heart Transplant (Indigo 202)

NOON – 12:30 PM
BOX LUNCH PICK-UP (Indigo Ballroom)

12:15 PM – 1:45 PM
Mid-Day Symposium 1: Pushing the Limits for Thoracic Organ Transplantation (Sapphire AE)

Mid-Day Symposium 2: The Failing Right Ventricle: Mechanisms and Management (Sapphire IM)

Mid-Day Symposium 3: Immunological Aspects of Engineered Heart Tissue and Cellular Replacement Therapies in Heart Failure (Aqua 306)

Mid-Day Symposium 4: Update on Pediatric MCS Therapy (Indigo 202)

JHLET EDITORIAL BOARD MEETING/LUNCH (Sapphire 400)

2:00 PM – 3:30 PM
Concurrent Session 6: VADs – Think Right Before Left (Sapphire BC)

Concurrent Session 7: Antibodies Before and After Heart Transplantation (Sapphire D)

Concurrent Session 8: Primary Graft Dysfunction After Lung Transplantation (Sapphire AE)

Concurrent Session 9: Clinical Immunosupression – TOR Inhibitors (Sapphire IM)


Concurrent Session 11: Tissue Engineering and Cell Transplantation (Indigo 202)

3:30 PM – 4:00 PM
COFFEE BREAK (Indigo Ballroom)

Concurrent Session 12: VADs Shift the Paradigm – From Cold and Wet to Warm and Dry (Sapphire BC)

Concurrent Session 13: Immunosuppression and Immune Surveillance in Heart Transplantation (Sapphire D)

Concurrent Session 14: Antibodies in Lung Transplantation (Sapphire AE)

Concurrent Session 15: “Pumping Lung” (Sapphire IM)

Concurrent Session 16: Experimental Models of Cardiac Allograft Vasculopathy (Aqua 306)

Concurrent Session 17: Much Ado About Infections After Surgery for Advanced Heart and Lung Diseases (Indigo 202)

5:30 PM – 6:30 PM
Mini Oral Session 1 Mechanical Circulatory Support (Sapphire BC)

Mini Oral Session 2 Clinical Heart Transplantation (Sapphire D)

Mini Oral Session 3 Lung Heart/Lung Transplantation (Sapphire AE)

Mini Oral Session 4 Basic Science and Immunobiology (Sapphire IM)

Mini Oral Session 5 Nursing Science, Allied Health, Social Science (Indigo 204B)

Mini Oral Session 6 Infectious Diseases (Indigo 202)

5:30 PM – 6:30 PM
PULMONARY HYPERTENSION COUNCIL MEETING (Sapphire 400)

6:30 PM – 7:30 PM
ID DEFINITIONS MEETING (Indigo 206)

PULMONARY AMR WORKGROUP MEETING (Sapphire 400)

ISHLT DCD REGISTRY MEETING (Sapphire 412)
FRIDAY, APRIL 15, 2011

6:30 AM – 6:30 PM
Speaker Ready Room Open (Sapphire 410)

7:00 AM – 5:30 PM
Registration Desk Open (Sapphire Foyer)

7:00 AM – 8:00 AM
Sunrise Symposium 5: “It’s Alive!” Myocardial Recovery During LVAD Support in 2011 (Sapphire AE)
Sunrise Symposium 6: Experimental Models of Lung Transplantation (Sapphire IM)
Sunrise Symposium 7: Pulmonary Hypertension Complicating Left Ventricular Failure: Problems and Progress (Aqua 306)
Sunrise Symposium 8: Why are Children Immunologically Different? (Indigo 202)

7:00 AM – 10:00 AM
Poster Mounting (Indigo Ballroom and Indigo Foyer)

8:00 AM – 10:00 AM
PLENARY SESSION: Gazing Into the Crystal Ball – Emerging Therapy in Thoracic Transplantation (Sapphire BCD)

9:00 AM – 6:00 PM
Press Office Open (Sapphire 411)

10:00 AM – 10:30 AM
ANNUAL BUSINESS MEETING (members only) (Sapphire BCD)
COFFEE BREAK (Indigo Ballroom)

10:00 AM – 4:00 PM
Exhibit Hall Open (Indigo Ballroom)
Poster Viewing (Indigo Ballroom and Indigo Foyer)

10:30 AM – NOON
Concurrent Session 18: The Challenges of Life-long VAD Care (Sapphire BCD)
Concurrent Session 19: Impact of Donor Selection on Heart Transplant Outcomes (Sapphire AE)
Concurrent Session 20: Collaborating to Promote and Enhance Quality of Life in End Stage Organ Disease (Sapphire IM)
Concurrent Session 21: Drug Therapy in Pulmonary Hypertension (Aqua 306)
Concurrent Session 22: Clinical Immunosuppression for Heart and Lung Transplantation (Indigo 202)

NOON – 12:30 PM
BOX LUNCH PICK-UP (Indigo Ballroom)

12:15 PM – 1:45 PM
Mid-Day Symposium 5: Future Therapies for End-Stage Thoracic Organ Failure (Sapphire AE)
Mid-Day Symposium 7: AST at ISHLT: Lessons From Other Organs (Aqua 306)
Mid-Day Symposium 8: Palliative Care Across the Illness Trajectory (Indigo 202)
JUNIOR FACULTY MENTOR LUNCH (Indigo 204) (pre-registration and ticket required)
COUNCIL CHAIRS’ LUNCHEON MEETING (Indigo 206)

2:00 PM – 3:30 PM
Concurrent Session 23: All About Recovery, Weaning and VAD Explant (Sapphire D)
Concurrent Session 24: While You Wait – Therapy and Function in Patients with Heart Failure (Sapphire AE)
Concurrent Session 25: Imaging and Hemodynamics in Pulmonary Hypertension (Sapphire IM)
Concurrent Session 26: Mesenchymal Cells and Lymphoid Neogenesis in Transplanted Lungs (Aqua 306)
Concurrent Session 27: Philip K. Caves Award Candidate Presentations (Indigo 202)

3:30 PM – 4:00 PM
COFFEE BREAK (Indigo Ballroom)
POSTER VIEWING/POSTER PRESENTER Q&A (Indigo Ballroom and Indigo Foyer)

4:00 PM – 5:30 PM
Concurrent Session 28: Newer Horizons in VAD Therapy (Sapphire D)
Concurrent Session 29: Complications Associated With Drugs and Antibodies Following Heart Transplantation (Sapphire AE)
Concurrent Session 30: Biomarkers in Lung Transplantation (Sapphire IM)
Concurrent Session 31: Experimental Studies in Immunosuppression (Aqua 306)
Concurrent Session 32: Pediatric Heart Transplant – Antibodies and Risk Factors (Indigo 202)

4:00 PM – 11:59 PM
Exhibit Hall Strike (Indigo Ballroom)
Poster Strike (Indigo Ballroom and Indigo Foyer)

5:30 PM – 6:30 PM
Mini Oral Session 7: Mechanical Circulatory Support (Sapphire D)
Mini Oral Session 8: Clinical Heart Transplantation (Sapphire AE)
Mini Oral Session 9: Basic Science and Immunobiology (Sapphire IM)
SATURDAY, APRIL 16, 2011

6:30 AM – 4:30 PM
Speaker Ready Room Open (Sapphire 410)

7:00 AM – 2:15 PM
Registration Desk Open (Sapphire Foyer)

7:00 AM – 8:00 AM
Sunrise Symposium 9: Acid-fast, Act Fast and Not So Fast Infections: You Make the Call! (Sapphire AE)

Sunrise Symposium 10: Standardized MCS Guidelines: We Have Arrived (Sapphire D)

Sunrise Symposium 11: Challenging Patients and Creative Solutions (Indigo 204)

Sunrise Symposium 12: ABCs of Clinical Transplantation for Scientists (Indigo 202)

Sunrise Symposium 13: Waiting in the Wings – Advanced Heart Failure (Aqua 306)

Sunrise Symposium 14: Immunobiology for the Clinician (Sapphire IM)

8:00 AM – 9:00 AM
Concurrent Session 33: VAD Support for Children (Sapphire D)

Concurrent Session 34: Impact of Gender and Race on Outcomes After Heart Transplant (Sapphire AE)

Concurrent Session 35: Doing More with LES in Lung Transplantation (Sapphire IM)

Concurrent Session 36: Mechanisms and Treatment of Obliterative Bronchiolitis (Aqua 306)

Concurrent Session 37: Broken Heart? We Can Offer a Second-Hand Pump (Indigo 202)

Concurrent Session 38: Viral and Fungal Impacts After Lung Transplantation (Indigo 204)

9:00 AM – 9:30 AM
COFFEE BREAK (Sapphire Foyer)

9:00 AM – 12:00 PM
Press Office Open (Sapphire 411)

9:30 AM – 11:30 AM
PLENARY SESSION (Sapphire D)

11:30 AM – 12:00 PM
BOX LUNCH PICK-UP (Sapphire Foyer)

11:45 AM – 12:45 PM
Mid-Day Symposium 9: Great Debates in Cardiac Transplant Immunosuppression (Sapphire D)

Mid-Day Symposium 10: New Developments in the Anticoagulation for VADs (Sapphire AE)

Mid-Day Symposium 11: Ethical Issues in Pediatric Cardiothoracic Transplant (Indigo 202)

Mid-Day Symposium 12: Quandary at the Lung Transplant Board Meeting (Aqua 306)

Mid-Day Symposium 13: Clinical Controversies in Pulmonary Hypertension: To Treat or Not To Treat? That Is the Question (Sapphire IM)

Mid-Day Symposium 14: What Is It? Intriguing Cases in Heart Transplant Pathology (Indigo 204)

11:45 AM – 1:00 PM
COUNCIL REPORTS TO THE BOARD AND MEMBERSHIP (Sapphire 400)

1:00 PM – 2:00 PM
Concurrent Session 39: How Do VADs Impact Our Decisions on Transplant? (Sapphire D)

Concurrent Session 40: Lining Up Risks: Pre-transplant Priority and Risk Assessment: Cardiac (Sapphire AE)

Concurrent Session 41: Lung Transplantation – Surgical Issues (Sapphire IM)

Concurrent Session 42: Ischemia Reperfusion Injury (Aqua 306)

Concurrent Session 43: Junior Faculty Case Presentations – Challenges in Thoracic Transplantation (Indigo 202)

Concurrent Session 44: Pediatric Heart and Lung Transplant Outcomes and Complications (Indigo 204)

2:00 PM – 2:15 PM
COFFEE BREAK (Sapphire Foyer)

2:15 PM – 4:40 PM
Closing Plenary Session (Sapphire D)

5:00 PM – 10:00 PM
ISHLTL BOARD OF DIRECTORS MEETING (Sapphire 400)
The International Society for Heart and Lung Transplantation is Most Grateful for the Educational Grants and Support of:

**Gold Level Partner**
ASTELLAS

**Silver Level Partner**
THORATEC

**Bronze Level Partners**
GILEAD
NOVARTIS
XDX

**Corporate Level Partner**
ACTELION

Toward this 31st Annual Meeting and Scientific Sessions.
Scientific Program

All meetings and activities will take place at the Hilton San Diego Bayfront unless otherwise specified. All papers will be presented in English. Meeting room assignments are subject to change.

TUESDAY, APRIL 12, 2011

8:00 AM – 5:00 PM
Exhibit Booth Installation/Set-up (Indigo Ballroom)

8:00 AM – 2:00 PM
ISHLT BOARD OF DIRECTORS MEETING (Sapphire 400)

NOON – 2:00 PM
ISHLT Academy Registration Open (Sapphire IM Foyer)

NOON – 8:00 PM
Speaker Ready Room Open (Sapphire 410)

2:00 PM – 4:00 PM
THORACIC REGISTRY STEERING COMMITTEE MEETING
(Indigo 204A)

BASIC SCIENCE AND TRANSLATIONAL RESEARCH COUNCIL MEETING (Indigo 204B)

2:00 PM – 9:00 PM
ISHLT ACADEMY: CORE COMPETENCIES IN LUNG TRANSPLANTATION (Sapphire IM)

4:00 PM – 6:00 PM
EDUCATION COMMITTEE MEETING (Indigo 206)

4:30 PM – 6:30 PM
REGISTRIES AND DATABASES COMMITTEE MEETING
(Indigo 204A)

5:00 PM – 8:00 PM
Registration Open (Sapphire Foyer)

6:00 PM – 7:00 PM
Academy Faculty Dinner (Indigo 204B)

WEDNESDAY, APRIL 13, 2011

6:30 AM – 6:30 PM
Speaker Ready Room Open (Sapphire 410)

7:00 AM – 6:30 PM
Registration Open (Sapphire Foyer)

7:30 AM – 12:30 PM
ISHLT ACADEMY: CORE COMPETENCIES IN LUNG TRANSPLANTATION (Sapphire IM)

8:00 AM – 6:30 PM
Exhibit Booth Set-up (Indigo Ballroom)

8:00 AM – 10:00 AM
PRE-MEETING SYMPOSIUM 1: “Risky Business!” Heart Failure, Transplant, and Mechanical Circulatory Support (Sapphire BC)

CHAIRS: Joseph G. Rogers, MD and Axel Rahmel, MD

8:00 AM
Assessment of Heart Failure Risk, Wayne C. Levy, MD, University of Washington Medical Center, Seattle, Washington

8:15 AM
Assessment of Transplant Risk in the US, David B. Dyke, MD, University of Michigan, Ann Arbor, Michigan

8:30 AM
Assessment of Transplant Risk in Europe, Bruno M. Meiser, MD, University of Munich/Grosshadern, Munich, Germany

8:45 AM
Assessment of MCS Risk, Katherine Lietz, MD, PhD, Yale University School of Medicine, New Haven, Connecticut

9:00 AM
Assessing The Risk of What?, Keith D. Aaronson, MD, University of Michigan Medical Center, Ann Arbor, Michigan

9:15 AM
Modeling Risk for Individual Patients, David C. Naftel, MD, University of Alabama at Birmingham, Birmingham, Alabama

9:30 AM
Case Presentations

9:30 AM
Chetan Patel, MD, Duke University Medical Center, Durham, North Carolina

9:38 AM
Alexander Stepanenko, MD, German Heart Institute, Berlin, Germany

9:45 AM
Panel Discussion/Q&A

8:00 AM – 10:00 AM
PRE-MEETING SYMPOSIUM 2: Optimizing Lung Allocation: Square Pegs in Round Holes? (Sapphire D)

CHAIRS: Gregory I. Snell, FRCP, MBB and David J. Lederer, MD

8:00 AM
North American Experience (Lung Allocation Score), Cynthia J. Gries, MD, MSc, University of Pittsburgh Medical Center Montefiore, Pittsburgh, Pennsylvania

8:25 AM
Lung Allocation Beyond the US, Paul A. Corris, MB FRCP, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

8:50 AM
Pros and Cons of Various Allocation Systems: An Independent Review, Lianne G. Singer, MD, FRCP, Toronto General Hospital, Toronto, Canada
9:15 AM  Should We Be Transplanting Patients from the Intensive Care Unit?  Selim M. Arcasoy, MD, Columbia University, New York, New York

9:40 AM  Panel Discussion/Q&A

8:00 AM – 10:00 AM  PRE-MEETING SYMPOSIUM 3: Preserving Microvascular Function in Lung Transplantation  (Sapphire AE)

CHAIRS:  Marlene Rose, PhD and Scott M. Palmer, MD, MHS

8:00 AM  The Critical Role of Airway Microvasculature in Lung Transplantation: An Overview of Pre-Clinical and Clinical Studies,  Mark R. Nicolls, MD, VA Palo Alto/Stanford University, Stanford, California

8:15 AM  Lung Transplant Airway Hypoxia: A Diathesis to Fibrosis?,  Gundeep S. Dhillon, MD, Stanford University Medical Center, Stanford, California

8:30 AM  Bronchial Artery Revascularization: The Copenhagen and Cleveland Clinic Experience,  Gosta Pettersson, MD, Cleveland Clinic Foundation, Cleveland, Ohio

8:45 AM  Microvascular Rarefaction in BOS: Results of the Papworth Hospital Autopsy Study,  Martin J. Goddard, FRCS, MRCPa, Papworth Hospital NHS Trust, Cambridge, United Kingdom

9:00 AM  The Fate of Endothelial Cells After Solid Organ Transplantation,  Jan Hillebrands, MD, University of Groningen Medical School Groningen, The Netherlands

9:20 AM  Preserving Airway Microvasculature in Lung Transplantation: Looking to the Future,  Martin R. Zamora, MD, University of Colorado Health Science Center, Aurora, Colorado

9:35 AM  Panel Discussion/Q&A

8:00 AM – 10:00 AM  PRE-MEETING SYMPOSIUM 4: What’s New in Pulmonary Arterial Hypertension? New Concepts, Therapies and Innovations!  (Aqua 306)

CHAIRS:  Myung Park, MD and Raymond L. Benza, MD

8:00 AM  The Risk Calculator: What is it and How Do I Use it for My PAH Patient?,  Adaani Frost, MD, Baylor College of Medicine, Houston, Texas

8:20 AM  Cardiac MRI in RV Assessment in PH: The Importance of RV and LV Interactions,  Himanshu Gupta, MD, FACC, University of Alabama at Birmingham, AL

8:40 AM  New Drugs Coming Down the Pipe Line from Oral Prostanoids to Antiproliferative Agents – How Do They Look?,  Jean-Luc Vachiery, MD, Erasme University Hospital, Brussels, Belgium

9:00 AM  Nine FDA Approved Therapies for PAH!: Do You Know How They Apply to Your Patients?,  Robert J. Schilz, DO, PhD, Case Western Reserve University, Cleveland, OH

9:20 AM  Case Presentation: 21-year-old Woman with New Onset PAH Presenting with Syncope – How Would You Treat This Patient?,  Robert P. Frantz, MD, Mayo Clinic, Rochester, Minnesota

9:40 AM  Panel Discussion/Q&A

8:00 AM – 10:00 AM  PRE-MEETING SYMPOSIUM 5: Old Problems, New Solutions: Clinical Exemplars for Nursing, Health Sciences, and Allied Health  (Indigo 202)

CHAIRS:  Sharon A. Beer, RN, MSc and Sharon Augustine, CRNP

8:00 AM  Exemplar: Genomics and Coumadin,  Bernice L. Coleman, PhD, RN, Cedars Sinai Medical Center, Los Angeles, California

8:25 AM  Exemplar: Translation of Research to Practice,  Judy A. Currey, PhD, Alfred Hospital/Deakin University, Melbourne, Australia

8:50 AM  Exemplar: Community Care of the Transplant/MCS Patient in a Nurse-Managed Clinic,  Renee L. Lassinger, RN, MSN, ANP, Mid-State Cardiology, Nashville, Tennessee

9:15 AM  Exemplar: New Adherence with Interventions for Organ Failure,  Sabina M. De Geest, RN, PhD, University of Basel, Basel, Switzerland

9:40 AM  Audience Discussion: What Challenging Problems Have You Resolved Creatively?
10:30 AM – 12:30 PM
PRE-MEETING SYMPOSIUM 7: Coronary Artery Vasculopathy: From Consensus to Controversy (Sapphire D)

CHAIRS: Jon Kobashigawa, MD and Maria Crespo-Leiro, MD

10:30 AM ISHLT Vasculopathy Nomenclature Consensus Statement, Maria G. Crespo-Leiro, MD, Hospital Universitario a Coruña, La Coruña, Spain

10:45 AM Transplant Vasculopathy: An Overview, Hannah A. Valantine, MD, Stanford University School of Medicine, Stanford, California

11:00 AM Role of Endothelial Progenitor Cells, Sudhir S. Kushwaha, MD, Mayo Clinic, Rochester, Minnesota

11:15 AM The Endothelial Cell as a Target for Therapy, Monica M. Colvin-Adams, MD, University of Minnesota, Minneapolis, Minnesota

11:30 AM Non-Invasive Risk Assessment and Diagnosis, Patricia P. Chang, MD, University of North Carolina, Chapel Hill, North Carolina

11:45 AM Strategies to Minimize the Development of Coronary Vasculopathy, James C. Fang, MD, University Hospital Advanced Heart Failure Transplantation, Cleveland, Ohio

NOON Strategies to Treat Established Vasculopathy, Andreas O. Zuckermann, MD, University of Vienna, Vienna, Austria

12:15 PM Panel Discussion/Q&A

10:30 AM – 12:30 PM
PRE-MEETING SYMPOSIUM 8: AMR 1 – Role of Antibody Detection in the Diagnosis of AMR (Sapphire AE)

CHAIRS: Desley Neil, BMedSc, MB and Adriana Zeevi, PhD

10:30 AM Introduction, Marlene Rose, PhD, Harefield Hospital, Harefield, United Kingdom

10:40 AM Diagnosis of AMR, Role of Antibodies Assessment, Risk-Stratification and Interpretation of HLA Antibodies in Heart and Lung Transplantation, Nancy L. Reinsmoen, PhD D Ahbi, Cedars-Sinai Health Systems, Los Angeles, California

11:00 AM Non-HLA Antibodies, Natural Antibodies and Other Issues in Assessing Risk for Heart Transplant Recipients, Marlene Rose, PhD, Harefield Hospital, Harefield, United Kingdom

11:20 AM Assessment of HLA Class I And Class II Antibodies in Lung Transplantation and Pediatrics, Adriana Zeevi, PhD, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

11:40 AM Role of Complement-Fixing and Non-Complement-Fixing Antibodies, William M. Baldwin, III, MD, Cleveland Clinic Foundation, Cleveland, Ohio

NOON Emerging Markers of Antibody Mediated Rejection, Michael C. Fishbein, MD, UCLA School of Medicine, Los Angeles, California

12:20 PM Panel Discussion/Q&A

10:30 AM – 12:30 PM
PRE-MEETING SYMPOSIUM 9: Preventable Death: Kids on the Waitlist (Aqua 306)

CHAIRS: Elfriede Pahl Schuette, MD and Carol K. Conrad, MD

10:30 AM Why Are Children Disadvantaged on The Thoracic Transplant Waiting List?, Stuart C. Sweet, MD, St Louis Children’s Hospital, St Louis, Missouri

10:50 AM Surgical Techniques to Address Donor-Recipient Size Mismatch, Takahiro Oto, MD, Okayama University Hospital, Okayama, Japan

11:10 AM How the Berlin Heart Has Impacted Decision Making in Critically Ill Heart Transplant Candidates, Ivan M. Rebeyka, MD, University of Alberta Hospital, Edmonton, Canada

11:30 AM Can We Save The Critically Ill Child: Transplanting From ICU, George B. Mallory, Jr., MD, Texas Children’s Hospital, Houston, Texas

11:50 AM DCD Heart Transplant: is it Time?, Asif Hasan, MD, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

12:10 PM Increasing Organ Donation Rates: The Impact of DCD, Gregory I. Snell, FRACP, MBB, Alfred Hospital, Melbourne, Australia

10:30 AM – 12:30 PM
PRE-MEETING SYMPOSIUM 10: CMV – The Gathering Storm (Indigo 202)

CHAIRS: Frauke Mattner, MD and Vincent G. Valentine, MD

10:30 AM Preventing CMV – Our Finest Hour, Scott M. Palmer, MD, MHS, Duke University Medical Center, Durham, North Carolina

10:54 AM CMV Immunoglobulin – The Grand Alliance?, Javier Carbone, MD, PhD, Gregorio Maranan Hospital, Madrid, Spain

11:18 AM Treating Ganciclovir-Resistant CMV-Closing the Ring, Sangeeta M. Bhorade, MD, University of Chicago, Chicago, Illinois

11:42 AM Pediatric Issues in CMV Management – The Hinge of Fate, Lara Danziger-Isakov, MD, MPH, Cleveland Clinic Foundation, Cleveland, Ohio

12:06 PM Diagnostics of CMV-Triumph and Tragedy, Glen P. Westall, FRACP, PhD, Alfred Hospital, Melbourne, Australia

NOON – 6:00 PM
Poster Mounting (Indigo Ballroom and Indigo Foyer)

12:45 PM – 1:15 PM
Box Lunches Pick-up (ticket required) (Sapphire Foyer)

12:45 PM – 1:45 PM
HEART FAILURE AND TRANSPLANT MEDICINE COUNCIL MEETING (Indigo 204A)

NURSING, HEALTH SCIENCES AND ALLIED HEALTH COUNCIL MEETING (Indigo 204B)
2:00 PM – 4:00 PM
PRE-MEETING SYMPOSIUM 13: AMR 2: AMR in the Lung:
Controversies in Clinical Treatment and Diagnosis (Sapphire AE)

CHAIRS: Deborah J. Levine, MD and Allan R. Glanville, MD, FRACP

2:00 PM Introduction, Allan R. Glanville, MD, FRACP, St. Vincent’s Hospital, Sydney, Australia
2:10 PM Antibody Mediated Rejection in Solid Organ Transplantation, Thalachallour Mohanakumar, PhD, Washington University School of Medicine, St Louis, Missouri
2:30 PM Pulmonary AMR: Acute and Chronic Presentation and Outcomes, Todd L. Astor, MD, Massachusetts General Hospital, Boston, MA
2:50 PM A Multi-Disciplinary Approach to Pulmonary AMR: Working Towards a Universal Paradigm: Clinically and Pathologically, Deborah J. Levine, MD, University of Texas Health Science Center, San Antonio, Texas
3:10 PM Improved Clinical Outcomes In the Pre-Sensitized Lung Transplant Recipient, Duane Davis, MD, Duke University Medical Center, Durham, North Carolina
3:30 PM Therapeutic Interventions for Pulmonary AMR: A Moving Target
A. 3:30 PM Interventions (Plasmapheresis/IVIG), Lianne G. Singer, MD, FRCPC, Toronto General Hospital, Toronto, Canada
B. 3:40 PM Pharmacologic Therapies (Velcade), Sangeeta M. Bhorade, MD, University of Chicago, Chicago, Illinois
3:50 PM Panel Discussion/Q&A

2:00 PM – 4:00 PM
PRE-MEETING SYMPOSIUM 14: Extracorporeal Support in Lung Transplantation (Sapphire IM)

CHAIRS: Hermann Reichenspurner, MD, PhD and Joseph B. Zwischenberger, MD

Part I:
How to Implant My Airbags? To Pump or Not to Pump
2:00 PM Why I Do All Cases Off Pump, Bryan F. Meyers, MD, Washington University School of Medicine, St Louis, Missouri
2:15 PM Why I Do All Cases On Pump, Alberto Pochettino, MD, University of Pennsylvania Health System, Philadelphia, Pennsylvania
2:25 PM Discussion/Q&A

Part II:
Cardiopulmonary Bypass Strategies for Double Lung Transplant
2:35 PM UCLA Experience, Abbas Ardehali, MD, University of California Los Angeles, Los Angeles, California
2:45 PM Newcastle Experience, Stephen C. Clark, MD, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
2:55 PM Vienna Experience, Clemens Aigner, MD, Medical University of Vienna, Vienna, Austria
3:05 AM Discussion/Q&A
**Part III: Applications of ECMO for Lung Transplant**

**3:15 AM Novalung as a Bridge**, Martin Strueber, MD, Hannover Medical School, Hannover, Germany

**3:25 AM Veno-Venous/Veno-Arterial ECMO as a Bridge**, David P. Mason, MD, Cleveland Clinic Foundation, Cleveland, Ohio

**3:35 PM Veno-Venous/Veno-Arterial ECMO For PGD**, Yoshida Toyoda, MD, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

**3:45 PM Discussion/Q&A**

**2:00 PM – 4:00 PM PRE-MEETING SYMPOSIUM 15: What’s Festing?** (Aqua 306)

**CHAIRS:** Margaret M. Hannan, MD and Valentina Stosor, MD

**2:00 PM Of Mycelia in Transplantation**, Sam S. Weigt, MD, University of California Los Angeles, Los Angeles, California

**2:30 PM Of Bacteria and Transplantation**, Margaret M. Hannan, MD, Mater Hospital, Dublin, Ireland

**3:00 PM Sense and Sensibilities of Fungal Diagnostics**, Shahid Husain, MD, MS, Toronto General Hospital, Toronto, Canada

**3:30 PM Strengths and Frailties of PCR for CMV-EBV**, Jutta Preiksaitis, MD, FRCPC, Transplant Infectious Diseases, University of Alberta, Edmonton, Alberta, Canada

**2:00 PM – 4:00 PM PRE-MEETING SYMPOSIUM 16: Quality of Life in the Interventions for End-Stage Thoracic Organ Disease** (Indigo 202)

**CHAIRS:** Nancy P. Blumenthal, CRNP and Fabienne Dobbels, MSc, PhD

**2:00 PM MCSD**, Kathleen L. Grady, PhD, APN, FAAN, Northwestern Memorial Hospital, Chicago, Illinois

**2:20 PM Heart Transplantation**, Heike Spaderna, PhD, Johannes Gutenberg University, Mainz, Germany

**2:40 PM Lung Transplantation**, Susan M. Chernenko, RN, MN, NP, Toronto General Hospital, Toronto, Canada

**3:00 PM Pediatric Transplantation**, Jo Wray, PhD, Royal Brompton and NHS Trust, Great Ormond Street Hospital, London, United Kingdom

**3:20 PM Pulmonary Hypertension**, Jessica Lazar, PA-C, Allegheny General Hospital, Pittsburgh, Pennsylvania

**3:40 PM Audience Discussion – What Challenging Problems Have You Resolved Creatively?**

**4:00 PM – 4:30 PM COFFEE BREAK** (Sapphire Foyer)

**4:30 PM – 6:30 PM PRE-MEETING SYMPOSIUM 17: Management of the Failing Right Ventricle at the Time of MCS Implant** (Sapphire BC)

**CHAIRS:** Thomas Krabatsch, MD and Robert L. Kormos, MD

**4:30 PM Assessing Right Ventricular Function**, Guy A. MacGowan, MD, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

**4:50 PM Biventricular Failure: Lessons Learned from the INTERMACS Experience**, Robert L. Kormos, MD, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

**5:10 PM Current TAH/Paracorporeal BiVAD Support Options**, Pascal Leprince, MD, PhD, Hospital Pitie-Salpetriere, Paris, France

**5:30 PM Management of the Tricuspid Valve in the Face of Biventricular Failure – Getting by Without an RVAD**, Carmelo Milano, MD, Duke University Medical Center, Durham, North Carolina

**5:50 PM When is Temporary RVAD Support Enough?** Vivek Rao, MD, PhD, Toronto General Hospital, Toronto, Canada

**6:10 PM New Continuous Flow TAH/BiVAD Support Strategies**, Roland Hetzer, MD, PhD, German Heart Institute, Berlin, Germany

**4:30 PM – 6:30 PM PRE-MEETING SYMPOSIUM 18: Donor Organ Optimization** (Sapphire D)

**CHAIRS:** Bruce R. Rosengard, MD, FRCS and Andres Varela, MD

**4:30 PM Clinical Experience with Ex-Vivo Lung Perfusion**, Shaf Keshavjee, MD, FRCSC, Toronto General Hospital, Toronto, Canada

**5:00 PM Warm Blood Perfusion for Heart Preservation**, Christoph Knosalla, MD, PhD, German Heart Institute, Berlin, Germany

**5:30 PM Lungs from DCD Donors – A Better Source than Brain-Dead Donors?** Martin Carby, FRCS (C-R), Harefield Hospital, Harefield, United Kingdom

**6:00 PM DCD Donor Resuscitation with Extracorporeal Support**, Michael H. Hines, MD, Wake Forest University, Winston-Salem, North Carolina

**4:30 PM – 6:30 PM PRE-MEETING SYMPOSIUM 19: AMR3 – The Role of Pathology in Diagnosis of AMR in the Heart** (Sapphire AE)

**CHAIRS:** Margaret M. Burke, FRCPath and Maria G. Crespo-Leiro, MD

**4:30 PM Introduction**, Annalisa Angelini, MD, University of Padua, Padova, Italy

**4:40 PM Current Status of Histopathological Diagnosis of AMR**, Gerald J. Berry, MD, Stanford University, Stanford, California

**5:00 PM Correlation Between IF and ICH Techniques: Are they Equivalent?** E. Renè Rodriguez, MD, Cleveland Clinic Foundation, Cleveland, Ohio

**5:20 PM Clinical Signs of AMR: When to Treat**, Nicholas R. Banner, FRCP, Harefield Hospital, Harefield, United Kingdom

**5:40 PM Therapeutic Intervention for AMR**, Gareth Parry, MB, FRCP, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

**6:00 PM New Therapies: Complement Blockade**, Carl Atkinson, PhD, Medical University of South Carolina, Charleston, South Carolina

**6:20 PM Panel Discussion/Q&A**
4:30 PM – 6:30 PM
PRE-MEETING SYMPOSIUM 20: Obliterative Bronchiolitis: Translation of Cells to Patients (Sapphire IM)

CHAIRS: Annette Boehler, MD and Christopher H. Wigfield, MD, FRCS

4:35 PM What is the Role of Airway Epithelium in the Development of OB? Andrew J. Fisher, FRCP, PhD, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

4:55 PM Where Does Airway Fibrosis in OB Come From? Daniel C. Chambers, MBBS, MD, The Prince Charles Hospital, Brisbane, Australia

5:20 PM Does Airway Smooth Muscle Contribute to the Development of OB? Geert M. Verleden, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium

5:45 PM Does the Endothelial Cell Contribute to OB? John A. Belperio, MD, David Geffen School of Medicine at UCLA, Los Angeles, California

6:10 PM Putting it All Together: Implications for Future Therapies, Robert M. Aris, MD, University of North Carolina, Chapel Hill, North Carolina

4:30 PM – 6:30 PM
PRE-MEETING SYMPOSIUM 21: Pediatric Cardiothoracic Transplant: Do We Have Consensus? (Aqua 306)

(Presented in collaboration with the International Pediatric Transplant Association)

CHAIRS: Richard Kirk, MA, FRCP, FRCPCH, Samuel B. Goldfarb, MD and Anne I. Dipchand, MD

4:30 PM Heart: Whom Should We List? Robert G. Weintraub, MB, BS, FRACP, FACC Royal Children's Hospital, Melbourne, Australia

4:50 PM Lung: Whom Should We List? Albert Faro, MD, Washington University School of Medicine, St Louis, Missouri

5:10 PM Heart: Who is a Good Donor? Kirk R. Kanter, MD, Emory University, Atlanta, Georgia

5:30 PM Lung: What is a Good Donor? Melinda P. Solomon, MD, FRCPCH, Hospital for Sick Children, Toronto, Canada

5:50 PM Heart: Consensus in Post-Transplant Management? Michael Burch, MD, Great Ormond Street Hospital, London, United Kingdom

6:10 PM Lung: Consensus in Lung-Transplant Management? Christian Benden, MD, University Hospital, Zurich, Switzerland

4:30 PM – 6:30 PM
PRE-MEETING SYMPOSIUM 22: Regulation in the Immune System (Indigo 202)

CHAIRS: James F. George, PhD and Timothy D. Lee, PhD

4:30 PM Regulatory T-Cells, Megan LeVings, PhD, University of British Columbia, Vancouver, Canada

5:00 PM Regulatory Dendritic Cells, Angus W. Thomson, PhD, DSc, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

THURSDAY, APRIL 14, 2011

6:30 AM – 6:30 PM
Speaker Ready Room Open (Sapphire 410)

7:00 AM – 5:30 PM
Registration Desk Open (Sapphire Foyer)

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 1: The Role of IL17 in Lung Transplantation (Sapphire AE)

CHAIRS: Thalachallour Mohanakumar, PhD and Gregory I. Snell, FRCP, MBB

7:00 AM IL-17 in Organ Transplantation: Where Does It Come From? Behdad Afzali, MD, Guy's Hospital, London, United Kingdom

7:20 AM Innate Immunity in the Transplanted Lung: The Role of IL-17, Andrew J. Fisher, FRCP, PhD, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

7:40 AM IL-17 in Acute and Chronic Lung Rejection: Implications for Treatment, Geert M. Verleden MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 2: VADS Gone Bad (Sapphire IM)

CHAIRS: Soon Park, MD, and Matthias Loebe, MD, PhD

7:00 AM Case of Inlet Canular Obstruction, Matthias Loebe, MD, PhD, Baylor College of Medicine, Houston, Texas

7:15 AM The Recurring Infection, Margarita T. Camacho, MD, Newark Beth Israel Medical Center, Newark, New Jersey

7:30 AM The Leaking Valve, Nader Moazami, MD, Minneapolis Heart Institute, Minneapolis, Minnesota

7:45 AM Where, Oh Where Am I Bleeding From? Ulrich P. Jorde, MD, Columbia University, New York, New York
11:00 AM (6) Are Blood Stream Infections Associated with Increased Risk of Stroke in Patients with a Continuous Flow Left Ventricular Assist Device?; J.A. Baumbatt,1 S. Pauwaa,2 A. Treitman,3 C. Gallagher,4 C. Blair,2 P. Pappas,2 A.J. Tatopoulos,2 G. Bhatar,2 Internal Medicine, University of Illinois in Chicago, Chicago, IL; 4Center for Heart Transplant and Assist Devices, Advocate Christ Medical Center, Oak Lawn, IL.

11:15 AM (7) Driveline Infections in LVADS: Is it the Pump or the Patient?; D.J. Goldstein,1 O.C. Naftel,1 W.L. Holman,2 L. Bellumkonda,3 S.V. Pamboukian,4 F.D. Pagani,2 J.K. Kirkin.2 Cardiovascular and Thoracic Surgery, Montefiore Medical Center, Bronx, NY; 2Medicine/Surgery, University of Alabama at Birmingham, Birmingham, AL; 4Medicine, Yale School of Medicine, New Haven, CT; 2Surgery, University of Michigan, Ann Arbor, MI.


10:30 AM – NOON CONCURRENT SESSION 2: Prediction and Management of Complications After Heart Transplantation (Sapphire AE)

CHAIRS: Howard J. Eisen, MD and Vivek Rao, MD, PhD


10:45 AM (11) Coronary Angioplasty/Stents for Cardiac Allograft Vasculopathy Does Not Alter Outcome for Heart Transplant Patients with ISHLT CAV2 or CAV3 Disease; J. Patel, B. Azarbal, M. Kittleson, M. Kawano, Z. Goldstein, M. Rafiei, A. Moradzadeh, L. Czer, R. Kass, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.

**10:30 AM – NOON CONCURRENT SESSION 5: Update on Pathological Diagnosis of AMR in Heart Transplant (Indigo 202)**

**CHAIRS:** Michael C. Fishbein, MD and Claus B. Andersen, MD, D.M.Sc

**10:30 AM (28)** Performance of Routine C4d and C3d Immunostaining on Protocol EMBs in a Prospective and Unselected Cohort of Heart Transplant Patients; A. Loupy, A. Cazes,1 R. Guillemain,2 C. Suberbielle,3 M. Tible,1 C. Amrein,1 J.-N. Fabiani,3 G.S. Hill,1 D. Nochy,1 P. Bruneval,1,4 J.-P. Duong Van Huyen.1,4,5 1Service d’Anatomie Pathologique, Hôpital Européen Georges Pompidou, Paris, France; 2Service de Chirurgie Cardiaque, Hôpital Européen Georges Pompidou, Paris, France; 3Laboratoire d’Histocompatibilité, Hôpital Saint-Louis, Paris, France; 4INSERM UMR 970, PARCC Centre de Recherche Cardiovasculaire, Hôpital Européen Georges Pompidou, Paris, France; 5Faculté de Médecine Paris Descartes, Paris, France.

**10:45 AM (29)** Inter-Observer Variation in Grading Capillary C4d Deposition in Cardiac Allograft Biopsies – A Single-Centre Study; A. Rice,1 B. Mitchelson,1 W. Banya,2 N. Banner,1 M. Burke.1 1Department of Histopathology and Transplant Unit, Royal Brompton and Harefield NHS Trust, Harefield, United Kingdom; 2Department of Medical Statistics, Royal Brompton and Harefield NHS Trust, London, United Kingdom.

**11:00 AM (30)** Does the Detection of Circulating Donor-Specific Antibody Impact Pathology Diagnosed Antibody-Mediated Rejection Outcome After Heart Transplant?; M. Kittleson,1 M. Kawano,2 Z. Goldstein,1 M. Rafiei,1 B. Azarbal,1 J. Moriguchi,1 A. Hage,1 N. Reinsmoen,1 E. Reed,2 D. Luthringer,1 F. Esmailian,1 J. Kobashigawa.1 1Cedars-Sinai Heart Institute, Los Angeles, CA; 2University of California Los Angeles, Los Angeles, CA.

**11:15 AM (31)** Value of Immunoperoxidase Staining of C3d in the Diagnosis of Antibody-Mediated Rejection in Heart Transplant Recipients; M. Fedrigo,1 A. Gambino,2 E. Benazzi,3 F. Poli,3 A.C. Frigo,4 F. Tona,2 A. Caforio,2 C. Castellani,1 G. Toscano,2 G. Feltrin,2 G. Gerosa,2 G. Thieme,1 A. Angelini.1 1Dpt of Medico-Diagnostic Science and Special Therapies, Pathology Institute, University of Padua, Padua, Italy; 2Dpt of Cardiac, Thoracic and Vascular Science, University of Padua, Padua, Italy; 3Dpt of Regenerative Medicine Transplant Immunology, IRCCS, Milan, Italy; 4Dpt Environmental Medicine and Public Health, University of Padua, Padua, Italy.

**11:30 AM (32)** Microvessel Density in Cardiac Allograft Biopsies of Patients with Clinically Significant Coronary Allograft Vasculopathy; M.P. Revejo,1 D. Budge,1 D.V. Miller,1 K.D. Brunisholz,1 T.L. Bair,1 M.E.H. Hammond,1 G.L. Snow,1 J. Stahlk,1 E.M. Gilbert,1 M.D. Everitt,1 R.A. Alharethi,1 A.G. Kfoury.1 1UTHA Cardiac Transplant Program, Salt Lake City, UT; 2Salt Lake City, UT; 3Salt Lake City, UT.

**11:45 AM (33)** Serial Phenotyping Identifies Circulating B Cell Signatures within Six Months of Cardiac Transplantation; E.L. Moseley,1 M.J. Goddard,1 A.R. Exley,1 J. Wallwork,3 C. Atkinson.3 1Department of Pathology, Papworth Hospital NHS Trust, Cambridge, United Kingdom; 2Research and Development Unit, Papworth Hospital NHS Trust, Cambridge, United Kingdom; 3Department of Pathology, Cambridge, UK.
SCIENTIFIC PROGRAM

Papworth Hospital NHS Trust, Cambridge, United Kingdom; *Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC.

NOON – 12:30 PM
Box Lunch Pick-Up (ticket required) (Indigo Ballroom)

12:15 PM – 1:45 PM
MID-DAY SYMPOSIUM 1: Pushing the Limits for Thoracic Organ Transplantation (Sapphire AE)

CHAIRS: James B. Young, MD and John B. O’Connell, MD

12:15 PM When is Obesity a Contra-Indication? Michael M. Givertz, MD, Brigham & Women’s Hospital, Boston, Massachusetts

12:26 PM When is History of Drug Abuse a Contra-Indication? Susan E. Abbey, MD, FRCPC, University Health Network, Toronto, Canada

12:37 PM How Much Alcohol is a Contra-Indication? Luciano Potena, MD, PhD, University of Bologna, Bologna, Italy

12:48 PM Infectious Disease: Is Hepatitis A Contra-Indication? Jeffrey J. Teuteberg, MD, University of Pittsburgh/Presbyterian Hospital, Pittsburgh, Pennsylvania

12:59 PM Can Patients with HIV Have a Transplant? Margaret M. Hannan, MD, Mater Hospital, Dublin, Ireland

1:10 PM When was the Last Cigarette? Savitri E. Fedson, MD, University of Chicago Hospitals, Chicago, Illinois

1:21 PM The Loner, Michael G. Petty, PhD(c), RN, CCNS,CNS, University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota

1:32 PM The Non-Compliant, Kathleen L. Grady, PhD, APN, FAAN, Northwestern Memorial Hospital, Chicago, Illinois

12:15 PM – 1:45 PM
MID-DAY SYMPOSIUM 2: The Failing Right Ventricle: Mechanisms and Management (Sapphire IM)

CHAIRS: Evelyn Horn, MD and Teresa De Marco, MD

12:15 PM Physiology of Primary and Secondary RV Failure: Mechanistic Implications for Diagnostic Testing, Therapeutic Selection, and Outcome Prediction, Thomas DiSalvo, MD, Vanderbilt University, Nashville, Tennessee

12:35 PM Management of Patients with PH and RV Failure Undergoing Anesthesia for Extrathoracic Surgical Procedures: Approaches to Avoid – or Manage – Cardiogenic Shock, Dana McGlothlin, MD, University of California, San Francisco, California

12:55 PM Peri-Operative Management of Patients with Right Ventricular Failure Undergoing Heart or Lung Transplantation or LVAD Implantation: Medical and Surgical Tricks-of-the-Trade, Srinivas Murali, MD, Allegheny General Hospital, Pittsburgh, Pennsylvania

1:15 PM Emerging Therapies to Treat Pulmonary Hypertension and Right Ventricular Failure: Gene Therapy, Pharmacologic Agents, and Mechanical Devices, Mardi Gomberg-Maitland, MD, University of Chicago, Chicago, Illinois

1:35 PM Panel Discussion/Q&A

12:15 PM – 1:45 PM
MID-DAY SYMPOSIUM 3: Immunological Aspects of Engineered Heart Tissue and Cellular Replacement Therapies in Heart Failure (Indigo 202)

CHAIRS: Doris A. Taylor, PhD and Sonja Schrepfer, MD, PhD

12:15 PM Update on Engineered Heart Tissue, Lenard Conradi, MD, University Medical Center, Hamburg, Germany

12:35 PM Augmenting Cardiomyocyte Proliferation in the Failing Heart, Loren J. Field, PhD, Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN

12:55 PM Immunological Aspects of Stem-Cell Based Therapeutic Approaches, Stefan Janssens, MD, PhD, Vesalius Research Center, University of Leuven, Leuven, Belgium

1:15 PM Panel Discussion/Q&A

12:15 PM – 1:45 PM
MID-DAY SYMPOSIUM 4: Update on Pediatric MCS Therapy (Indigo 202)

CHAIRS: Elizabeth Blume, MD and Roland Hetzer, MD, PhD

12:15 PM Anatomy and Physiology in Congenital Heart Disease Complicating MCS Device Implant, Eric Devaney, MD, University of Michigan, Ann Arbor, Michigan

12:35 PM Current Device Options for Pediatric Patients and Implantation Techniques for the Single Ventricle, Michael Hubler, MD, German Heart Institute, Berlin, Germany

12:55 PM Update on the North American Berlin Heart Pediatric Excor® Experience, Holger W. Buchholz, MD, University of Alberta Hospital, Edmonton, Canada

1:15 PM Update on the NIH PumpKIN Trial, Bartley P. Griffith, MD, University of Maryland, Baltimore, Maryland

1:35 PM Panel Discussion/Q&A

12:15 PM – 1:45 PM
JHLT EDITORIAL BOARD MEETING/LUNCH (Sapphire 400)

2:00 PM – 3:30 PM
CONCURRENT SESSION 6: VADs – Think Right Before Left (Sapphire BC)

CHAIRS: Jaap Lahpor, MD, PhD and Benjamin C. Sun, MD


Continuous Flow Ventricular Assist Devices Improve Functional Tricuspid Regurgitation and Right Ventricular Function; P. Atluri, 1 B.W. Ullery, 1 J.W. MacArthur, 1 E.D. Kozin, 1 W. Hiesinger, 1 J.P. Donnelly, 1 M.A. Acker, 1 J.E. Rame, 2 Y.J. Woo, 3
1Division of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA; 2Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA.

Tricuspid Valve Insufficiency in Patients with Axial-Flow Left Ventricular Assist Devices; S. Maltais, 1 S.H. McKellar, 1 T. Hasin, 2 Y. Topilsky, 2 R. Tsutsui, 2 L.D. Joyce, 2 R.C. Daly, 2 S.S. Kushwaha, 2 S.J. Park. 1 Cardiothoracic Surgery, Mayo Clinic, Rochester, MN; 2Cardiology (Medicine), Mayo Clinic, Rochester, MN.


Predictability of Postoperative Right Ventricular Function Before Left Ventricular Assist Device Implantation; M. Dandel, 1 A. Stepanenko, 1 E. Potapov, 1 T. Krabatsch, 1 C. Knosalla, 1 H.B. Lehmkuhl, 1 R. Hetzer. Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany.


The Effects of Moderate Strength Pre-Transplant Circulating Antibodies on Outcome After Heart Transplantation; J. Patel, 1 M. Kittleson, 1 M. Kawano, 1 Z. Goldstein, 1 E. Stimpson, 1 J. Rush, 1 M. Raffel, 1 N. Reinsmoen, 1 E. Reed, 2 M. Hamilton, 1 A. Trento, 1 J. Kobashigawa. 1 Cedars-Sinai Heart Institute, Los Angeles, CA; 2University of California, Los Angeles, Los Angeles, CA; 3University of Pennsylvania, Philadelphia, PA.

The Importance of Low-Titer Anti-HLA Antibodies in Cardiac Transplantation; G.F. Egnacycz, 1 D.-F. Chen, 1 C.B. Patel, 1 K.R. White, 1 G.M. Felker, 1 P. Rosenberg, 1 A.F. Hernandez, 1 C.A. Milano, 1 J.G. Rogers. 1Division of Cardiology, Duke University Medical Center, Durham, NC; 2Division of Pathology, Duke University Medical Center, Durham, NC; 3Division of Cardiothoracic Surgery, Duke University Medical Center, Durham, NC.


Timing of the Development of Donor Specific Antibody After Heart Transplantation Impacts Long-Term Outcome; M. Kittleson, 1 J. Patel, 1 M. Kawano, 1 Z. Goldstein, 1 M. Raffel, 1 N. Reinsmoen, 1 E. Reed, 2 A. Hage, 1 E. Schwarz, 1 F. Esmailian, 1 J. Kobashigawa. 1 Cedars-Sinai Heart Institute, Los Angeles, CA; 2University of California, Los Angeles, Los Angeles, CA.

Antibody-Mediated Rejection in Heart Transplantation: Clinical Follow-Up; S.E. Fedson, 1 M.K. Mizra, 2 Y. Chi, 2 A.N. Husain. 1 Medicine, Univ of Chicago, Chicago, IL; 2Pathology, University of Chicago, Chicago, IL.


Predictability of Postoperative Right Ventricular Function Before Left Ventricular Assist Device Implantation; M. Dandel, 1 A. Stepanenko, 1 E. Potapov, 1 T. Krabatsch, 1 C. Knosalla, 1 H.B. Lehmkuhl, 1 R. Hetzer. Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany.


The Effects of Moderate Strength Pre-Transplant Circulating Antibodies on Outcome After Heart Transplantation; J. Patel, 1 M. Kittleson, 1 M. Kawano, 1 Z. Goldstein, 1 E. Stimpson, 1 J. Rush, 1 M. Raffel, 1 N. Reinsmoen, 1 E. Reed, 2 M. Hamilton, 1 A. Trento, 1 J. Kobashigawa. 1 Cedars-Sinai Heart Institute, Los Angeles, CA; 2University of California, Los Angeles, Los Angeles, CA; 3University of Pennsylvania, Philadelphia, PA.

The Importance of Low-Titer Anti-HLA Antibodies in Cardiac Transplantation; G.F. Egnacycz, 1 D.-F. Chen, 1 C.B. Patel, 1 K.R. White, 1 G.M. Felker, 1 P. Rosenberg, 1 A.F. Hernandez, 1 C.A. Milano, 1 J.G. Rogers. 1Division of Cardiology, Duke University Medical Center, Durham, NC; 2Division of Pathology, Duke University Medical Center, Durham, NC; 3Division of Cardiothoracic Surgery, Duke University Medical Center, Durham, NC.


Timing of the Development of Donor Specific Antibody After Heart Transplantation Impacts Long-Term Outcome; M. Kittleson, 1 J. Patel, 1 M. Kawano, 1 Z. Goldstein, 1 M. Raffel, 1 N. Reinsmoen, 1 E. Reed, 2 A. Hage, 1 E. Schwarz, 1 F. Esmailian, 1 J. Kobashigawa. 1 Cedars-Sinai Heart Institute, Los Angeles, CA; 2University of California, Los Angeles, Los Angeles, CA.

Antibody-Mediated Rejection in Heart Transplantation: Clinical Follow-Up; S.E. Fedson, 1 M.K. Mizra, 2 Y. Chi, 2 A.N. Husain. 1 Medicine, Univ of Chicago, Chicago, IL; 2Pathology, University of Chicago, Chicago, IL.
Cantu,1 S. Palmer,4 A. Weinacker,8 S. Bhorade,4 V. Lama,9 J. Orens,7 J. Sonett,2 K. Wille,8 M. Crespo,4 D. Weill,7 B. Kohl,1 C. Deutschman,1 S. Arcasoy,2 A. Shah,7 P.D. Shah,8 E.I. Demisse,1 J. Reynolds,1 J. Belpiero,12 D. Wilkes,12 L. Ware,16 J.D. Christie,1 1University of Pennsylvania, Philadelphia, PA; 2Columbia University, New York; 3Duke University, Durham; 4University of Chicago, Chicago; 5University of Michigan at Ann Arbor, Ann Arbor; 6Stanford University, Stanford; 7Johns Hopkins University, Baltimore; 8University of Alabama at Birmingham, Birmingham; 9UPMC Montefiore Hospital-NW628, Pittsburgh; 10Vanderbilt University, Nashville; 11Clarion Transplant -Methodist Campus, Indianapolis; 12UCLA, Los Angeles; 13IUPUI, Indianapolis.

3:00 PM (50) VE-Cadherin Is Associated with Primary Graft Dysfunction in Lung Transplant Recipients; S. Aharinejad, M. Salama, S. Taghavi, M.A.R. Hoda, W. Klepetko. Cardiothoracic Surgery, Medical University of Vienna, Vienna, Austria.


2:00 PM – 3:30 PM CONCURRENT SESSION 9: Clinical Immunosuppression – TOR Inhibitors (Sapphire IM)

Chairs: Roelof A. De Weger, PhD and Simon Urschel, MD

2:00 PM (52) Reduction of Cardiac Allograft Vasculopathy with Everolimus over Mycophenolate Mofetil: Intravascular Ultrasound Results of a Randomized Multicenter Trial; J. Kobashigawa,1 D. Pauly,4 H. Ross,9 S. Wang,4 B. Cantin,4 J. Burton,6 A. Keogh,7 H. Eisen,8 P. Lopez,5 G. Dong,10 H. Jiang,10 M. Cines,10 R. Starling.11 1Heart Transplant Program, Cedars-Sinai Heart Institute, Los Angeles, CA; 2Division of Cardiovascular Medicine, University of Florida College of Medicine, Florida; 3Department of Cardiology/Heart Transplant, University Health Network, Toronto General Hospital, Toronto, Canada; 4Division of Cardiovascular Surgery, National Taiwan University, Taipei, Taiwan; 5Lipid Research Centre, Laval University Medical Centre and Faculty of Medicine, Quebec, Canada; 6Department of Medicine, University of Alberta Hospital, Edmonton, Canada; 7Heart and Lung Transplant Unit, St Vincents Hospital, Darlinghurst, Australia; 8Division of Cardiology, Drexel University College of Medicine, Philadelphia; 9Novartis Pharma AG, Basel, Switzerland; 10Novartis Pharmaceuticals Corporation, East Hanover; 11Heart Failure Center, Cleveland Clinic Foundation, Cleveland.

2:15 PM (53) Everolimus Introduction and Calcineurin Reduction in Thoracic Transplant Recipients with Advanced Chronic Renal Failure; S. Arora,1 B. Rundqvist,7 S.-A. Mortensen,3 H. Eisikjaer,6 G. Riise,2 L. Mared,4 O. Bjertuft,1 B. Ekmehag,4 K. Janson,2 S. Simonsen,1 E. Gude,7 D. Solbu,4 M. Iversen,2 L. Gullestad.1 1Oslo University Hospital Rikshospitalet, Oslo, Norway; 2Sahlgrenska University Hospital, Gothenburg, Sweden; 3Sk另一半 University Hospital, Aarhus, Denmark; 4Lund Hospital, Lund, Denmark; 5Heart Center University Hospital, Linkoping, Sweden; 6Novartis Norge, Oslo, Norway.


2:45 PM (55) Everolimus with Reduced CsA vs MMF with Standard CsA Exposure in De Novo Heart Transplant Recipients: 12 Month Efficacy and Safety Analysis; H. Eisen,8 D. Pauly,4 R. Starling,7 H. Lehmkuhl,4 H. Ross,9 A. Kfoury,4 S. Wang,4 B. Cantin,4 A. Van Bakel,9 A. Zuckermann,10 P. Lopez,5 G. Dong,10 C. Panis,12 H. Jiang,12 C. Cornu-Arnts,1 J. Kobashigawa,13 Division of Cardiology, Drexel University College of Medicine, Philadelphia; 14Division of Cardiovascular Medicine, University of Florida College of Medicine, Florida; 15Heart Failure Centre, Cleveland Clinic Foundation, Cleveland; 16Deutsches Herzzentrum Berlin, Berlin, Germany; 17Department of Cardiology/Heart Transplant, University Health Network, Toronto General Hospital, Toronto, Canada; 18Intermountain Medical Center, Murray; 19Division of Cardiovascular Surgery, National Taiwan University, Taipei, Taiwan; 20Lipid Research Centre, Laval University Medical Centre and Faculty of Medicine, Quebec, Canada; 21Medical University of South Carolina, Charleston; 22Department of Cardiothoracic Surgery, University of Vienna, Vienna, Austria; 23Novartis Pharma AG, Basel, Switzerland; 24Novartis Pharmaceuticals Corporation, East Hanover; 25Heart Transplant Program, Cedars-Sinai Heart Institute, Los Angeles, CA.

3:00 PM (56) Safety and Efficacy of Conversion to Sirolimus vs Continued Calcineurin Inhibitor Use in Cardiac Transplant Recipients with Renal Insufficiency; A. Zuckermann,10 A. Keogh,7 M.G. Crespo-Leiro,4 D. Mancini,4 F. Gonzalez Vilchez,5 L. Almenat,9 E. Eisen,9 S. See Tai,8 S. Kushwaha,8 AKH Wien, Vienna, Austria; 2St. Vincent’s Hospital, Darlinghurst, Sydney, NSW, Azerbaijan; 3Hospital Universitario A Coruña, La Coruña, Spain; 4Columbia University Medical Center, New York, NY; 5Hospital Marques de Valdecilla, Santander Catabria, Spain; 6Hospital La Fe, Valencia, Spain; 7University of Pennsylvania, Philadelphia, PA; 8Wyeth Pharmaceuticals (acquired by Pfizer Inc), Collegeville, PA; 9Mayo Clinic Rochester, Rochester, MN; 10Medical University of Vienna, Vienna, Austria.

3:15 PM (57) Heart Transplant Recipients Treated with Everolimus Have Less Increase in Intimal Thickness vs MMF, Irrespective of Lipid Values; D. Pauly,1 R. Starling,7 J. Kobashigawa,3 S. Wang,4 B. Cantin,4 A. Keogh,7 H. Lehmkuhl,4 S. Hirt,4 P. Lopez,5 G. Dong,10 M. Cines,10 H. Jiang,10 E. Eisen.11 Division of Cardiovascular Medicine, University of Florida College of Medicine, Florida; 2Heart Failure Center, Cleveland Clinic Foundation, Cleveland; 3Heart Transplant Program, Cedars-Sinai Heart Institute, Los Angeles, CA; 4Division of Cardiovascular Surgery, National Taiwan University, Taipei, Taiwan; 5Lipid Research Centre, Laval University Medical Centre and Faculty of Medicine, Quebec, Canada; 6Heart and Lung Transplant Unit, St Vincents Hospital, Darlinghurst, Australia; 7Deutsches Herzzentrum Berlin, Berlin, Germany; 8Universitaetsklinikum Regensburg, Regensburg, Germany; 9Novartis Pharma AG, Basel, Switzerland; 10Novartis Pharmaceuticals Corporation, East Hanover; 11Division of Cardiology, Drexel University College of Medicine, Philadelphia.
2:00 PM – 3:30 PM

**CONCURRENT SESSION 10:** What You Can’t Control – External Factors Impacting Patient Outcomes in Thoracic Transplant

**CHAIRS:** Bronwyn J. Levvey, RN Grad Dip Clin Ep and Katherine Hoercher, RN

**2:00 PM (58) Sorting Out the Intricacies of Multiplicity Risk on Outcomes After Heart Transplantation:** E. Stimpson, L. Piponniau, J. Patel, A. Velleca, M. Kawano, Z. Goldstein, M. Rafiei, N. Reinsmoen, L. Czer, F. Esmaillian, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA; University of California Los Angeles, Los Angeles, CA.


**2:30 PM (60) The Life of the Octogenarian Heart Transplant Patient:** D. Lockhart, L. Piponniau, A. Velleca, J. Patel, M. Kittleson, B. Kearney, T. Kao, M. Johnson, M. Kawano, Z. Goldstein, M. Rafiei, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA; University of California Los Angeles, Los Angeles, CA.

**2:45 PM (61) The Association Between Poor Socioeconomic Status and Poor Long-Term Outcomes Following Heart Transplantation:** R.R. Davies, S.K. Singh, M.J. Russo, R.C. Robbins, P.E. Oyer, H.R. Mallidi. Cardiothoracic Surgery, Stamford University, Palo Alto, CA; Surgery (Cardiothoracic), University of Chicago, Chicago, IL.

**3:00 PM (62) Barriers to Optimal Palliative Care of Lung Transplant Candidates:** R.E. Colman, R. Curtis, J. Nelson, J. Barkley, A. Beal, J. Edelman, L. Effrein, D. Hadjiladi, D.J. Levine, K. Meyer, M. Padilla, M. Strek, B. Varkey, K. Wille, L.G. Singer. Department of Medicine, University of Toronto, Toronto, ON, Canada; Division of Pulmonary and Critical Care Medicine, Harborview Medical Center; University of Washington, Seattle, WA; Department of Medicine, Hertzberg Palliative Care Institute, Mount Sinai School of Medicine, New York, NY; Division of Pulmonary and Critical Care Medicine, VA New York Harbor Healthcare System, New York, NY; Department of Medicine, Hofstra North Shore-LIJ School of Medicine, Hempstead, NY; Division of Pulmonary and Critical Care Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA; Division of Pulmonary and Critical Care Medicine and CT Surgery, University of Texas Health Center, San Antonio, TX; Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI; Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Chicago, Chicago, IL; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI; Department of Medicine, University of Alabama at Birmingham, Birmingham, AL; Carolinas Healthcare System, Charlotte, NC; Department of Medicine, University of Washington Medical Center, Seattle, WA; Department of Medicine, Mount Sinai School of Medicine, New York, NY.

**3:15 PM (63) Donor Quality of Life in Living-Donor Lobar Lung Transplantation:** M. Nishioka, C. Yokoyama, M. Inoue, Y. Yamada, C. Suzuki, M. Iwasaki, N. Sunami, T. Oto. Lung Transplant Unit, Okayama University Hospital, Okayama, Japan.

**2:00 PM – 3:30 PM

**CONCURRENT SESSION 11:** Tissue Engineering and Cell Transplantation (Indigo 202)

**CHAIRS:** Bartley P. Griffith, MD and Esme Dijke, PhD

**2:00 PM (64) Controlled Angiogenesis in the Heart:** L.F. Melly, A. Marsano, U. Helmrich, M. Heberer, F. Eckstein, T.P. Carrel, N. Giraud-Flück, H.T. Tevaearai, A. Banfi. Cell and Gene Therapy, University Hospital, Basel, Switzerland; Clinic for Cardiac Surgery, University Hospital, Basel, Switzerland; Laboratory for Cardiovascular Research, Inselspital, Berne, Switzerland.

**2:15 PM (65) Magnetic Resonance Imaging and Bioluminescence Signal Assessment for Evaluation of Biodistribution, Vitality and Proliferation of Induced Pluripotent Stem Cells (iPS) Following Transplantation in Heart Failure:** S.V. Rojas, M. Meier, A. Martens, H. Baraki, N. Schecket, C. Rathert, R. Zweigerdt, U. Martin, A. Haverich, K. Ingo. Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany; Central Animal Laboratory, Hannover Medical School, Hannover, Germany; Leibniz Research Laboratories for Biotechnology and Artificial Organs, Hannover Medical School, Hannover, Germany.

**2:30 PM (66) Fabrication of Engineered Pulsatile 3-Dimensional Scaffold-Free Cardiac Tissue from Embryonic Stem Cells:** R. Noguchi, K. Nakayama, K. Ishihara, Y. Murata, K. Node, S. Morita, Thoracic and Cardiovascular Surgery, Saga University, Saga City, Japan; Biomedical Engineering Course Advanced Technology, Fusion Graduate School of Science and Engineering, Saga University, Saga City, Japan; Physics, Division of Organ and Cell Physiology, Saga University, Saga City, Japan; Histology, Division of Anatomy and Physiology, Saga University, Saga City, Japan; Cardiovascular and Renal Medicine, Saga University, Saga City, Japan.

**2:45 PM (67) Myoblast Sheet Implantation Can Prevent the Impairment of Diabetic Diastolic Function After Left Ventricular Restoration by Modulating the Extracellular Matrix Gene Expression:** N. Schecker, U. Helmrich, F. Eckstein, K. Ingo. Department of Cardiothoracic Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany; Central Animal Laboratory, Hannover Medical School, Hannover, Germany.

**3:00 PM (68) Liver Dysfunction Predicts Adverse Long-Term Outcome After Stem Cell Transplantation in Dilated Cardiomyopathy:** B. Vrtovec, P. Mojsilovic, D. Domanovic, M. Sever, L. Lezac, M. Sebestjen, V. Androvec, G. Torre-Amione. Advanced Heart Failure and Transplantation Programme, UMC Ljubljana, Ljubljana, Slovenia; National Blood Transfusion Center, Ljubljana, Slovenia; Cardiovascular Medicine, Stanford University School of Medicine, Palo Alto; DeBakey Heart Center, Houston, TX.

**3:15 PM (69) Intracoronary Autologous Peripheral Stem Cell Therapy: A Promising Treatment for Heart Failure in Pediatric Dilated Cardiomyopathy:** J.J. Menendez, J. Rivas, L. Guerra, F. Gutierrez-Larraya, R. Arrieta, L. Romero, R. Alvarado-Doforno, A. Gonzalez. Pediatric Intensive Care Unit, Hospital Universitario La Paz, Madrid, Spain; Pediatric Cardiology, Hospital Universitario La Paz, Madrid, Spain; Haematology, Cell
3:30 PM – 4:00 PM
COFFEE BREAK (Indigo Ballroom)

POSTER VIEWING/POSTER PRESENTER Q&A
(Indigo Ballroom and Indigo Foyer)

4:00 PM – 5:30 PM
CONCURRENT SESSION 12: VADs Shift the Paradigm: From Cold and Wet to Warm and Dry (Sapphire BC)

CHAIRS: Katherine Lietz, MD, PhD and Tobias Deuse, MD, PhD

4:00 PM
(70) The HeartMate II Risk Score: Predicting Survival in Candidates for Left Ventricular Assist Device Support; J. Cowger,1 K. Sundareswaran,2 J.G. Rogers,2 S.J. Park,2 F.D. Paganini,2 G. Bhat,2 B. Jaski,2 D.J. Farrar,2 M.S. Slaught2;1 University of Michigan Health System, Ann Arbor, MI; 2Duke University Medical Center, Durham, NC; 1Mayo Clinic, Rochester, MN; 2Thoratec Corporation, Pleasanton, CA; 1Duke University Medical Center, Durham, NC; 1Mayo Clinic- Arizona Campus, Scottsdale, AZ.

4:15 PM
(71) Application of the Destination Therapy Risk Score to HeartMate II Clinical Trial Data; J.J. Teuteberg,1 G. Ewald,2 R. Adamson,2 K. Lietz,4 L. Miller,4 A. Tatooles,4 R.L. Kormos,3 K. Sundareswaran,2 D. Farrar,2 J. Rogers,2 Cardiovascular Institute, University of Pittsburgh, Pittsburgh, PA; 2Cardiology, Washington University, St Louis, MO; 3Cardiovascular Surgery, Sharp Memorial, San Diego, CA; 4Cardiology, Yale University, New Haven, CT; 5Cardiovascular Medicine, University of South Florida, Tampa, FL; 6Cardiovascular Surgery, Advocate Christ Medical Center, Oak Lawn, IL; 7Heart, Lung, Esophageal Surgery Institute, University of Pittsburgh, Pittsburgh, PA; 8Thoratec Corporation, Pleasanton, CA; 9Cardiology, Duke University, Durham, NC.

4:30 PM
(72) Degree of End Organ Damage as a Predictor of Outcomes After Mechanical Circulatory Support Device Implantation – A More Quantitative Assessment; K. Shahzad,3 Q. Li,3 H. Akashi,4 M. Cadeiras,5 T.S. Kato,3 H. Takayama,2 Y. Naka,5 M.C. Deng,5 1Department of Medicine, Columbia University Medical Center, New York, NY; 2Department of Surgery, Columbia University Medical Center, New York, NY; 3Department of Medicine, University of Alabama Birmingham, Birmingham, AL.

4:45 PM
(73) Patients with Low Compared to High Body Mass Index Gain More Weight After Continuous Flow LVAD Implant; C.B. Sai-Sudhakar,1 R.J. Brewer,2 S. Emami,3 M.S. Slaughter,4 Y. Ravi,1 K. Sundareswaran,4 D.J. Farrar,4 R. John,6 Surgery, Ohio State University Medical Center, Columbus, OH; 6Cardiac Surgery, Henry Ford Hospital, Detroit, MI; 3Medicine, Ohio State University Medical Center, Columbus, OH; 4Surgery, University of Louisville Medical Center, Louisville, KY; 6Thoratec Corporation, Pleasanton, CA; 1Surgery, University of Minnesota Medical Center, Minneapolis, MN.

5:00 PM
(74) Pre- and Post-Operative Risk Factors Associated with Neurological Complications in Patients Supported by Ventricular Assist Device; T.S. Kato,2 L. Chan,2 J. Yang,2 H. Akashi,3 K. Shahzad,3 M. Deng,4 N. Uriel,5 P. Colombo,1 M. Farr,1 C.P. Schulze,1 H. Takayama,2 Y. Naka,5 U. Jorde,1 D. Mancini,1 Department of Medicine, Division of Cardiology, Columbia University Medical Center, New York, NY; 3Department of Surgery, Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY.

5:15 PM
(75) Does the “Obesity Paradox” in Chronic Heart Failure Fade After Mechanical Circulatory Support with Continuous Flow Devices: Analysis from the Interagency Registry for Mechanically Assisted Circulatory Support; J.P. Donnelly,1 Y.J. Woo,1 R.J. Morris,1 L.R. Goldberg,1 J.W. Wald,1 P. Atluri,1 M.L. O’Hara,1 K.A. Breuer,1 J.F. Marble,1 N.Y. Avraham,2 F.A. Arabia,2 J.G. Rogers,2 M.A. Acker,1 J.E. Rame,1 Hospital of the University of Pennsylvania, Philadelphia, PA; 2Abington Memorial Hospital, Abington, PA; 3New York Presbyterian- Weill Cornell Medical Center, New York, NY; 4Duke University Medical Center, Durham, NC; 5Mayo Clinic- Arizona Campus, Scottsdale, AZ.

4:00 PM – 5:30 PM
CONCURRENT SESSION 13: Immunosuppression and Immune Surveillance (Sapphire D)

CHAIRS: Josef Stehlik, MD, MPH and Andreas O. Zuckermann, MD

4:00 PM
(76) Everolimus for the Prevention of Microvasculopathy in Biopsy: Final Results from Re-Evaluation of the RAD B253 Trial; N.E. Hiemann,1 G. Bhat,2 B. Kastrup,2 J. Segovia,3 J.L. Parshuram,4 S. Simonsen,5 M. Crespo-Leiro,6 H. Eiskjaer,7 J. Vanhaecke,7 J.M. Arizon,4 A. Poncelet,9 A. Ragnarsson,1 H. Eiskjaer,6 J.F. Marble,1 N.E. Hiemann,1 K.A. Breuer,1 J.F. Marble,1 N.E. Hiemann,1 S. Emani,1 R.J. Brewer,1 M.S. Slaughter,1 K. Sunderswaran,2 R.J. Morris,1 L. Miller,6 1Hospital of the University, St Louis, MO; 2Cardiology, Columbia University Medical Center, New York, NY; 3Hospital Universitario Reina Sofia, Cordoba, Spain; 4Mayo Clinic, Scottsdale, Arizona; 5Hospital Universitario de Granada, Granada, Spain; 9Cliniques Universitaires Saint-Luc, Brussels, Belgium; 7Medicinska Hochschule Hannover, Hannover, Germany; 8Hospital Puerta de Hierro Majadahonda, Madrid, Spain; 9Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom; 10Oslo University Hospital Rikshospitalet, Oslo, Norway; 11Hospital Universitario Juan Canalejo, La Coruña, Spain; 12Aarhus University Hospital, Skejby, Denmark; 13University Hospital Gasthuisberg, Leuven, Belgium; 14Hospital Universitario Reina Sofia, Córdoba, Spain; 15Cliniques Universitaires Saint-Luc, Brussels, Belgium; 16John Paul II Hospital, Krakow, Poland; 17Az. Ospedaliera Ospedali Niguarda Ca’ Granda, Milan, Italy.

4:15 PM
(77) Effect of Everolimus Introduction and Calcineurin Inhibitor Reduction on Cardiac Allograft Vasculopathy Assessed by Virtual Histology; S. Ariño,1 I. Erikkstad,2 B. Wenerblom,2 V. Sigurdardottir,3 H. Eiskjaer,7 H. Bøtter,7 S.-A. Mortensen,8 K. Saunameki,4 B. Ekmeheag,9 K. Jansson,4 S. Simonsen,1 E. Gude,1 A. Ragnarsson,1 D. Solbu,1 L. Gullstad,1 Oslo University Hospital Rikshospitalet, Oslo, Norway; 2Sahlgrenska University Hospital, Gothenburg, Sweden; 3Skeiby University Hospital, Aarhus, Denmark; 4Rigshospitalet, Copenhagen, Denmark; 5Lund Hospital, Lund, Sweden; 6Heart Center University Hospital, Linkoping, Sweden; 7Novartis Norge, Oslo, Norway.
4:30 PM  (78) Do Longitudinal Stable Lower AlloMap® Scores Portend Better Outcomes After Heart Transplantation?; D. Budge, K.D. Brunisholz, H. Wolters, H.A. Valantine, M.X. Pham, J.T. Teuteberg, M.C. Deng, R.C. Starling, T.P. Cappola, A. Kao, A.S. Anderson, W.G. Cotts, G.A. Ewald, D.A. Baran, R.C. Bogaei, J. Yee, A.G. Kfoury. 1UTAH Cardiac Transplant Program at Intermountain Medical Center, Salt Lake City; 2Xdx, Inc., Brisbane; 3Stanford University Medical Center, Stanford; 4VA Palo Alto Health Care System, Palo Alto; 5University of Pittsburgh Medical Center, Pittsburgh; 6Columbia University Medical Center, New York; 7Cleveland Clinic, Cleveland; 8Hospital of the University of Pennsylvania, Philadelphia; 9Mid America Heart Institute, Saint Luke’s Hospital, Kansas City; 10University of Chicago Medical Center, Chicago; 11Northwestern University, Chicago; 12Washington University School of Medicine, St Louis; 13Newark Beth Israel Medical Center, Newark; 14Texas Heart Institute, Houston.

4:45 PM  (79) Routine Use of Surveillance Endomyocardial Biopsy (EMB) is Only Useful Within the Six Months Post-Transplant: Its Routine Use Thereafter Should be Abandoned; C.M. Orrego, A. Cordero-Reyes, J.D. Estep, G. Torre-Amione. 1The Methodist DeBakey Heart & Vascular Center, The Methodist Hospital, Houston, TX; 2Director General de Institutos y Centros Médicos del Tecnológico de Monterrey, Hospital San José, TEC de Monterrey, Monterrey, NL, Mexico.

5:00 PM  (80) Can Monotherapy After One Year Post-Transplant be Effective Without Increasing the Risk of Acute Cellular Rejection?; J. Patel, K. Choksey, L. Ahedor, S. Fietell, A. Hicks, T. Rowe, S. Hankins, H. Eisen. 1Division of Cardiology, Drexel University College of Medicine, Philadelphia, PA; 2Center for Advanced Heart Failure Care, Hahnemann University Hospital, Philadelphia, PA.

5:15 PM  (81) Early vs. Delayed EVERolimus in De Novo HEART Transplant Recipients; L. Potena, M. Rinaldi, C. Maiello, U. Livi, G. Gerosa, G. Faggian, C. Pellegrini, F. Musumeci, M. Frigerio, N. Marraudino, M. Porcu, A. Veneziano, M. Maccherini. 1U.O Cardiologia, Azienda Ospedaliera S.Orsola Malpighi, Bologna, Italy; 2Struttura complessa di Cardiochirurgia, Azienda Ospedaliera Molinette S. Giovanni Battista, Torino, Italy; 3U.O.C Chirurgia Cardiovascolare e Trapianti, Ospedale Monaldi, Napoli, Italy; 4SOC Chirurgia Cardiotoracica, Azienda Ospedaliero Universitaria S.Maria della Misericordia, Udine, Italy; 5U.O di Cardiochirurgia, Azienda Ospedaliera Universitaria di Padova, Padova, Italy; 6Divisione Clinica di Cardiochirurgia, Ospedale Civile Maggiore, Verona, Italy; 7U.O.C Cardiochirurgia, PoliClinico San Matteo, Pavia, Italy; 8UOC di Cardiochirurgia, Azienda Ospedaliera San Camillo Forlanini, Roma, Italy; 9Divisione di Cardiologia, Azienda Ospedaliera Niguarda Ca’Granda, Milano, Italy; 10U.O di Cardiochirurgia, PoliClinico di Bari, Bari, Italy; 11Struttura Complessa di Cardiologia, Azienda Ospedaliera G.Brotzu, Cagliari, Italy; 12Medical Department, Novartis Farma, Origgio (Varese), Italy; 13U.O.C di Cardiochirurgia dei Trapianti, Azienda Ospedaliera Universitaria Senese, Siena, Italy.

4:00 PM  (82) Antibody Directed Therapy for DSA Results in Diminished Autoimmune Response and Favorable Long-Term Outcome Following Human Lung Transplantation; V. Tiriveedhi, J. Weber, R. Hacheem, A. Aloush, D. Phelan, E. Trulock, B. Meyers, A. Patterson, T. Mohanakumar. 1Department of Surgery, Washington University School of Medicine, St Louis, MO; 2Department of Medicine, Washington University School of Medicine, St Louis, MO; 3UTAH Laboratory, Barnes-Jewish Hospital, St Louis, MO; 4Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO.

4:15 PM  (83) Detection of Class I Anti-HLA Antibodies by Luminex Pre-Transplant Predicts Poor Outcomes Following Lung Transplantation; G.P. Westall, L. Mitchell, B. Lewey, F. Hudson, L. Cantwell, G. Snell. 1Lung Transplant Unit, Alfred Hospital, Melbourne, VIC, Australia; 2Victorian Transplantation and Immunogenetics Service, Australian Red Cross Blood Service, Melbourne, VIC, Australia.

4:30 PM  (84) The Impact of Donor Specific HLA Antibodies in Lung Transplantation After Induction with Alemtuzumab; M.R. Morrell, K. Sphirty, C.J. Gries, M.M. Crespo, B. Johnson, J.M. Pilewski, Y. Toyoda, C.A. Bermudez, J.K. Bhamu, D. Zaldonis, A. Zeevi. 1Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA; 2Division of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA; 3Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA.

4:45 PM  (85) Antibody-Mediated Rejection After Lung Transplantation; R.R. Hachen, J.P. Ritter, R.D. Yusen, A.R. Wills, J.A. Iuppa, D. Byers, T. Mohanakumar, A. Patterson, E.P. Trulock. 1Pulmonary & Critical Care, Washington University School of Medicine, St Louis, MO; 2Pathology & Immunology, Washington University School of Medicine, St Louis, MO; 3Pharmacy, Barnes-Jewish Hospital, St Louis, MO; 4Surgery, Washington University School of Medicine, St Louis, MO; 5Cardiothoracic Surgery, Washington University School of Medicine, St Louis, MO.

5:00 PM  (86) Highly Sensitized Lung Transplant Recipients Have Equivalent Outcomes as Non-Sensitized Patients in the Post-LAS Era; T.J. George, G.J. Arnaoutakis, C.A. Merlo, J.V. Conte, A.S. Shah. 1The Division of Cardiac Surgery, The Johns Hopkins Medical Institutions, Baltimore, MD; 2The Division of Pulmonary and Critical Care Medicine, The Johns Hopkins Medical Institutions, Baltimore, MD.

5:15 PM  (87) The Impact of Pre-Formed Donor-Specific HLA Antibodies on Early Clinical Outcomes in Lung Transplant Recipients; K. Fujimoto, N. Shigemura, B. Sareyyupoglu, A. Bansal, K. Minakata, H. Shayan, T. Ota, J. Bham, P. Bonde, J. Thacker, C. Bermudez, D. Zaldonis, Y. Toyoda. 1Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA; 2Pathology, Surgery and Immunology, University of Pittsburgh, Pittsburgh, PA.
4:00 PM – 5:30 PM CONCURRENT SESSION 15: “Pumping Lung” (Sapphire IM)

CHAIRS: Martin Carby, FRCS (C-R) and Shaf Keshavjee, MD, FRCSI

4:00 PM (88) Clinical Ex-Vivo Lung Perfusion – Pushing the Limits; C. Aigner,1 A. Slama,1 K. Hötzenecker,1 B. Urbanek,2 W. Schmid,3 A. Scheed,1 G. Lang,1 S. Keshavjee,1 W. Klepetko.1 1Dept. of Thoracic Surgery, Medical University of Vienna, Vienna, Austria; 2Dept. of Anaesthesiology, Medical University of Vienna, Vienna, Austria; 3Dept. of Thoracic Surgery, Toronto General Hospital, Toronto, Canada.

4:15 PM (89) Early Outcomes of Bilateral Sequential Single Lung Transplantation After Ex-Vivo Lung Evaluation and Reconditioning; B. Zych,1 A.F. Popov,1 M. Carby,2 A.R. Simon,1 K.C. Redmond.1 1Department of Cardiothoracic Transplantation & Mechanical Support, Royal Brompton & Harefield Hospital, London, Harefield, United Kingdom; 2Respiratory Medicine, Royal Brompton & Harefield Hospital, London, Harefield, United Kingdom.

4:30 PM (90) Clinical Lung Transplantation After Ex-Vivo Evaluation of Uncontrolled Non-Heart-Beating Donors Lungs: Initial Experience; F.J. Moradiellos,1 J.M. Naranjo,1 M. Córdoba,1 C. Salas,2 D. Gómez,3 J.L. Campo-Cañaveral,1 S. Crowley,1 M. Valle,3 A. Varela de Ugarte.1 1Thoracic Surgery Department, Puerta de Hierro University Hospital, Madrid, Spain; 2Pathology Department, Puerta de Hierro University Hospital, Madrid, Spain; 3Pneumology Department, Puerta de Hierro University Hospital, Madrid, Spain.

4:45 PM (91) Reconditioning of Lungs from Non-Heart-Beating Donors with Normothermic Ex-Vivo Lung Perfusion; D. Nakajima,1 T. Yamada, F. Chen, J. Sakamoto, A. Ohsumi, T. Fujinaga, T. Shoji, H. Sakai, T. Bando, H. Date. Thoracic Surgery and Organ Preservation Technology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

5:00 PM (92) Donor Accidental Aspiration Injury – Can We Correct It by Ex-Vivo-Lung-Perfusion (EVLP)?; S. Wipper, A. Lüke, J. Sandte, J. Schirmer, H. Reichenspurner, F.M. Wagner. Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany.


4:00 PM – 5:30 PM CONCURRENT SESSION 16: Experimental Models of Cardiac Allograft Vasculopathy (Aqua 306)

CHAIRS: Agnes M. Azimzadeh, PhD and Marlene Rose, PhD

4:00 PM (94) Gamma Delta T-Cells Contribute to Acute and Chronic Allograft Rejection Via IL-17 Induced Inflammation in a Murine Heart Transplantation Model; N. Kimura,1 S. Nakae,2 S. Itoh,1 D.R. Merk,1 Y. Gong,1 X. Wang,1 B. Patiolla,1 E. Neophy- tou,1 P.A. Chang,1 R.C. Robbins,1 M.P. Fischbein.1 1Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA; 2Frontier Research Initiative, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.


4:30 PM (96) An Artificial Nanoemulsion Carrying Paclitaxel Decreases the Cardiac Allograft Vasculopathy. A Study in a Rabbit Graft Model; N.A.G. Stolf, E.R. Tavares, C. Contreras, R.C. Maranhão. Heart Institute University of Sao Paulo Medical School, São Paulo, Brazil.

4:45 PM (97) Autoimmunity to Cardiac Myosin is Associated with Acute and Chronic Rejection of Cardiac Allografts in Non-Human Primates; A.M. Azimzadeh,1 A. Newton,1 X. Cheng,1 K. Tahir,1 A. Ward,1 T. Zhang,1 S. Kelishadi,1 D. Fairweather,1 M. Cunningham,3 R.N. Pierson III.1 1Surgery, University of Maryland School of Medicine, Baltimore, MD; 2Environmental Health Sciences, Johns Hopkins University, Baltimore, MD; 3Microbiology & Immunology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK.

5:00 PM (98) Role of Antibodies to HLA, Collagen-V and K-α1-Tubulin in Antibody-Mediated Rejection and Cardiac Allograft Vasculopathy; V. Tiriveedhi,1 D.S. Nath,2 D. Phelan,3 N. Moazami,4 G. Ewald,5 T. Mohanakumar,1, A. Ward,1 T. Zhang,1 S. Kelishadi,1 D. Fairweather,1 M. Cunningham,3 R.N. Pierson III.1 1Surgery, Washington University School of Medicine, St Louis, MO; 2Department of Surgery, Children’s National Medical Center, Washington, DC; 3HLA Laboratory, Barnes-Jewish Hospital, St Louis, MO; 4Surgery, Minneapolis Cardiothoracic Surgery Consultants, Minneapolis, MN; 5Cardiovascular Division, Washington University School of Medicine, St Louis, MO; 6Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO.

5:15 PM (99) Phosphorylated Signaling Proteins as Biomarkers of Antibody-Mediated Heart Allograft Rejection; F Li, C. Lai, J.A. Kobashigawa, M.C. Fishbein, E.F. Reed. UCLA Immunogenetics Center, University of California, Los Angeles, CA.

4:00 PM – 5:30 PM CONCURRENT SESSION 17: Much Ado About Infections After Surgery for Advanced Heart and Lung Diseases (Indigo 202)

CHAIRS: J. David Vega, MD and Martha L. Money, MD

4:00 PM (100) A 16-Year Multi-Institutional Study of the Role of Age and EBV Status on PTLD Incidence among Pediatric Heart Transplant Recipients; J.F. George,1 R. Chinnock,2 R.N. Brown,1 A.I. Dipchand,3 S.A. Webber.1 1Surgery, Univ Alabama at Birmingham, Birmingham, AL; 2Loma Linda Univ. Children’s Hospital, Loma Linda, CA; 3Labatt Family Heart Centre and SickKids Transplant Centre, Hospital for Sick Children, Toronto, ON, Canada; 4Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA.

4:30 PM (102) **Maintenance of Antibody Response to Pneumococcal Capsular Polysaccharide Vaccination in Adult Patients After Heart Transplantation**; E. Sarmiento,¹ N. Del Pozo,¹ J. Rodríguez-Molina,¹ J. Navarro,¹ J. Fernandez-Yañez,² J. Palomo,² J. Carbone,¹Clinical Immunology, Gregorio Marañon Hospital, Madrid, Spain; ¹Cardiology, Gregorio Marañon Hospital, Madrid, Spain.

4:45 PM (103) **Targeted Antibiotic Prophylaxis for Lung Transplantation in Cystic Fibrosis Patients Colonised with Pseudomonas Aeruginosa**; H.N. Haja Mydin,¹ PA. Corris,¹² G. Meachery,¹ A. Nicholson,² S. Peart,² C. Fagan,² J.L. Loridan,¹³ A.J. Fisher,¹³ F.K. Gould,²¹ Department of Cardiopulmonary Transplantation, The Freeman Hospital, Newcastle upon Tyne, United Kingdom; ²Department of Medical Microbiology, The Freeman Hospital, Newcastle upon Tyne, United Kingdom; ³Transplantation and Immunobiology Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom.

5:00 PM (104) **Reduced Lifetime Incidence of Cytomegalovirus with Extended Prophylaxis: Long-Term Follow Up from a Randomized Controlled Trial**; C.A. Finlen Copeland,¹ W.A. Davis,¹ L.D. Snyder,¹ M. Banks,² R. Avery,² S.M. Palmer,¹² Medicine, Duke University Medical Center, Durham, NC; ¹Duke Clinical Research Institute, Durham, NC; ²Medicine, Cleveland Clinic, Cleveland, OH.


5:30 PM – 6:30 PM MINI ORAL SESSION 1 Mechanical Circulatory Support (Sapphire BC)

CHAIRS: Martin Strueber, MD and William G. Cotts, MD

5:30 PM (106) **Cryoblation During HeartMate II® LVAD Implantation Reduces Postoperative Ventricular Tachyarrhythmias**; D.P. Mullloy,¹ C.M. Bhamidipati,¹ D.J. LaPar,¹ M.L. Stone,¹ G. Ailawadi,¹ J.A. Bergin,² I.L. Kron,² S. Mahapatra,² J.A. Kern.¹ ¹Surgery, Division of Thoracic and Cardiovascular Surgery, University of Virginia Health System, Charlottesville, VA; ²Medicine, Division of Cardiovascular Medicine, University of Virginia Health System, Charlottesville, VA.

5:35 PM (107) **Bridge to Lung Transplantation for Pulmonary Fibrosis: From Mechanical Ventilation to Veno-Venous Extracorporeal Membrane Oxygenation with Atrial Septostomy**; J.P. Garcia, Z.N. Kon, B. McCormick, B. Wehman, B. Reicher, A. Iacono, B.P. Griffith. University of Maryland School of Medicine, Baltimore, MD.


5:45 PM (109) **Avoiding Driveline Infections in Patients with Left Ventricular Assist Devices**; A.J. Tatooles,¹ C.T. Gallagher,² P.S. Pappas,¹ M.A. Bresticker.¹ Cardiovascular and Thoracic Surgery, Advocate Christ Medical Center, Oak Lawn, IL; ²Cardiac Surgery Clinical Research Center, Inc, Advocate Christ Medical Center, Oak Lawn, IL.

5:50 PM (110) **HeartMate II Left Ventricular Assist Device Inflow Cannula Implantation: Apical versus Diaphragmatic Approach**; Z.T. Demiroz,¹ R. Radovancevic,¹ W.E. Cohn, I.D. Gregoric, O.H. Frazier. Texas Heart Institute at St. Luke’s Episcopal Hospital, Houston.

5:55 PM (111) **Flat Blood Pressure Response to Exercise in Patients with the Total Artificial Heart**; H.S. Kohli,¹ J. Canada, R.A. Arena, D.G. Tang, M.A. Peberdy, S. Harton, M. Flattery, G.J. Katlaps, M.L. Hess, V. Kasirajan, K.B. Shah. Virginia Commonwealth University, Richmond, VA.

6:00 PM (112) **Right Ventricular Optimisation in Patients with Biventricular Failure Receiving a Left Ventricular Assist Device – A Safe Strategy To Avoid Mechanical RV Support**; T.A. Butt, F. Oezalp, D. O’Leary, C. Roysam, N. Wrightson, T. Pillay, G. MacGowan, S. Schueler. Cardiothoracic Surgery, Freeman Hospital, Newcastle upon Tyne, United Kingdom.


6:10 PM (114) **Routine Use of Less Invasive Non-Sternotomy Technique for Implantation of HeartMate II Left Ventricular Assist Device**; A.C. Anyanwu,¹ I. Plotkin,¹ F. Millia,² S. Pinney,² D.H. Adams.¹ Cardiothoracic Surgery, Mount Sinai Medical Center, New York, NY; ²Transplant Cardiology, Mount Sinai Medical Center, New York, NY.

6:15 PM (115) **Veno-Venous ECMO for Acute Lung Failure in Adults**; C. Schmid,¹ A. Philipp,¹ M. Hilker,¹ L. Rupprecht,¹ A. Keyser,¹ M. Lubnow,¹ T. Müller.¹ Cardiothoracic Surgery, University Medical Center, Regensburg, Germany; ²Internal Medicine II, University Medical Center, Regensburg, Germany.

5:50 PM (122) Age-Related Decrement in Peak VO2 in Chronic Heart Failure: Remaining Aerobic Capacity (ml/min/kg) versus Loss of Aerobic Functioning (% Predicted); G.V. Guimarães,1 J.A. Neder,2 V.O. Carvalho,2 V.S. Issa,2 S.A. Ferreira,1 E.A. Bocchi,1 HCFMUSP, Heart Institute, Sao Paulo, SP, Brazil; 2CEPEUSP, Laboratory of Physical Activity and Health, Sao Paulo, SP, Brazil; 3UNIFESP, Respiratory Function and Clinical Exercise Physiology, Sao Paulo, SP, Brazil.

5:55 PM (123) Serum GSTP1 as a Sensitive Marker for Monitoring Cardiac Function Prior to Heart Transplantation; S. Aharinejad,1 O. Andrukhova,2 M. Salama,1 A.R. Rosenhek,2 G. Lauffer,1 A. Zuckermann,1 Cardiac Surgery, Medical University of Vienna, Vienna, Austria; 2Internal Medicine, Medical University of Vienna, Vienna, Austria; 3Pathophysiology, University of Veterinary Medicine, Vienna, Austria.

6:00 PM (124) Echocardiographic Predictors of Adverse Outcome in Patients Referred for End-Stage Heart Failure; M. Barbanti,1 A. Cordero-Reyes,2 A. Malaty,3 R.P. Vivo,2 G. Torre-Amione,2 J.D. Estep,1 Internal Medicine, The Methodist Hospital, Houston, TX; 3The Methodist DeBakey Heart and Vascular Center, The Methodist Hospital, Houston, TX, United Kingdom; 2Cardiology, University of Texas Medical Branch, Galveston, TX; 4Director General de Institutos y Centros Medicos del Tecnoologico de Monterrey, Hospital San Jose TEC de Monterrey, Monterrey, NL, Mexico.

6:05 PM (125) Absence of Remodeling Benefit of LV-CRT over BIV-CRT in Patients with Heart Failure and Wide QRS: Insight from the Evaluation of Resynchronization Therapy for Heart Failure (EARTH) TRIAL; A. Ducharme, H. Prylutska, F. Harel, E. O’Meara, N. Frasure-Smith, M. White, B. Thibault. Medicine, Montreal Heart Institute, Montreal, QC, Canada.

6:10 PM (126) Short-Term Support Via Direct Mechanical Ventricular Actuation Improves Cardiac Function in Chronically Failing Hearts; P.L. McConnell,1 C. Del Rio,2 T. Preston,2 B.A. Schmidt,3 R.J. Darner,3 M.P. Anstadt,3 Cardiothoracic Surgery, Nationwide Children's Hospital, Columbus, OH; 2Qmed, Columbus, OH; 3Surgery, Wright State University School of Medicine, Dayton, OH.

6:15 PM (127) Heart Transplantation in Diabetic versus Non-Diabetic in the Current Era: Have Outcomes Become Equivalent?; K.B. Allen,1 A.M. Borken,1 S. Aggarwal,1 N. Long,1 P. Jones,2 A. Magalski,3 A. Kao,1 T. Stevens,2 M. Everly,3 S. Lawhorne,3 B. Austin,3 Department of Cardiothoracic Surgery, Mid America Heart and Vascular Institute, St. Luke's Hospital, Kansas City, MO; 2Department of Biostatistics, Mid America Heart and Vascular Institute, St. Luke’s Hospital, Kansas City, MO; 3Department of Cardiology, Mid America Heart and Vascular Institute, St. Luke’s Hospital, Kansas City, MO.

6:20 PM (128) Computed Tomographic Coronary Angiography to Screen for Allograft Vasculopathy After Heart Transplantation; M.G. Panicker,1 A.G. Mitchell,2 N.R. Banner,1 T.K. Mittal,1 Cardiology and Transplant Medicine, Harefield Hospital, Royal Brompton and Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom; 2Cardiology, Harefield Hospital, Royal Brompton and Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom; 3Cardiothoracic Imaging, Harefield Hospital, Royal Brompton and Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom.

MINI ORAL SESSION 3 Lung/Heart-Lung Transplantation

CHAIRS: Glen P. Westall, FRACP, PhD and Pali D. Shah, MD

5:30 PM  

5:35 PM  

5:40 PM  
**Cytomegalovirus Primary Mismatch Increases the Risk of Restrictive Allograft Syndrome After Lung Transplantation**; M. Sato, S. Husain, T.K. Waddell, C. Chaparro, L.G. Singer, M.A. Hutchison, S. Keshavjee. The Toronto Lung Transplant Program, University Health Network, University of Toronto, Toronto, ON, Canada.

5:45 PM  
**The Impact of Vaccination on Allosensitization in Candidates on the Lung Transplant Wait List**; G. Smith, J. Chu, L. Danziger-Isakov, R. Avery, D. Van Duin, E. Poggio, L. Klingman, M. Budev, K. McCurry, M. Askar. Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH; 

5:50 PM  
**The Phenotype of Chronic Lung Allograft Dysfunction (CLAD) Determines Survival**; R. Vos, G.M. Verleden, S.E. Verleden, S. De Vleeschauwer, D. Van Raemdonck, L.J. Dupont, B. Vanaudenaerde. Lung Transplantation Unit, University Hospital Gasthuisberg, Leuven, Belgium; 

5:55 PM  

6:10 PM  

6:00 PM  

6:05 PM  
**Restrictive Lung Disease as a Manifestation of Chronic Allograft Dysfunction Following Lung Transplantation**; M. Paraskeva, M. Bailey, G.I. Snell, G.P. Westall. Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital, Melbourne, VIC, Australia; 

6:15 PM  
**BOS, “DeBos” and “ReBos” When is a Drop in the FEV1 Really Permanent?**; M.M. Fergusson, R. Brenner, J. Collen, T. Reffett, A.W. Brown, O.A. Shlobin, S. Ahmad, M. Lemma, S.D. Nathan. Advanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, VA; 

6:20 PM  
**Early Analysis of Clinical Outcomes in HLA Sensitized Lung Transplant Recipients**; M.W. Ibrahim, J.D. Smith, H. Newell, M.L. Rose, M. Carby. Transplantation, Roaylbrompton Hospital NHS Trust, Harefield, Middd, United Kingdom.

6:25 PM  

5:30 PM – 6:30 PM
MINI ORAL SESSION 4 Basic Science and Immunobiology

CHAIRS: Howard J. Eisen, MD and Mandep R. Mehra, MD

5:30 PM  

5:35 PM  
**Tacrolimus versus Cyclosporine in Combination with Mycophenolate Mofetil After Heart Transplantation – Ten Year Results of a Prospective Randomized Trial**; S. Guethoff, B. Meiser, P. Ueberfuhr, S. Eifert, B. Reichart, I. Kaczmarek. Department of Cardiac Surgery, University of Munich, Munich, Germany; 

5:40 PM  
**Single-Center Experience with 360 Lung Transplantations: Influence of Different Immunosuppressive Protocols on Long-Term Survival, Acute Rejection and on**
**Modulation of Adiponectin, a Cardiovascular Hormone, in the Myocardium of Patients with End-Stage Heart Failure; A. Beiras-Fernandez, F. Weis, S. Kreth, I. Kaczmarek, C. Lederose, A. Beiras, B. Reichart. 1Cardiac Surgery, University Hospital Ludwig-Maximilians University, Munich, Germany; 2Anesthesiology, University Hospital Ludwig-Maximilians University, Munich, Germany; 3Morphological Sciences, University of Santiago de Compostela, Santiago, Spain.**

**Transbronchial Lung Biopsy After Lung Transplantation: Different A and B Scores in Different Lobes; P. Jaksh, A. Scheed, G. Dekan, S. Geleff, W. Klepetko. 1Thoracic Surgery, Medical University Vienna, Vienna, Austria; 2Division of Pathology, Medical University Vienna, Vienna, Austria.**

**Structural Changes in Cardiac Hypertrophy in the Myocardium of Patients with End-Stage Heart Failure; M. Plit, A.R. Glanville. The Lung Transplant Unit, St Vincents Hospital, Sydney, NSW, Australia.**

**Is Your Patient’s Sex Life Dysfunctional? Check the Prolactin Level!; M.A. Malouf, R.F. Pearson, A. Fienes, A. Havryk, M. Pitt, A.R. Glanville. The Lung Transplant Unit, St Vincents Hospital, Sydney, NSW, Australia.**

**Are Social Support and Coping Mediators of Quality of Life (QOL) Long-Term After Heart Transplantation (HT)?; C. White-Williams, S. Myers, D. Naftel, R. Bourge, K. Grady. 1University of Alabama at Birmingham, Birmingham; 2Northwestern University, Chicago.**

**Palliative Care Involvement in Advanced Heart Failure Pre and Post Cardiac Transplantation; E.R.V. Schwarz, A. Baraghoush, A. Phan, M.M. Hamilton, J.A. Kobashigawa, P. Bharadwaj. 3Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA; 4Internal Medicine, Cedars-Sinai Medical Center, Los Angeles, CA; 5Palliative Care, Cedars-Sinai Medical Center, Los Angeles, CA.**

**Quality of Life in Pediatric Heart Transplant Recipients: A Comparison With Children With and Without Heart Disease; K. Uzark, J.K. Johnston, M. Zamberlan, P. Murphy, C. Nasman, J. Dupuis, S. Rodgers, C. Limbers, J.W. Varni. 1Children's Memorial Hospital, Chicago, IL; 2Children's Hospital of Michigan, Detroit, MI; 3Children's Hospital of Michigan, Detroit, MI.**

**5:00 PM  (148) Donor Lung Surfactant Protein D Gene Polymorphisms are Associated with Bronchiolitis Obliterans Syndrome and Mortality After Lung Transplantation; B. Aramini, S. Diangelo, D. Lederer, J. Wilt, L. Shah, S. Mattioli, S. Kashyap, J. Floros, S. Arcasoy, J. Sonett, E. D'Ovidio. 1PhD Program in “Pneumono-Cardio-Thoracic Sciences of Medical and Surgical Interest,” University of Bologna, Bologna, Italy; 2Penn State University, Hershey; 3Lung Transplant Program, University of Toronto, Toronto, Canada; 4Lung Transplant Program, Columbia University, New York.**

**BOS is Associated with Increased Expression of C4d on Airway Bronchial Epithelial Cells Using Flow Cytometry – Potential Use in Diagnosing AMR; G. Hodge, S. Hodge, D. Chambers, P. Hopkins, P.N. Reynolds, M. Holmes, C-L. Liew. 1Lung Research, Hanson Institute, Adelaide, Australia; 2Thoracic Medicine, Royal Adelaide Hospital, Adelaide, Australia.**

**Interleukin 5 Predicts Antibody-Mediated Rejection in Cardiac Transplant Recipients; N.M. Heikal, F.M. Bader, T. Martins, M. Barakat, J. Stehilk, A.G. Kfoury, E.M. Gilbert, A. Wilson, J.C. Delgado, H.R. Hill. 1Department of Pathology, RUP Institute for Clinical and Experimental Pathology, University of Utah School of Medicine, Salt Lake City, UT; 2Division of Cardiology, University of Utah School of Medicine, Salt Lake City, UT.**

**6:15 PM  (151) microRNA Regulation of Phenotypically Transformed Normal Pulmonary Artery Endothelial Cells; J.C. Iturriaga, H. Grenett, N. Olave, S. Yala, X. Wang, S.V. Pamboukian, J.A. Tallaj, R.C. Bourge, M. Cadeiras. University at Alabama at Birmingham Hospital, Birmingham.**
**MINI ORAL SESSION 6 Infectious Diseases (Indigo 202)**

**CHAIRS:** Martin R. Zamora, MD and Dirk Van Raemdonck, MD, PhD


**6:00 PM** (173) *Universal Prophylaxis versus Pre-Emptive Treatment of CMV Infection in Heart Transplantation – Single Center Experience;* J. Vymetalova, M. Kubanek, T. Gazdic, B. Skalicka, J. Vrbska, I. Malek, J. Kautzner. Cardiology, Institute of Clinical and Experimental Medicine, Prague, Czech Republic.


**6:25 PM** (165) *The Impact of a Diet and Exercise Intervention on Quality of Life After Paediatric Heart Transplantation – A Randomized Controlled Trial;* J. Wray, C. Orrelles, H. Latch, M. Burch. Cardiorespiratory, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom.

**6:30 PM – 6:40 PM** THURSDAY, 4·14


**5:45 PM** (169) *Clinical Significance of Cytomegalovirus (CMV) Detected by RT-PCR in Bronchoalveolar Lavage Fluid of Stable Lung Transplant Recipients;* J. Gottlieb, E. Schilschewsky, T. Fuehner, M. Dierich, T. Wolte. Respiratory Medicine, Hannover Medical School, Hannover, Germany.


FRIDAY, APRIL 15, 2011

6:30 AM – 6:30 PM  
Speaker Ready Room Open (Sapphire 410)

7:00 AM – 5:30 PM  
Registration Desk Open (Sapphire Foyer)

7:00 AM – 8:00 AM  
SUNRISE SYMPOSIUM 5: “It’s Alive!” Myocardial Recovery During LVAD Support in 2011 (Sapphire AE)  
CHAIRS: O. Howard Frazier, MD and Steven S. L. Tsui, MD, FRCS

7:00 AM  
The Disconnect Between Cellular and Clinical Recovery: What are We Missing?  
Kenneth B. Margulies, MD, University of Pennsylvania Health System, Philadelphia, Pennsylvania

7:20 AM  
Myocardial Recovery During LVAD Support: Pulsatile versus Continuous Flow Devices,  
Thomas Krabatsch, MD, PhD, German Heart Institute, Berlin, Germany

7:40 AM  
Techniques to Facilitate Device Explantation Following Recovery: Case Presentation,  
Evgenij V. Potapov, MD, PhD, German Heart Institute, Berlin, Germany

6:15 PM (175)  
Humoral Immunity Reconstitution After Intravenous Immunoglobulin Replacement Therapy in Heart Recipients with Post Transplant IgG Hypogammaglobulinemia and CMV Infection;  
J. Carbó,1 N. Del Pozo,1 J. Rodríguez-Molina,1 J. Navarro,1 A. Gallego,1 J. Fernandez-Yañez,2 J. Palomo,2 P. Muñoz,3 E. Sarmiento,1 1Clinical Immunology, Gregorio Marañón Hospital, Madrid, Spain; 2Cardiology, Gregorio Marañón Hospital, Madrid, Spain; 3Microbiology, Gregorio Marañón Hospital, Madrid, Spain.

6:20 PM (176)  
Late CMV Infection Complicates Heart Transplantation After Extended Duration Prophylaxis (Proph) with Valganciclovir (VGC);  
V. Stosor,1,2 M. Angarone,1 E. McGee,2 G. Ferguson,4 J. Kruse,4 E. Schupbach,4 K. Grady,4 M.G. Ison,1,4 W. Cotts,4 1Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL; 2Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine, Chicago, IL; 3Bluhm Cardiovascular Institute, Northwestern University Feinberg School of Medicine, Chicago, IL; 4Northwestern Memorial Hospital, Chicago, IL.

5:30 PM – 6:30 PM  
PULMONARY HYPERTENSION COUNCIL MEETING (Sapphire 400)

6:30 PM – 7:30 PM  
ID DEFINITIONS MEETING (Indigo 206)

PULMONARY AMR WORKGROUP MEETING (Sapphire 400)  
ISHLT DCD REGISTRY MEETING (Sapphire 412)

7:00 AM  
Heterotopic and Orthotopic Tracheal Transplantation,  
Sonja Schreper, MD, PhD, University Heart Center Hamburg, Germany

7:20 AM  
Orthotopic Lung Transplantation in the Mouse,  
Alexander S. Krupnick, MD, Washington University School of Medicine, St. Louis, Missouri

7:40 AM  
Large Animal Models of Lung Transplantation,  
James S. Allan, MD, Massachusetts General Hospital, Boston, Massachusetts

7:00 AM – 8:00 AM  
SUNRISE SYMPOSIUM 6: Experimental Models of Lung Transplantation (Sapphire IM)  
CHAIRS: Daniel Kreisel, MD, PhD and Florian M. Wagner, MD

7:00 AM  
Case Presentation: A 64-Year-Old Woman with Mitral Stenosis and Paroxysmal Atrial Fibrillation Complicated by Severe Pulmonary Hypertension and Scleroderma,  
Robert P. Frantz, MD, Mayo Clinic, Rochester, Minnesota

7:10 AM  
Operative Assessment and Management of Mitral Valve Disease Complicated by Pulmonary Hypertension,  
Soon Park, MD, Mayo Clinic, Rochester, Minnesota

7:30 AM  
Case Presentation: Pulmonary Hypertension with Left Heart Failure,  
Veronica Franco, MD, Ohio State University, Columbus, Ohio
7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 8: Why Are Children Immunologically Different? (Indigo 202)
CHAIRS: Marc G. Schecter, MD and Melanie D. Everitt, MD
7:00 AM Developmental Immunology: How do the Younger Patients Differ? Simon Urschel, MD, University of Alberta, Edmonton, Alberta, Canada
7:20 AM Infection Risk in the Younger Population, Lara Danziger-Isakov, MD, MPH, The Cleveland Clinic Foundation, Cleveland, Ohio
7:40 AM Exploiting the Differences In Children, Lori J. West, MD, DPhil, University of Alberta, Alberta Diabetes Institute, Edmonton, Alberta, Canada

7:00 AM – 10:00 AM
Poster Mounting (Indigo Ballroom and Indigo Foyer)

8:00 AM – 10:00 AM
PLENARY SESSION: Gazing into the Crystal Ball – Emerging Therapy in Thoracic Transplantation (Sapphire BCD)
CHAIRS: Stuart W. Jamieson, MB, FRCS and Paul A. Corris, MB, FRCP
8:00 AM The Future of Immune Modulation in the Clinical Setting, David S. Wilkes, MD, Indiana University School of Medicine, Indianapolis, Indiana
8:24 AM Survivors of CHD, What will be Best Therapy: Transplantation versus MCS? Michael Hubler, MD, German Heart Institute, Berlin, Germany
8:48 AM Cell Based Alternatives to MCS: Reconstruction Ahead? Eduardo Marbán, MD, PhD, Cedars Sinai Heart Institute, Los Angeles, California
9:12 AM Engineering Lungs for Transplant: The Potential Benefits of Ex-Vivo Therapy, Shaf Keshavjee, MD, FRCS, Toronto General Hospital, Toronto, Canada
9:36 AM Lung Assist Devices. What will be Possible in the Clinical Setting in Five Years? Joseph B. Twizdenberger, MD, University of Kentucky, Lexington, Kentucky

9:00 AM – 6:00 PM
Press Office Open (Sapphire 411)

10:00 AM – 10:30 AM
ANNUAL BUSINESS MEETING (members only) (Sapphire BCD)
COFFEE BREAK (Indigo Ballroom)
10:30 AM – NOON
CONCURRENT SESSION 19: Impact of Donor Selection on Heart Transplant Outcomes (Sapphire AE)

CHAIRS: Andrew J. Boyle, MD and David O. Taylor, MD


11:00 AM (185) Impact of Donor and Recipient Sex on Survival and Acute Rejection After Heart Transplantation: Analysis of the ISHLT Database; K.K. Khush, J. Kubo, M. Desai, H.A. Valantine. 1Division of Cardiovascular Medicine, Stanford University, Palo Alto, CA; 2Quantitative Sciences Unit, Stanford University, Palo Alto, CA.

11:15 AM (186) Donor B-Type Natriuretic Peptide Predicts Early Cardiac Performance After Heart Transplantation; A. Vorlat, V.M. Conraads, P.G. Jorens, I. Rodriguez, M.J. Claeyts. 1Cardiology, University Hospital Antwerp, Edegem, Belgium; 2Critical Care Medicine, University Hospital Antwerp, Edegem, Belgium; 3Cardiac Surgery, University Hospital Antwerp, Edegem, Belgium.


10:30 AM – NOON
CONCURRENT SESSION 20: Collaborating to Promote and Enhance QOL in End-Stage Organ Disease (Sapphire IM)

CHAIRS: Samantha J. Anthony, PhD, MSW and Michael G. Petty, PhD(c), RN, CCNS, CNS


10:45 AM (190) Driver’s Education: A Single Center Experience on the Incidence and Safety of Driving with LVADS; S. Emani, C.M. O’Keefe, S. Wissman, K.S. MacBrair, L. White, A.K. Hasan, C.B. Sai-Sudhakar, B.C. Sun. 1Medicine, Ohio State University Medical Center, Columbus, OH; 2Comprehensive Transplant Center-Mechanical Circulatory Support, Ohio State University Medical Center, Columbus, OH; 3Cardiovascular Clinical and Translational Research Organization, Ohio State University Medical Center, Columbus, OH; 4Surgery, Ohio State University Medical Center, Columbus, OH; 5Cardiothoracic Surgery, Minneapolis Heart Institute, Minneapolis, MN.


11:30 AM (193) The Incremental Cost of Complications After Left Ventricular Assist Device Placement: A. Iribarne, R. Easterwood, S.-W. Pak, M.J. Russo, K.N. Hong, J. Yang, H. Takayama, D.M. Mancini, Y. Naka. 1Department of Surgery, Columbia University Medical Center, New York, NY; 2Section of Cardiac and Thoracic Surgery, The University of Chicago, Chicago, IL.


10:30 AM – NOON
CONCURRENT SESSION 21: Drug Therapy in Pulmonary Hypertension (Aqua 306)

CHAIRS: Dana P. McGlothlin, MD and Veronica Franco, MD

10:30 AM (195) Safely Transitioning from Inhaled Iloprost to Inhaled Treprostinil Sodium – Results from a Multicenter Open-Label Study in Patients with Pulmonary Arterial Hypertension; R.C. Bourge, V.F. Tapson, Z. Safdar, R.L. Benza, R.N. Channick, E.B. Rosenzweig, S. Shapiro, C.S. McSwain, A. Gotzkowsky, A. Nelsen, L.J. Rubin. 1Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL; 2Pulmonary and Critical Care, Duke University Medical Center, Durham, NC; 3Pulmonary Critical Care Medicine, Baylor College of Medicine, Houston, TX; 4Cardiovascular Diseases, Allegheny General Hospital, Pittsburgh, PA; 5Pulmonary Hypertension Pro-
gram, Massachusetts General Hospital, Boston, MA; 9Pediatric Cardiology, Columbia University, College of Physicians and Surgeons, New York, NY; 10Pulmonary and Critical Care, David Geffen School of Medicine at UCLA, Los Angeles, CA; 11United Therapeutics Corporation, Research Triangle Park, NC; 12Medicine, University of California San Diego, LaJolla, CA.

10:45 AM (196) Sildenafil to Tadalafil Transition in Patients with Pulmonary Arterial Hypertension: A Retrospective Review; O.A. Shlobin, A.W. Brown, N. Weir, L. Merte, S. Ahmad, K. Brown, S.D. Nathan. Advanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, VA.

11:00 AM (197) Longitudinal Hemodynamic Changes in Pediatric Patients with Severe Pulmonary Arterial Hypertension (PAH) on Prostanoid Therapy; S.L. Siehr, D. Ivy, K. Miller-Reed, M. Ogawa, D. Rosenthal, J.A. Feinstein. Pediatric Cardiology, Stanford University, Lucile Packard Children’s Hospital, Palo Alto, CA; 13Pediatric Cardiology, University of Colorado Denver, The Children’s Hospital, Aurora, CO.

11:15 AM (198) COMPASS-3: Quality of Life in Patients with Pulmonary Arterial Hypertension; F. Torres, S. Murali, F.J. Soto, H. Gupta, M.H. Park, N. Frey, R.L. Benza. University of Texas Southwestern Medical Center, Dallas, TX; 14Allegheny General Hospital, Pittsburgh, PA; 15Prevea Health, Sheboygan, WI; 16University of Alabama at Birmingham, Birmingham, AL; 17University of Maryland School of Medicine, Baltimore, MD; 18Actelion Pharmaceuticals US, Inc., South San Francisco, CA.

11:30 AM (199) Impact of Pulmonary Hypertension on Transplant Outcomes in Pediatric Cardiomyopathy Patients; S. Buddhe, W. Du, T. L’Ecuyer. Children’s Hospital of Michigan, Detroit, Michigan.

11:45 AM (200) Perioperative Sildenafil Administration Decreases the Risk of Early Death Due to the Transplanted Heart Right Ventricular Failure; M. Maruszewski, M. Zakliczynski, J. Nozynski, M. Zembala. Cardiac Surgery and Transplantation, Silesian Cancer Center for Heart Diseases, Zabrze, Poland.

10:30 AM – NOON CONCURRENT SESSION 22: Clinical Immunosuppression for Heart and Lung Transplantation (Indigo 202)

CHAIRS: Thomas M. Egan, MD, MSC and Paul A. Corris, MB FRCP

10:30 AM (201) Development of a Composite Endpoint (CEP) for Clinical Trials on Immunosuppressants (IS) in Lung Transplantation; C. Monchaud, B. Marin, M. Estenne, P. Marquet. 19UMR-S850, INSERM, CHU Limoges, Limoges, France; 20Service de Pharmacologie, Toxicologie et Pharmacovigilance, CHU Limoges, Limoges, France; 21Unité Fonctionnelle de Recherche Clinique et de Biostatistique, CHU Limoges, Limoges, France; 22Service de Pneumologie, Hôpital Erasme, Université Libre de Bruxelles, Bruxelles, Belgium.


11:00 AM (203) The Influence of Induction Regimen on the Early Incidence of Biopsy-Determined Acute Rejection in Lung Transplant Patients; J.A. Golden, S.G. Dilly, T.J. Breen, B. Johnson. 19University of California, San Francisco, San Francisco, CA; 23APT Pharmaceuticals, Burlingame, CA; 24University of Pittsburgh, Pittsburgh, PA.


11:30 AM (205) Everolimus Prevents the Quilty Phenomenon – A Risk Factor for Microvasculopathy in Biopsy (RAD B253 Trial); N.E. Hiemann, C. Bara, J. Segovia, J. Parameshwar, S. Simonson, M. Crespo-Leiro, H. Eiskjaer, J.K. Bhama, J.A. Golden, R.L. Kormos, D.M. McNamara, Y. Toyoda, M. Shullo. 19Cardiovascular Institute, University of Pittsburgh, Pittsburgh, PA; 27University of California, San Francisco, San Francisco, CA; 28Aarhus University Hospital, Skejby, Denmark; 29University Hospital Gasthuisberg, Leuven, Belgium; 30University Hospital of Heraklion, Crete, Greece; 31Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain; 32Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom; 33Oslo University Hospital Rikshospitalet, Oslo, Norway; 34Hospital Universitario Juan Canalejo, La Coruña, Spain; 35Aarhus University Hospital, Skejby, Denmark; 36University Hospital Gasthuisberg, Leuven, Belgium; 37Hospital Universitario Reina Sofía, Córdoba, Spain; 38Cliniques Universitaires Saint-Luc, Bruxelles, Belgium; 39John Paul II Hospital, Krakow, Poland; 40Az. Ospedaliera Ospedale Niguarda Ca’ Granda, Milan, Italy.

11:45 AM (206) Improvement of Renal Function After Cyclosporine Reduction Is Influenced by Baseline Proteinuria in Patients Converted to Everolimus: Long Term Follow-Up of the Shirakiss Randomized Study; P. Prestinenzi, L. Potena, J.G. Bianchi, M. Masetti, P. Romani, G. Magnani, F. Fallani, F. Coccolo, A. Russo, F. Grigioni, A. Branzi. Cardiovascular Department, University of Bologna, Bologna, Italy.

NOON – 12:30 PM Box Lunch Pick-Up (ticket required) (Indigo Ballroom)

12:15 PM – 1:45 PM MID-DAY SYMPOSIUM 5: Future Therapies for End-Stage Thoracic Organ Failure (Sapphire AE)

CHAIRS: Walter Weder, MD and Robert B. Love, MD
12:15 PM Regeneration of Bioartificial Airways/Lungs, Thomas K. Waddell, MD, PhD, Toronto General Hospital, Toronto, Canada

12:45 PM Regenerative Therapy for Pulmonary Hypertension, Duncan J. Stewart, MD, FRCP, Ottawa Hospital Research Institute, Ottawa, Canada

1:15 PM Is There a Future for Engineered Heart and Lung?, Doris Taylor, PhD, University of Minnesota, Minneapolis, MN


CHAIRS: Stuart C. Sweet, MD, PhD and Sean P. Pinney, MD

12:15 PM United States: Stuart C. Sweet, MD, PhD, St Louis Children’s Hospital, St Louis, MO, USA

12:25 PM England: John J. Dunning, FRCS, Papworth Hospital, Cambridge, United Kingdom

12:35 PM Australia: Anne Keogh, MBBS, MD, St. Vincent’s Hospital, Sydney, Australia

12:45 PM Spain: Nicolas Manito, MD, Hospital Universitari de Bellvitge, Barcelona, Spain

12:55 PM Canada: Heather J. Ross, MD, MHSc, FRCP(c), Toronto General Hospital, Toronto, Canada

1:05 PM Eurotransplant: Jacqueline M. Smits, MD, PhD, Eurotransplant International Foundation, Leiden, The Netherlands

1:15 PM Japan: Takeshi Nakatani, MD, PhD, National Cardiovascular Center, Osaka, Japan

1:30 PM Panel Discussion/Q&A

12:15 PM – 1:45 PM MID-DAY SYMPOSIUM 7: AST at ISHLT: Lessons From Other Organs (Aqua 306)

CHAIRS: John Dark, MB, FRCS and Maryl R. Johnson, MD

12:15 PM Emerging Pharmacologic Immunosuppression: Updates from Clinical Trials in Kidney Transplantation, Robert S. Gaston, MD, University of Alabama at Birmingham, Alabama

12:45 PM Emerging Biologics in Organ Transplantation, Flavio Vincenti, MD, University of California, San Francisco, California

1:15 PM Lessons Learned from Transplant Patients on Immunosuppressive Drugs, Kenneth Newell, MD, PhD, Emory Transplant Center, Atlanta, GA

12:15 PM – 1:45 PM MID-DAY SYMPOSIUM 8: Palliative Care Across the Illness Trajectory (Indigo 202)

CHAIRS: Annette DeVito Dabbs, RN, PhD and James K. Kirklin, MD

12:15 PM Introduction: Definition of Palliative Care and Applications to Transplant, Winifred G. Teuteberg, MD, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

12:25 PM Practical Hints in Palliative Care, Patricia A. Uber, PharmD, University of Maryland, Baltimore, Maryland

12:35 PM Pulmonologist’s View of Palliative Care in the Pre-Transplant Period, Martin Carby, MD, Harefield Hospital, Harefield, United Kingdom

12:45 PM The Nurses’ View of Palliative Care in Post-Transplant Care, Mikyung Song, RN, PhD, University of North Carolina, Chapel Hill, North Carolina

12:55 PM The MCS Coordinator Perspective on Palliative Care, Annemarie Kaan, MCN, RN, St. Paul’s Hospital, Vancouver, British Columbia, Canada

1:05 PM The Cardiologist’s View of Palliative Care in Chronic Heart Failure Before or After Transplantation, Savitri Fedson, MD, University of Chicago Hospitals, Chicago, Illinois

1:15 PM Panel Discussion/Q&A

12:45 PM – 1:45 PM JUNIOR FACULTY MENTOR LUNCH (Indigo 204)

COUNCIL CHAIRS’ LUNCHEON MEETING (Indigo 206)

2:00 PM – 3:30 PM CONCURRENT SESSION 23: All About Recovery, Weaning and VAD Explant (Sapphire D)

CHAIRS: Daniel J. Goldstein, MD and Nicola E. Hiemann, MD

2:00 PM (207) Myocardial Recovery After Support with HeartMate I and HeartMate II Left Ventricular Assist Devices; M. Noor, 1,2 C. Bowles, 1 A. Firouzi, 1 A. Simon, 1 N.R. Banner, 1,2 1Department of Cardiopulmonary Transplantation, Royal Brompton and Harefield NHS Foundation Trust, Harefield Hospital, Harefield, Middlesex, United Kingdom; 2National Heart and Lung Institute, Imperial College London, London, United Kingdom.

2:15 PM (208) Gene and Protein Expression in Myocardium of Heart Failure Patients Following Mechanical Circulatory Assist; A.J. Meredith, 1,4 L.A. Matzke, 1 A. Samra, 1 A. Cheung, 2,3 B.M. McManus, 1,2 Heart + Lung Institute at St. Paul’s Hospital, University of British Columbia, Vancouver, Canada; 2Department of Surgery, University of British Columbia, Vancouver, Canada; 3PROOF Centre of Excellence, Vancouver, Canada.

2:30 PM (209) Hemodynamic Responses to Acute Interruption of Left Ventricular Assist Device Support May Predict Outcomes After Weaning from the Device; S. Saito, 1 T. Sakaguchi, 1 Y. Sakata, 2 S. Miyagawa, 1 H. Nishi, 1 Y. Yoshikawa, 1 S. Fukushima, 1 I. Komuro, 1 Y. Sawa, 1 Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan; 2Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.

2:45 PM (210) Impact of Continuous versus Pulsatile Unloading Pattern on Myocardial Matrix Biomarkers in Patients with Left Ventricular Assist Device; T.S. Kato, 1 A. Chokshi, 1 P. Singh, 1 F. Cheema, 1 H. Akashi, 1 K. Shahzad, 1 S. Iwata, 1 S. Homma, 1 H. Takayama, 2 Y. Naka, 2 U. Jorde, 1 M. Farr, 1 D. Mancini, 1
3:00 PM (211) **Correlation of Fibrosis and Hypertrophy with Myocardial Improvement During Left Ventricular Assist Device (LVAD) Support; A.M. Segura, P. Barton, R. George, A. Khaghani, L.M. Buja, O.H. Frazier, E. Birks.** Texas Heart Institute at St. Luke’s Episcopal Hospital, Houston; Imperial College, Harefield, Middlesex, United Kingdom; University of Louisville, Rudd Heart and Lung Institute, Louisville; Spectrum Health, Grand Rapids, Michigan.

3:15 PM (212) **Long Term Outcome of LVAD Bridge to Recovery Patients; M. Noor, C. Bowles, M. Hedger, S. Rahman Haley, A. Simon, N.R. Banner.** Department of Cardiopulmonary Transplantation, Royal Brompton and Harefield NHS Foundation Trust, Harefield Hospital, Harefield, Middlesex, United Kingdom; Imperial College London, London, United Kingdom.

2:00 PM – 3:30 PM

**CONCURRENT SESSION 24: While You Wait – Therapy and Function in Patients with Heart Failure (Sapphire AE)**

**CHAIRS:** Anne Keogh, MBBS, MD and Guy A. MacGowan, MD, FACC, FRCPI

2:00 PM (213) **Altitude Training Improves Exercise Performance and Quality of Life in Patients with Chronic Heart Failure; V. Bhatia, P. Formica, A. Browne, C. Tan, J.J. Shin, Q. Smith, S. Maybaum.** Center for Advanced Cardiac Therapy, Division of Cardiology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY.

2:15 PM (214) **Improved Survival with Sustained Release Metoprolol when Compared to Carvedilol in Patients with Ischemic Heart Failure: A Comparative Effectiveness Analysis; S. Shore, V. Aggarwal, R. Zolty.** Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY; Division of Cardiology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.

2:30 PM (215) **Higher Doses of Spirinolactone are Associated with Lower Survival in Patients with Congestive Heart Failure; S. Shore, V. Aggarwal, R. Zolty.** Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY; Division of Cardiology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.

2:45 PM (216) **Effect of LVAD on the Prognostic Value of Baseline GFR for Long-Term Renal Function in Patients Undergoing Heart Transplant (HTX); F. Latif, S. W-Pak, N. Uriel, A. Ganda, B. Hirsh, N. Gusksaya, J. Radhakrishnan, S. Restaino, R. Bijou, H. Takayama, Y. Naka, D. Mancini, U.P. Jorde.** Internal Medicine -Division of Cardiology, New York Presbyterian Hospital-Columbia University, New York, NY; Surgery-Division of Cardiothoracic Surgery, New York Presbyterian Hospital-Columbia University, New York, NY; Internal Medicine-Division of Nephrology, New York Presbyterian Hospital-Columbia University, New York, NY; Internal Medicine, New York Presbyterian Hospital-Columbia University, New York, NY.
3:00 PM  (223) MRI Evaluation of the Right Ventricle in Pediatric Pulmonary Arterial Hypertension; S.E. Blalock,1 M. Ogawa,2 F. Chan,3 D. Maxey,2 D.N. Rosenthal,2 J.A. Feinstein.2 1Pediatrics, Division of Cardiology, University of Texas Southwestern Medical Center Dallas, Dallas, TX; 2Pediatrics, Division of Cardiology, Stanford University, Palo Alto, CA; 3Radiology, Stanford University, Palo Alto, CA.

3:15 PM  (224) Resting Hemodynamics May Not Accurately Classify Mild to Moderate Pulmonary Hypertension; P.J. Engel,1 R.P. Baughman.1 1Department of Medicine, University of Cincinnati Medical Center, Cincinnati, OH; 2The Christ Hospital Heart & Vascular Center, Cincinnati, OH.

2:00 PM – 3:30 PM  
CONCURRENT SESSION 26: Mesenchymal Cells and Lymphoid Neogenesis in Transplanted Lungs (Aqua 306)

CHAIRS: Karl B. Lemstrom, MD, PhD and Hermann Reichenspurner, MD, PhD

2:00 PM  (225) Local Mesenchymal Origin of Myofibroblasts in the Fibrotic Lesions in Human Lung Allografts; N. Walker, L. Badri, A. Wadhwa, V. Lama. Internal Medicine, University of Michigan, Ann Arbor, MI.


2:30 PM  (227) Development of Lymphoid-Like Stroma in Chronic Lung Allograft Dysfunction After Lung Transplantation; M. Sato,1,2 S. Hirayama,1 Y. Matsuda,1 D.M. Hwang,1,2 D. Wagner,1,2 G. Zehong,1 M. Liu,1 S. Keshavjee.1,2 1Latner Thoracic Surgery Research Laboratories, Toronto General Research Institute, University of Toronto, Toronto, ON, Canada; 2The Toronto Lung Transplant Program, University Health Network, University of Toronto, Toronto, ON, Canada.


3:00 PM  (229) Lung Progenitor Cell Profiles in Bronchiolitis Obliterans Syndrome are Mediated by Circulating Inflammatory and Stem Cell-Specific Factors; S.E. Gilpin, M. Sato, M. Cypel, S. Keshavjee, T.K. Waddell. University of Toronto, Toronto, ON, Canada.

3:15 PM  (230) Modulation of Allograft Airway Fibrosis Via Regulation of Classical and Alternative Pathway Macrophage Activation by Lentiviral IL-10 Treatment; S. Hirayama,1 M. Sato,1 Y. Matsuda,1 G. Zehong,1 T. Koike,1 M. Liu,1 J.A. Medin,2 S. Keshavjee.1 1Latner Thoracic Surgery Research Laboratories, University Health Network, University of Toronto, Toronto, ON, Canada; 2Ontario Cancer Institute and the University of Toronto, Toronto, ON, Canada.

2:00 PM – 3:30 PM  
CONCURRENT SESSION 27: Philip K. Caves Award Candidate Presentations (Indigo 202)

CHAIRS: Duane Davis, MD and Elaine Reed, MD

2:00 PM  (231) Respiratory Viruses Convert CD4+CD25+Foxp3+ Regulatory T-Cells (Tregs) into Th-17 Cells: Role in Promoting Autoimmunity and Chronic Lung Allograft Rejection; A. Bharat, V. Subramanian, E.P. Trulock, G.A. Patterson, T. Mohanakumar. Washington University, St Louis.

2:15 PM  (232) Monitoring of Specific Anti-EBV CD8+ T-Cell Activity Identifies Transplanted Patients with Reduced Cellular Control of EBV and Increased Risk for PTLD; S. Schubert,1 S. Hingler,1 H.B. Lehmkuhl,2 M. Huebler,2 R. Hetzer,1 M. Yegitbasi,1 K. Schmitt,1 F. Berger.1 1Department of Congenital Heart Disease/Pediatric Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany; 2Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany.

2:30 PM  (233) Epitope Switch of Self-Antigen Collagen V Is Associated with Th-17 Phenotype and Autoimmune Responses: Role in Chronic Rejection Following Human Lung Transplantation; V. Tirvetehti,1 N. Angaswamy,1 D. Brand,2 J. Weber,2 R. Hacheem,2 E.P. Trulock,2 B. Meyers,1 G.A. Patterson,1 T. Mohanakumar.1,2 1Department of Surgery, Washington University School of Medicine, St Louis, MO; 2Department of Medicine, Washington University School of Medicine, St Louis, MO;

2:45 PM  (234) Cardiac Transplantation Efficiency of Induced Pluripotent Stem Cells (iPS) Is Improved by a Fibrinogen Matrix in an Experimental Model of Ischemic Heart Failure; S.V. Rojas,1 A. Martens,1 H. Baraki,1 K. Schwank,2 R. Zweigerdt,2 U. Martin,2 A. Haverich,1 I. Kutschka,1 1Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany; 2Leibniz Research Laboratories for Biotechnology and Artificial Organs, Hannover Medical School, Hannover, Germany.

3:00 PM  (235) Haptoglobin: A Novel Innate Ligand that Induces Inflammation After Tissue Necrosis; H. Shen,1 C. Colangelo,1 T. Wu,1 M. Maffei,1 D.R. Goldstein.1 1Yale University, New Haven; 2Dulbecco Telethon Institute, Pisa, Italy.

3:15 PM  (236) Latent Infection with P. Aeruginosa Prevents the Maintenance of Lung Allograft Acceptance in a MyD88 Dependent Manner; S. Yamamoto,1 Y. Matsuda,1,2 M. Cypel,2 M. Liu,1 S. Keshavjee.1 1Department of Thoracic Surgery, University of Toronto, Toronto, ON, Canada; 2University of Washington, Seattle, WA.

3:30 PM – 4:00 PM  
COFFEE BREAK (Indigo Ballroom)

POSTER VIEWING/POSTER PRESENTER Q&A  
(Indigo Ballroom and Indigo Foyer)
116

4:00 PM – 5:30 PM
CONCURRENT SESSION 32: Pediatric Heart Transplant – Antibodies and Risk Factors (Indigo 202)

CHAIRS: Debra A. Dodd, MD and Kimberly Gandy, MD, PhD

4:00 PM (261) ABO-Incompatible Heart Transplantation in Infants: Analysis of the Pediatric Heart Transplant Study (PHTS) Database; H.T. Henderson,1 C.E. Canter,2 W.T. Mahle,1 A.I. Dippich,1 K. LaPorte,1 K.B. Schechtman,4 J. Zheng,4 A. Asante-Korang,5 R.K. Singh,5 K.R. Kanter.1 Children’s Healthcare of Atlanta, Emory University, Atlanta, GA; 2St Louis Children’s Hospital, Washington University School of Medicine, St Louis, MO; 3Hospital for Sick Children, University of Toronto, Toronto, ON, Canada; 4Division of Biostatistics, Washington University School of Medicine, St Louis, MO; 5All Children’s Hospital, University of South Florida, St Petersburg, FL; 6Pediatric Cardiology, Columbia University Medical Center, New York, NY.

4:15 PM Experience with ABO-Incompatible Cardiac Transplantation in Sensitized Patients; C. Irving,1 G. Parry,1 D. Crossland,1 J. Cassidy,2 L. Ferguson,2 M. Guillian,2 Y. Thiru,2 A. Hasan,1 M. Griselli,1 R. Kirk.1 Paediatric Cardiothoracic Transplantation, Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom; 2Paediatric Cardiac Intensive Care, Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom.

4:30 PM Exploring the Limits of ABO-Incompatible Heart Transplantation – A Multicenter Study; S. Urschel,1 I.M. Larsen,1 R. Kirk,1 J. Flett,2 M. Burch,2 N. Shaw,2 J. Birmbaum,4 H. Netz,4 E. Pahl,6 K.L. Mathews,6 R. Chinnock,6 J.K. Johnston,6 K. Derkatz,1 L.J. West.1 Department of Pediatrics, University of Alberta, Edmonton, AB, Canada; 2Pediatric Cardiology, Freeman Hospital, Newcastle, United Kingdom; 3Pediatric Cardiology, Great Ormond Street Hospital, London, United Kingdom; 4Pediatric Cardiology and Intensive Care, Ludwig Maximilian University, Munich, Germany; 5Pediatric Cardiology, Children’s Memorial Hospital, Chicago, IL; 6Pediatric Cardiology, Loma Linda University Children’s Hospital, Loma Linda, CA.

4:45 PM The Influence of HLA Matching on Outcomes in Pediatric Heart Transplantation; S. Ginde,1 T.M. Ellis,2 M. Nugent,2 P. Simpson,2 G. Stendahl,1 S. Berger,1 S. Zangwill.1 Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI; 2Histocompatibility and Immunogenetics, The Blood Center of Southeastern Wisconsin, Milwaukee, WI; 3Quantitative Health Sciences, Medical College of Wisconsin, Milwaukee, WI.

5:00 PM Does Biopsy-Diagnosed Antibody-Mediated Rejection Portend Adverse Events After Pediatric Heart Transplantation?; M.D. Everett,1,2 M.E.H. Hammond,1 G.L. Snow,1

5:50 PM  (271) Development of Aortic Insufficiency (AI) in Patients Supported with Continuous Flow Left Ventricular Assist Devices (LVAD); B. Soleimani, A. Manoskey, A. Haozzi, E. Stephenson, A. Nunez, C. Brehm, A. El-Banayosy, W. Pae. Heart & Vascular Institute, Penn State Hershey Medical Center, Hershey, PA.

6:00 PM  (273) Use of Nesiritide and Renal Function Following Total Artificial Heart Implantation; W.K. Stribling, K.B. Shah, K.J. Gunnerson, G.J. Katiaps, M.L. Hess, V. Kasirajan, D.G. Tang. 1Cardiology, Virginia Commonwealth University, Richmond, VA; 2Critical Care Medicine, Virginia Commonwealth University, Richmond, VA; 3Cardiothoracic Surgery, Virginia Commonwealth University, Richmond, VA.

6:05 PM  (274) Arrhythmias in Patients with Cardiac Implantable Electrical Devices (CIED) Following Implantation of a Left Ventricular Assist Device (LVAD); A.N. Rosenbaum, S. Sakaguchi, R. John, P.M. Eckman. 1Department of Medicine, Cardiovascular Division, University of Minnesota, Minneapolis, MN; 2Department of Surgery, Division of Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN.

6:10 PM  (275) Left Ventricular Assist Device Speed Optimization Utilizing Gas Exchange Analysis; M.A. Caccamo, R.K. Hames, A. Hamel, B. Nelson, R. John, P.M. Eckman. 1Cardiovascular Medicine, University of Minnesota, Minneapolis, MN; 2Intergrative Human Physiology, University of Minnesota, Minneapolis, MN; 3Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN.

6:15 PM  (276) Demonstration of Hypercoagulability After Implantation of the HeartWare Ventricular Assist Device by Using Thromboelastography; B. Gordon, G. MacGowan, T. Butt, F. Oezalp, A. McDiamid, T. Pillay, G. Parry, P. Kesteven, S. Schueler, T. Biss. 1Cardiology, Cardiovascular Surgery and Cardiac Transplantation, Freeman Hospital, Newcastle upon Tyne, United Kingdom; 2Haematology, Freeman Hospital, Newcastle upon Tyne, United Kingdom.

6:20 PM  (277) Analysis of Bleeding and Thromboembolic Events During Mechanical Circulatory Support with an Axial Flow Left Ventricular Assist Device; M.C. Bunte, L. Thuitt, E.H. Blackstone, G.V. Gonzalez-Stawinski, M.M. Mountis, R. Robert and Suzanne Tomisch Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH; 2Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH.

6:05 PM (286) Erectile Dysfunction in Heart Transplanted Patients: Correlation with Peripheral and Cardiac Vasculopathy and Role of Endothelial Progenitor Cells; C. d’Agostino,1 N. Caretta,2 G. Feltrin,1 F. Tona,1 A. Gambino,1 G. Gerosa,1 C. Foresta.2 1Dept. of Cardiac, Thoracic and Vascular Science, Cardiac Surgery, Padova, Italy; 2Department of Histology, Microbiology and Medical Biotechnologies, Section of Clinical Pathology & Centre for Male Gamete Cryopreservation, Padova, Italy.

6:10 PM (287) Erectile Dysfunction, Penile Atherosclerosis and Coronary Artery Disease in Heart Transplant Recipients; N. Caretta,1 G. Feltrin,1 C. d’Agostino,2 A. Gambino,2 G. Gerosa,1 1Department of Histology, Microbiology and Medical Biotechnologies, Section of Clinical Pathology & Centre for Male Gamete Cryopreservation, Padova, Italy; 2Department of Cardiac, Thoracic and Vascular Science, Cardiac Surgery, Padova, Italy.

6:15 PM (288) How Has the Introduction of Solid Phase Technology for the Assessment of Preoperative PRA Affected Outcomes in Orthotopic Heart Transplantation? – A Single Centre Experience; S.R. Meyer,1 A. Khani-Hanjani,1 J.C. Mullen,1 R. Purdy,1 L.J. West,1 D.H. Kim,2 P.M. Campbell.3 1Surgery, University of Alberta, Edmonton, AB, Canada; 2Laboratory Medicine, University of Alberta, Edmonton, AB, Canada; 3UTAH Cardiac Transplant Program, Salt Lake City, UT.


6:25 PM (290) Donor-Specific Antibodies Against HLA After Heart Transplantation are Increased at Younger Age and in Combination with MICA Antibodies; M.J. Barten, M.T. Dieterlen, R. Riede, S. Klein, S. Dhein, F.W. Mohr, H.B. Bittner. Clinic for Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany.

5:30 – 6:30 PM
MINI ORAL SESSION 9 Basic Science and Immunobiology (Sapphire IM)

CHAIRS: Gaurard Byrne, MD and Bruno Reichart, MD

5:30 PM (291) New Carbohydrate and Membrane Protein Antigens Involved in Cardiac Xenotransplantation; G.W. Byrne,1 P.G. Stalboerger,1 Z. Du,1 C.G.A. McGregor.1,2 1Surgery, Mayo Clinic, Rochester, MN; 2Surgery, University College London, London, United Kingdom.

5:35 PM (292) Quercetin Glucuronide Improves Cardiac Function in an Ex-Vivo Model of Pig-to-Man Heart Transplantation; A. Bauer,1 J. Juchem,2 J. Postrach,2 R. Ebert,1 J.M. Abicht,1 M. Thomann,2 P. Brenner,2 B. Reichart,2 S. Nees.4 1Department of Anesthesiology, Ludwig-Maximilian University, Munich, Germany; 2Department of Cardiac Surgery, Ludwig-Maximilian University, Munich, Germany; 3Walter Brendel Centre of Experimental Medicine, Ludwig-Maximilian University, Munich, Germany; 4Department of Physiology, Ludwig-Maximilians University, Munich, Germany.
6:15 PM (300) Active Roles of F1 Tolerizing Cells in Early In Vivo Events Leading to Neonatal Tolerance Induction; R.A. Bascom, K. Tao, S.L. Tollenaar, L.J. West. University of Alberta, Edmonton, Canada.

6:20 PM (301) Intramyocardial Injection of Irradiated Apoptotic Peripheral Blood Mononuclear Cells (PBMC) Preserves Ventricular Function After Myocardial Infarction; M. Lichtnerauer, K. Hoetzenecker, M. Hasun, A. Baumgartner, M. Mildner, N. Nickl, G. Werba, M. Zimmermann, A. Mitterbauer, B.K. Podesser, W. Klepetko, H.J. Ankersmit. Department of Thoracic Surgery, Medical University Vienna, Vienna, Austria; Ludwig Boltzmann Cluster for Cardiovascular Research, Vienna, Austria; Department of Dermatology, Medical University Vienna, Vienna, Austria.

6:25 PM (302) Wnt3a Induces Myofibroblast Differentiation by Upregulating TGF-β Signaling through SMAD2 in a β-Catenin-Dependent Manner: Implications for Chronic Rejection; J.M. Carthy, B.M. McManus. Department of Pathology and Laboratory Medicine, University of British Columbia/Institute for Heart + Lung Health, Vancouver, BC, Canada.

5:30 PM – 6:30 PM MINI ORAL SESSION 10 Pulmonary Hypertension (Aqua 306)

CHAIRS: Mandeep R. Mehra, MBBS, FACC, FACP and Srinivas Murali, MD

5:30 PM (303) A Pilot Observational Study of the Correlation Between Depression and Quality of Life Measured by the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR); S. Studer, M. Regala, C. Migliore, I. Sharif, L. Shihabuddin, M. Zucker, D. Baran. Division of Pulmonary and Critical Care Medicine, Newark Beth Israel Medical Center, Newark, NJ; Heart Failure Treatment and Transplant, Newark Beth Israel Medical Center, Newark, NJ; Department of Medicine, Newark Beth Israel Medical Center, Newark, NJ; Department of Psychiatry, Newark Beth Israel Medical Center, Newark, NJ.

5:35 PM (304) Impact of Health-Related Quality of Life on Survival in Pulmonary Arterial Hypertension; M. Bueso, D. Boyce, N. Lechtzin, R.E. Girgis, A.L. Zaiman, P.M. Hassoun, S.C. Mathai. Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.

5:40 PM (305) Adaptation and Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for Sweden; N. Selimovic, S.P. McKenna, J. Viriden, E. Kjörr, J. Twiss, B. Rundqvist. Dept.of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; Actelion Pharmaceuticals, Stockholm, Sweden; Galen Research, Manchester, United Kingdom.

5:45 PM (306) Is Inflammation Playing a Role in the Pathophysiology of Chronic Thromboembolic Pulmonary Hypertension

5:50 PM (307) Pro-Inflammatory HDL in Idiopathic and Connective Tissue Disease-Associated Pulmonary Arterial Hypertension (PAH) Is Improved Ex Vivo by an Apolipoprotein-AI Mimetic Peptide: A Potential “Target” for Therapies; D.J. Ross, K. Navab, B.J. Van Lenten, D.E. Furst, P.J. Clements, A. Ardehali, J. Aboulhosn, A.M. Fogelman, M. Navab. Department of Medicine, Ronald Reagan – U.C.L.A Medical Center; David Geffen School of Medicine, Los Angeles, CA; Department of Surgery, Ronald Reagan – U.C.L.A Medical Center; David Geffen School of Medicine, Los Angeles, CA.

5:55 PM (308) Role of Inflammation in Patients with Both Pulmonary Hypertension and Atrial Fibrillation; J.N. Salamon, M.R. Sardar, W. Saeed, R. Zolty. Cardiology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY; Cardiology, Montefiore Medical Center, Bronx, NY.

6:00 PM (309) Mortality in Pulmonary Hypertension Stratified by Sedimentation Rate; J.N. Salamon, R. Zolty. Cardiology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY; Cardiology, Montefiore Medical Center, Bronx, NY.

6:05 PM (310) Hypoalbuminemia Is a Predictor of Mortality in Pulmonary Arterial Hypertension: A Retrospective Analysis; M.R. Sardar, W. Saeed, Z. Rab, J.N. Salamon, R. Zolty. Cardiology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY; Medicine, Albert Einstein College of Medicine, Bronx, NY.


6:20 PM (313) Effect of Nesiritide on Renal Function in Patients with Decompensated Diastolic Heart Failure Secondary to Pulmonary Hypertension; I. Kelesidis, P. Khullar, W. Saeed, T. Vittorio, R. Zolty. Department of Medicine/Cardiology, Albert Einstein College of Medicine (AECOM), Bronx, NY.

6:25 PM (314) Treadmill Stress Cardiac Magnetic Resonance to Evaluate Right Ventricular Function and Hemodynamic Response to Exercise in a Patient with Pulmonary Arterial Hypertension; V. Franco, S. Raman. Cardiovascular Medicine, Ohio State University, Columbus, OH.
5:30 PM – 6:30 PM
MINI ORAL SESSION 11  Donor Management/Pediatrics
(Indigo 202)

CHAIRS: Michael Burch, MD and Cynthia J. Gries, MD, MSc


5:35 PM  (316)  Add to the Cigarette Warning Label: History of Donor Smoking Leads To Increase in Cardiac Allograft Vasculopathy; A. Velleda,1 L. Pippioniau,2 M. Kittleson,2 D. Lockhart,1 T. Kao,1 B. Kearney,1 M. Johnson,1 E. Stimpson,2 J. Rush,1 M. Kawano,1 E. Moreno,2 J. Kobashigawa.1 1Cedars-Sinai Heart Institute, Los Angeles, CA; 2University of California Los Angeles, Los Angeles, CA; 3Los Angeles, CA.

5:40 PM  (317)  Impact of Routinely Performed Coronary Angiography in Older Heart Donors on Heart Transplantation Results; G. Schmidt,1 F. Polster,2 R. Yeter,3 S. Herbert,1 R. Krüger,2 M. de la Chevallerie,1 C. Wesslau,2 R. Hetzer,1 O. Grauhan,1 1Heart and Thorax Surgery, German Heart Institute Berlin (DHZB), Berlin, Germany; 2DSO-NO, Deutsche Stiftung Organ Transplantation, Berlin, Germany.

5:45 PM  (318)  Long-Term Survival and BOS After Lung Transplantation Are Comparable Between Brain-Dead and Cardiac-Dead Donors; S. De Vleeschauwer,1 D. Van Raemdonck,2 S. Wauters,3 S. Verleden,4 A. Willem-Widyastuti,4 B. Vanauwenhaerde,4 G. Verleden.1 1Lab of Pneumology, KULeuven, Leuven, Belgium; 2Lab of Thoracic Surgery, KULeuven, Leuven, Belgium.

5:50 PM  (319)  Utilization of Donors After Cardiac Death (DCD) for Lung Transplantation (LTx): Rational for Expansion; P. L. Mahoney,1 D.J. Manst,2 C.G. Alex,2 R.B. Love,1 C.H. Wigfield.1 1Thoracic and Cardiovascular Surgery, Loyola University Medical Center, Maywood, IL; 2Dept. of Pulmonary Medicine and Critical Care, Loyola University Medical Center, Maywood, IL; 3Stritch School of Medicine, Loyola University Medical Center, Maywood, IL.

5:55 PM  (320)  Japanese Strategies for Maximizing Heart and Lung Availability: Experience from 100 Consecutive Brain Dead Donors; N. Fukushima,1 M. Ono,2 S. Saito,3 Y. Saiki,4 S. Kubota,4 Y. Tanoue,5 S. Konaka,7 J. Ashikari,4 1Transplant Medicine, Osaka University Hospital, Suita, Osaka, Japan; 2Cardiothoracic Surgery, Tokyo University, Tokyo, Jordan; 3Heart Institute Japan, Tokyo Women’s Medical College, Tokyo, Japan; 4Cardiovascular Surgery, Tohoku University, Sendai, Miyagi, Japan; 5Cardiovascular Surgery, Hokkaido University, Sapporo, Hokkaido, Japan; 6Cardiovascular Surgery, Kyushu University, Fukuoka, Japan; 7Medical Headquarter, Japan Organ Transplant Network, Tokyo, Japan.

6:00 PM  (321)  Hypoalbuminemia and Poor Growth Predict Worse Outcomes Post Heart Transplant in Children; C.O. Castleberry,1 C. White-Williams,1 D.C. Naftel,2 M.A. Tresler,2 S.D. Miyamoto,3 K. Ainley,4 D. Murphy,5 R. Spicer,5 G. Palm,1 L. Bannis-

ter,4 K.O. Schowengerdt,4 L. Gilmore,10 B.D. Kaufman,11 S. Zang-
will,12 1Children’s Hospital of Wisconsin, Milwaukee; 2University of Alabama, Birmingham, AL; 3Children’s Hospital Heart Institute Aurora, Aurora, CO; 4Arkansas Children’s Hospital, Little Rock, AR; 5Riley Hospital for Children, Indianapolis, IN; 6Cincinnati Children’s Hospital, Cincinnati, OH; 7Children’s Memorial Hospital, Chicago, IL; 8The Hospital for Sick Children, Toronto, ON, Canada; 9Cardinal Glennon Children’s Medical Center, St Louis, MO; 10Columbia University-Babies Hospital, New York, NY; 11Children’s Hospital of Philadelphia, Philadelphia, PA.

6:05 PM  (322)  Donor Specific Antibodies (DSA): Can They Predict C4d Staining and Antibody Mediated Rejection (AMR)?; D.M. Peng,1 R.J. Boucek,1 Y.M. Law,1 M.S. Kemna,1 K. Nelson,2 P. Warner.2 1Pediatrics, University of California Los Angeles, Los Angeles, CA; 2Puget Sound Blood Center, Seattle, WA.

6:10 PM  (323)  Simultaneous Heart and Kidney Transplantation in Children: Analysis of the United Network of Organ Sharing Database; F. Zafar,1 I. Adachi,1 J.S. Heinle,1 A.G. Cabrera,2 W.J. Dreyer,3 J.W. Rossano,4 D.L.S. Morales.1 1Congenital Heart Surgery, Texas Children’s Hospital/Baylor College of Medicine, Houston, TX; 2Pediatric Cardiology, Texas Children’s Hospital/Baylor College of Medicine, Houston, TX.

6:15 PM  (324)  Superior Outcomes of Heart Transplant in Congenital Heart Disease with Physiologic Single-Lung; W.A. Zuckerman,1 M.E. Richmond,1 R.K. Singh,1 J.M. Chen,1 L.J. Addonizio,1 1Division of Pediatric Cardiology, Columbia University Medical Center, New York, NY; 2Department of Cardiothoracic Surgery, Cornell University Medical Center, New York, NY.

6:20 PM  (325)  Outcomes of Lung Transplantation in Children with Idiopathic Pulmonary Arterial Hypertension: St. Louis Children’s Hospital Experience; B.S. Goldstein,1 C.B. Huddleston,1 S.C. Sweet,2 J. Mao,1 R.M. Grady.1 1Pediatric Cardiology, Washington University/St Louis Children’s Hospital, St Louis, MO; 2Pediatric Pulmonology, Washington University/St Louis Children’s Hospital, St Louis, MO.

6:25 PM  (326)  An Integrated Pediatric Pump-Lung for Cardiac/Cardiopulmonary Support; Z.J. Wu,1 B.N. Gellman,2 T. Zhang,1 K. Dasse,2 J.P. Garcia,1 B.P. Griffith.1 1Surgery, University of Maryland Baltimore, Baltimore, MD; 2Levitrone, LLC., Waltham, MA.

5:30 PM – 7:00 PM
MECHANICAL CIRCULATORY SUPPORT COUNCIL MEETING
(Indigo 204)

PAST PRESIDENTS’ COUNCIL MEETING/RECEPTION
(Indigo 206)

2012 PROGRAM COMMITTEE MEETING
(Sapphire 400)

6:30 PM – 7:30 PM
JUNIOR FACULTY AND TRAINEE COUNCIL MEETING
(Indigo 204)

8:00 PM – 10:00 PM
PRESIDENT’S GALA RECEPTION
(Sapphire Ballroom)
SATURDAY, APRIL 16, 2011

6:30 AM – 4:30 PM
Speaker Ready Room Open (Sapphire 410)

7:00 AM – 2:30 PM
Registration Desk Open (Sapphire Foyer)

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 11: Challenging Patients and Creative Solutions
(Indigo 204)
CHAIRS: Kevin C. Carney, RN, CCTC and Christiane Kugler, PhD

7:00 AM
Lung Transplant, Holli C. Blazey, MSN, CRNP, Cleveland Clinic Foundation, Cleveland, Ohio

7:20 AM
Heart Transplant, Sharon Beer, RN, Queen Elizabeth Hospital, Birmingham, United Kingdom

7:40 AM
MCSD, Laura J. Blue, RN, Duke University Medical Center, Durham, North Carolina

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 12: ABCs of Clinical Transplantation for Scientists
(Indigo 202)
CHAIRS: Daniel H. Kim, MD and Stephan M. Ensminger, MD, PhD

7:00 AM
Medical Aspects of Heart Failure and Transplant Management, Josef Stehlik, MD, MPH, University of Utah, Salt Lake City, Utah

7:15 AM
Surgical Aspects of MCS and Heart Transplantation, Bruce R. Rosengard, MD, FRCS, Massachusetts General Hospital, Boston, Massachusetts

7:30 AM
Medical Aspects of Pulmonary Failure and Transplant Management, Jonathan B. Orens, MD, Johns Hopkins University, Baltimore, Maryland

7:45 AM
Surgical Aspects of Lung Transplantation, John Dark, MB, FRCS, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 13: Waiting in the Wings – Advanced Heart Failure
(Aqua 306)
CHAIRS: Jeffrey J. Teuteberg, MD and Mariell Jessup, MD

7:00 AM
Data Presentation: Who Are The Patients at Referral Centers? Jennifer Cowger, MD, University of Michigan, Ann Arbor, Michigan

7:10 AM
Data Presentation: Who Wants A VAD? Garrick Stewart, MD, Brigham and Women’s Hospital, Boston, Massachusetts

7:20 AM
Data Presentation: What Is Current “Optimal Medical Therapy” in Advanced Heart Failure, J. Eduardo Rame, MD, Pennsylvania Heart and Vascular Center, Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania

7:30 AM
Data Presentation: How is Quality of Life and Function With Advanced Heart Failure? Parag C. Patel, MD, University of Texas Southwestern, Dallas, Texas

7:40 AM
Data Presentation: Co-Morbidities in the Heart Failure Clinic Eligibility, Michelle M. Kittleson, MD, PhD, Cedars-Sinai Heart Institute, Los Angeles, California

7:50 AM
Discussion/Q&A
Broken Heart? We Can Offer a Second-Hand Pump

**CONCURRENT SESSION 37: Broken Heart? We Can Offer a Second-Hand Pump** (Indigo 202)

**CHAIRS:** Alan H. Menkis, MD, FRCS(c) and Stephen R. Large, MB MA MS F

**8:00 AM (346)** US- Derived Quantitative Donor Risk Score Predicts Mortality After Orthotopic Heart Transplantation in the UK; C.A. Rogers,¹,² E. Akan,¹,² R.S. Bonser,³ N.R. Banner.³ On behalf of the UK Cardiothoracic Transplant Audit Steering Group, Clinical Effectiveness Unit, The Royal College of Surgeons of England, London, United Kingdom; ¹Cardiopulmonary Transplantation, Queen Elizabeth Hospital, Birmingham, United Kingdom; ²Cardiopulmonary Transplantation, Harefield Hospital, Harefield, Middlesex, United Kingdom.

**8:10 AM (347)** Donor Hypo- and Hypernatremia are Predictors for Increased 1-Year Mortality After Cardiac Transplantation; D. Hoefner,¹ E. Ruttmann-Ulmer,¹ J. Smits,² M. Grimm,¹ H. Antreter.¹ ¹Cardiac Surgery, Medical University Innsbruck, Innsbruck, Austria; ²Eurotransplant International Foundation, Leiden, Netherlands.

**8:20 AM (348)** Hearts from DCD Donors Display Excellent Biventricular Function Following Transplantation; A.A. Ali,¹ P. White,² B. Xiang,¹ R. Arora,¹ T. Lee,¹ E. Ashley,³ S.R. Large,² G. Tian,¹ D. Freed.¹ ¹Surgery, University of Manitoba, Winnipeg, MB, Canada; ²Cardiopulmonary Surgery, Papworth Hospital, Cambridge, United Kingdom; ³Cardiovascular Medicine, Stanford University, Palo Alto, CA.

**8:30 AM (349)** The Impact of Preservative Solution on Heart Transplant Outcomes; T.J. George,¹ G.J. Arnaoutakis, W.A. Baumgartner, A.S. Shah, J.V. Conte. The Division of Cardiac Surgery, The Johns Hopkins Medical Institutions, Baltimore, MD.

**8:40 AM (350)** Successful Twelve Hours of Cardiac Preservation with Custodiol-N, a Novel Organ Protection Solution in an Orthotopic Heart Transplantation Model; G. Szabo,¹ G. Veres,¹ T. Radovits,¹ A. Weymann,¹ B. Schmack,¹ K. Carck,¹ F. Horkay,² B. Merkel,³ P. Sos,³ I. Hartyanszky.² ¹Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany; ²Department of Cardiac Surgery, Semmelweis University, Budapest, Hungary; ³Department of Cardiothoracic Surgery, Semmelweis University, Budapest, Hungary.

**8:50 AM (351)** Continuous Crystalloid Microperfusion Provides Cardiovascular Preservation Superior to Cold Storage for Donation After Cardiac Death; J.W. Choong,¹ R. Ou, A.J. Gay, Y.W. Lim, R.F. Salamonson, S. Repse, F.L. Rosenfeldt. Cardiac Surgical Research Unit, Alfred Hospital, Melbourne, VIC, Australia.

**8:00 AM – 9:00 AM CONCURRENT SESSION 38: Viral and Fungal Impacts After Lung Transplantation** (Indigo 204)

**CHAIRS:** Erik A. M. Verschuuren, MD, PhD and Stanley I. Martin, MD

**8:00 AM (352)** Community Acquired Respiratory Viral Infection Is a Risk Factor for Death After Lung Transplantation; D.C. Chambers,¹ A. Burke,¹ T.W.V. Daniels,² S.T. Yerkovich,¹ P.M. Hopkins.¹
10:00 AM **Awards Presentations**

10:15 AM (358) **FEATURED ABSTRACT** Is Mechanically Bridging Patients with a Failing Cardiac Graft to Re-Transplantation an Effective Therapy? Analysis of the UNOS Database; F. Zafar,1 I. Adachi,1 J.S. Heinle,3 A.G. Cabrera,2 J.W. Rossano,2 C.D. Fraser,3 D.L.S. Morales1 1Congenital Heart Surgery, Texas Children’s Hospital/Baylor College of Medicine, Houston, TX; 2Pediatric Cardiology, Texas Children’s Hospital/Baylor College of Medicine, Houston, TX.

10:30 AM (359) **FEATURED ABSTRACT** Risk Assessment in Pulmonary Hypertension Associated with Left Heart Disease; R. Agarwal,1 A.J. Foreman,3 S.J. Shah, C. Glassner,1 S.L. Coslet,1 A.S. Anderson,1 M. Gomberg-Maitland.1 1Section of Cardiology, Department of Medicine, University of Chicago, Chicago, IL; 2Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL; 3ICON Clinical Research, San Francisco, CA.

10:45 AM **Choices After Age 70: Three Perspectives**

10:45 AM **Case Presentation**, Lynne W. Stevenson, MD, Brigham & Women’s Hospital, Boston, Massachusetts

10:50 AM **Mechanical Circulatory Support**, Roland Hetzer, MD, PhD, German Heart Institute, Berlin, Germany

11:00 AM **Heart Transplantation**, Nicholas G. Smedira, MD, Cleveland Clinic Foundation, Cleveland, Ohio

11:10 AM **Palliative Care – Less Is More**, Heather J. Ross, MD, MHSc, ICON Clinical Research, San Francisco, CA.

11:20 AM **Discussion/Q&A**

11:30 AM – NOON

Box Lunch Pick-up (ticket required) (Sapphire Foyer)

11:45 AM – 12:45 PM

**MID-DAY SYMPOSIUM 9**: Great Debates in Cardiac Transplant Immunosuppression (Sapphire D)

**CHAIRS**: James C. Fang, MD and Juan F. Delgado-Jimenez, MD

11:45 AM **Resolved: All Heart Transplant Recipients Should Receive Induction Therapy**

**Pro**: Javier Segovia, MD, PhD, Hospital Puerta De Hierro, Madrid, Spain

**Con**: James C. Fang, MD, University Hospital, Advanced Heart Failure and Transplant, Shaker Heights, OH

12:05 PM **Resolved: All Heart Transplant Recipients Should be Off Corticosteroids by Three Months Post-Transplant**

**Pro**: David A. Baran, MD, Newark Beth Israel Medical Center, Newark, New Jersey

**Con**: Maria G. Crespo-Leiro, MD, Hospital Universitario A Coruña, La Coruña, Spain
11:45 AM – 12:45 PM
MID-DAY SYMPOSIUM 13: Clinical Controversies in Pulmonary Hypertension: To Treat or Not To Treat? That Is The Question
(Sapphire IM)

CHAIRS: Robert J. Schilz, DO, PhD and Ivan Robbins, MD

11:45 AM
How to Treat Class III PAH Patients: Stepwise Treatment Combining Oral and Inhaled Therapies is the Best Approach, Anne Keogh, MBBS, MD, St. Vincent’s Hospital, Sydney, Australia

12:00 PM
How to Treat Class III PAH Patients: Continuous Prostanoids Should Be the First Line of Treatment, Harrison W. Farber, MD, Boston University School of Medicine, Boston, Massachusetts

12:15 PM
Exercise-Induced PH: Does It Exist? Should We Treat It? A Case Based Discussion, Myung Park, MD, University of Maryland, Baltimore, MD

12:30 PM
Pulmonary Hypertension and Interstitial Lung Disease: Should Therapies Be Directed at Pulmonary Hypertension? A Case Based Discussion, Steven D. Nathan, MD, Fairfax Inova Hospital, Falls Church, Virginia

11:45 AM – 1:00 PM
COUNCIL REPORTS TO THE BOARD AND MEMBERSHIP (Sapphire 400)

1:00 PM – 2:00 PM
CONCURRENT SESSION 39: How Do VADs Impact Our Decisions on Transplant? (Sapphire D)

CHAIRS: Edwin C. McGee, Jr., MD and Cumara C. Sivathasan, MBBS, FRCS

1:00 PM (360) The Effect of Ventricular AssistDevices on Long-Term Post-Transplant Outcomes: A Systematic Review of Observational Studies; A.C. Alba,1 M. McDonald,1 V. Rao,2 H.J. Ross,1 D.H. Delgado.1 Division of Cardiology and Heart Transplantation, Toronto General Hospital, Toronto, ON, Canada; 2Division of Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada.
1:00 PM – 2:00 PM
CONCURRENT SESSION 42: Ischaemia Reperfusion Injury
(Aqua 306)

CHAIRS: Hari R. Mallidi, MD and Carl Atkinson, PhD

1:00 PM (375) Egr-1 Controls Ischemia-Reperfusion Injury After Lung Transplant by Regulating the PMN Infiltrations; S. Yamamoto, M. Yamane, M. Okazaki, S. Otani, N. Waki, T. Otto, S. Miyoshi. Cancer and Thoracic Surgery, Okayama University Graduate School of Medicine, Okayama, Japan.

1:10 PM (376) Consequences of Brain Death Are Triggered by Intragraft Immune Competent Cells; B. Floerchinger,1,2 X. Yuan,1 M.-O. Timsit,1 X. Ge,1 Y.-L. Lee,1 C. Schmid,1,2 S.G. Tullius.1 1Transplantation Laboratory, Brigham and Women’s Hospital, Boston, MA; 2Department of Cardiothoracic Surgery, University Hospital of Regensburg, Regensburg, Germany.

1:20 PM (377) Enhanced Pro-Survival Signaling by Phosphatase Inhibition – A Potential Strategy for Improving Post-Storage Function of Marginal Donor Hearts; L. Gao,1 J. Kwan,1 A. Doyle,1 P. Macdonald,1,2 M. Hicks.1 1Cardiac Physiology and Transplant Program, Victor Chang Cardiac Research Institute, Darlington, NSW, Australia; 2Heart & Lung Transplantation Unit, St Vincent’s Hospital, Darlinghurst, NSW, Australia; 3Clinical Pharmacology & Toxicity, St Vincent’s Hospital, Darlinghurst, NSW, Australia.

1:30 PM (378) Constandy Stable Hypoxia Inducible Factor-1 in Myeloid Cells Prevents Acute Rejection In Mouse Cardiac Allografts; M.A.I. Keränen,1 S. Sirviala,1 R. Krebs,1 R. Tuuminen,1 R.S. Johnson,2 A.I. Nykänen,1 K.B. Lemström.1,2 1Transplantation Laboratory, Haartman-Institute, University of Helsinki, Helsinki, Finland; 2Randall Johnson Lab, University of California, San Diego; 3Department of Cardiothoracic Surgery, Helsinki University Central Hospital, Helsinki, Finland.

1:40 PM (379) The Role of C3 Activation in Airway Hypoxia and Ischemia in Murine Model of Orthotopic Tracheal Transplantation; M.A. Khan,1 X. Jiang,1 C. Atkinson,1 S. Tomlinson,2 M.R. Nicolls.1 1Medicine, VA Palo Alto, Stanford University, Palo Alto, CA; 2Basic Sciences, Medical University of South Carolina, Charleston, SC.

1:50 PM (380) Extracorporeal Shock Wave Therapy Reverses Ischemia-Related Left Ventricular Dysfunction and Remodeling: Molecular-Cellular and Functional Assessment; F.-Y. Lee,1 J.-J. Sheu,1 C.-K. Sun,2 C.-J. Wang,3 S. Chua,2 Y.-C. Lin,4 S. Leu,4 C.-J. Wu,4 M. Fu,4 H.-K. Yip,4 1Cardiothoracic and Vascular Surgery, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung Hsien, Taiwan, Taiwan; 2General Surgery, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung Hsien, Taiwan, Taiwan; 3Orthopedic Surgery, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung Hsien, Taiwan, Taiwan; 4Cardiology, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung Hsien, Taiwan, Taiwan.
General Posters
(Indigo Ballroom and Indigo Foyer)

Presenters will be available during the afternoon breaks from 3:30 pm – 4:00 pm on Thursday and Friday to discuss their posters and answer any questions.

THURSDAY, APRIL 14, 2011


(394) Ex-Vivo Perfusion Worsened Lung Injuries Induced by Gastric Acid Aspiration in Pigs; T. Khalifé-Hocquemiller, E. Sage, P. Dorfmuller, S. Eddahibi, E. Fadel. LCE INSERM U999, Hopital Marie Lannelongue, Le Plessis Robinson, France.


(396) Supercooling Preservation at -2°C Protects Rat Lung Grafts from Ischemia-Reperfusion Injury Via Elevated Expression of Heat Shock Protein 70; T. Okamoto, X. Tang, C. Farver, K. McCurry. Pathobiology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH; Anatomic Pathology, Cleveland Clinic, Cleveland, OH; Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH.

(397) Effects of Calcium Sensitizer Levosimendan on Myocardial Function After Cardiopulmonary Bypass (CPB) with Deep Hypothermic Circulatory Arrest in Rats;
(398) Increased Tissue Endothelial Progenitor Cells in End-Stage Lung Diseases with Pulmonary Hypertension; M. Schiavon, F. Calabrese, F. Lunardi, G. Fadini, C. Agostini, G. Marulli, M. Loy, F. Rea. Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy; Medical Diagnostic Sciences and Special Therapies, University of Padua Medical School, Padua, Italy; Clinical and Experimental Medicine, University of Padua Medical School, Padua, Italy.

(399) Dysregulation of Mitochondria Fission and Fusion Proteins in Explanted Failure Human Hearts; H.N. Sabbah, R.C. Gupta, S. Rastogi, M. Wang. Medicine, Henry Ford Hospital, Detroit, MI.

(400) Metabolic Modulation – A Feasible Concept To Tackle Intimal Proliferation?; T. Deuse, T. Gossler, X. Hua, M. Stubbendorff, B. Haddad, H. Reichenspurner, R.C. Robbins, E. Michelakis, S. Schrepfer. TSI Lab, University Heart Center Hamburg, Hamburg, Germany; CT Surgery, Stanford University, Stanford, CA; Pulmonary Hypertension Program, Department of Medicine, University of Alberta, Edmonton, AB, Canada.


(402) WITHDRAWN

(403) Murine Cytomegalovirus Infection Is Associated with Increased Number of T- and Dendritic Cells in Murine Aortic Allografts; C. Heim, S. Eckl, S. Abele-Ohl, M. Ramsperger-Gleixner, S. Mahmoudian, T. Stammering, M. Weyand, S.M. Emsninger. Cardiac Surgery, University Hospital, Erlangen- Nürnberg, Germany; Institute for Clinical and Molecular Virology, Erlangen- Nürnberg, Germany.


(405) Detection of Autoantibodies Against Cardiac Myosin Binding Protein-C in Patients with Dilated Cardiomyopathy; N. Nair, S. Muthusamy, G.J. Dehmer, S. Sadayappan. Division of Cardiology, Scott & White Healthcare, Texas A & M HSC College of Medicine, Temple, TX; Department of Cell and Molecular Physiology, Loyola University Chicago, Stritch School of Medicine, Maywood, IL.

(406) Antibody Produced in the Presence of CNI Immunosuppression Contributes to Allograft Vasculopathy; A.J. Gareau, B. Nashan, T.D.G. Lee. Dalhousie University, Halifax, NS, Canada; University Medical Center, Hamburg-Eppendorf.

(407) Quantification of Circulating Cell-Free DNA in Pediatric Heart Transplant Recipients; C.D. Castleberry, M. Hidesträäd, A. Tomita-Mitchell, T.M. Ellis, H.L. Liang, S. Harris, M. Goetsch, G. Stendahl, R. Hoffmann, B. Shames, J. Tweddell, S. Zangwill, M.E. Mitchell. Children’s Hospital of Wisconsin, Milwaukee, WI; Medical College of Wisconsin, Milwaukee, WI; Blood Center of Wisconsin, Milwaukee, WI.

(408) Inflammatory and Suppressive Graft Antigen-Specific CD4+ T-Cells Co-Exist in Heart Allografts; R.C. Shelstad, S.J. Shumway, M.K. Jenkins. Division of Cardiothoracic Surgery, Department of Surgery, University of Minnesota, Minneapolis, MN; Microbiology, University of Minnesota, Minneapolis, MN.

(409) Laboratory Monitoring of Cell-Mediated Immunity and Cytokines in Cardiac Transplant Recipients for Prediction of Infection Episodes; N.M. Heikal, H.R. Hill, M. Barakat, T. Martins, J.C. Delgado, J. Stehlik, A.G. Kfoury, E.M. Gilbert, A. Wilson, F.M. Bader. Department of Pathology, ARUP Institute for Clinical and Experimental Pathology, University of Utah School of Medicine, Salt Lake City, UT; Division of Cardiology, University of Utah School of Medicine, Salt Lake City, UT.


(411) Acceptance of Third-Party Cardiac Allografts in Neonatally Tolerized Mice Is Not Due to Generalized Immunosuppression; S. Wang, B. Motyka, E. Dijké, S. Tollenar, K. Tao, S.R. Meyer, L.J. West, Department of Pediatrics, University of Alberta, Edmonton, Canada; Department of Surgery, University of Alberta, Edmonton, Canada; Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Canada.

(412) Lung Transplant Immunosuppressive Drugs Influence Pulmonary Surfactant Protein A (SP-A) Expression; B. Aramini, P.M. Geraghty, D. Lederer, J. Wilt, L. Shah, S. Mattioli, J. Flores, S. Arcasoy, J.R. Sonett, E.F. D’Ovidio. PhD Program in “Pneumo-Cardio-Thoracic Sciences of Medical and Surgical Interest,” University of Bologna, Bologna, Italy; Columbia University, New York; Penn State University, Hershey.

(413) Pharmacokinetics of Mycophenolate Mofetil (MMF) in Lung Transplantation: Comparison with Renal Transplantation; B.C.M. de Winter, C. Monchaud, A. Prémade, C. Pison, R. Kessler, M. Reynaud-Gaubert, D. Oromer, M. Stern, R. Guillemain, K. Nnoo, M. Estenne, P. Marquet, A. Rousseau, UMR-S850, INSERM, CHU Limoges, Univ Limoges, Limoges, France; Service de Pharmacie, Toxicologie et Pharmacovigilance, CHU Limoges, Limoges, France; Pôle Médicine Aiguë et Communautaire, Pneumologie, CHU Grenoble, Univ Grenoble, Grenoble, France; Service de Pneumologie, Nouvel Hôpital Civil, Strasbourg, France; Service de Pneumologie, CHU Nord, Marseille, France; Service de Chimurgie Thoracique, Hôpital du Haut-Lévêque, Bordeaux, France; Service de Pneumologie, Hôpital
Myeloperoxidase Tissue Level (MPO) Reflects Protective Effect of Ventilation Before Organ Reconditioning of Gastric Acid Injured Lung Grafts; Five-Year Results of a Multicenter Observational Study Comparing Tacrolimus and Cyclosporine in Heart Transplantation; A. Zuckermann. Medical University of Vienna, Vienna, Austria.


Hypothermic Ex-Vivo Perfusion Prevents Ischemia Reperfusion Injury in Rat Lungs from Non-Heart-Beating Donors; D. Nakajima, T. Yamada, F. Chen, J. Sakamoto, A. Ohsumi, T. Fujinaga, T. Shoji, H. Sakai, T. Bando, H. Date. Thoracic Surgery and Organ Preservation Technology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Reconditioning of Gastric Acid Injured Lung Grafts with Surfactant in Lung Transplantation; I. Inci, S. Hillinger, S. Arni, W. Jungraithmayr, B. Leskosek, W. Weder. Thoracic Surgery, University Hospital, Zurich, Switzerland.


Orens, C.A. Merlo, A.S. Shah. Division of Cardiac Surgery, The Johns Hopkins Medical Institutions, Baltimore, MD. Division of Pulmonary and Critical Care Medicine, The Johns Hopkins Medical Institutions, Baltimore, MD.

446 Cardiopulmonary Bypass and Outcomes of Lung Transplantation in the Modern Era: “To Pump or Not to Pump;” C.A. Bermudez, V.T. Jarido, Y. Toyoda, D. Zaldonis, J.M. Pilewski, J. Bhama, B. Johnson, N. Shigemura, P. Bonde, C. Gries, M. Crespo. Heart, Lung, and Esophageal Surgery Institute, University of Pittsburgh Medical Center, Pittsburgh, PA; Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA.


448 Combined Thoracic Organ and Liver Transplantation in Multi-Organ End-Stage Patients As a Successful Therapeutic Strategy; B. Ramlawi, J.J. Garcia-Morales, J.D. Estep, H. Seetharamaju, R.B. Kesavan, B.A. Bruckner, A.D. Parulekar, P.J. Kolodziejski, N. Shigemura, G.P. Noon, O. Gaber, M. Loebel. Cardiovascular Surgery, Methodist DeBakey Heart & Vascular Center, Houston, TX; Baylor College of Medicine, Houston, TX.

449 Regional Differences in United States Lung Transplantation According to UNOS Geographic Regions; G.J. Arnaoutakis, T.J. George, A. Kilic, C.A. Merlo, A.S. Shah. Division of Cardiac Surgery, The Johns Hopkins Medical Institutions, Baltimore; Division of Pulmonary and Critical Care Medicine, The Johns Hopkins Medical Institutions, Baltimore.

450 Sensitized Recipients Can Undergo Pulmonary Transplantation with Excellent Intermediate and Long-Term Outcomes; L.M. Ferrer, K. Mudy, Y. Bell, J. Gaughan, S.H. Leech, F. Cordova, A.A. Mangi. Cardiac Surgery, Temple University Hospital, Philadelphia, PA; General Surgery, Temple University Hospital, Philadelphia, PA; Pulmonary and Critical Care, Temple University Hospital, Philadelphia, PA; Pathology, Temple University Hospital, Philadelphia, PA.

451 Minimally Invasive Bilateral Sequential Lung Transplantation (MBSLTx) Is Associated with Reduced Length of Stay at ICU; A.F. Popov, D. Rajarathnam, B. Zych, H. Krueger, C. Martin, A.R. Simon. Department of Cardiothoracic Transplantation & Mechanical Support, Royal Brompton & Harefield Hospital, London, Harefield, United Kingdom; Respiratory Medicine, Royal Brompton & Harefield Hospital, London, Harefield, United Kingdom.

452 Gastrointestinal Bleeding in Patients with Ventricular Assist Devices: A Diagnostic and Treatment Algorithm; M. Azzouz, S.D. Young, M.M. Meyer, B. Sun, M.S. Firstenberg. Gastroenterology, Hepatology, and Nutrition, The Ohio State University Medical Center, Columbus, OH; Cardiac Surgery, The Ohio State University Medical Center, Columbus, OH; Cardiac Thoracic Surgery, Minneapolis Heart Institute, Minneapolis, MN.

453 Gastrointestinal Bleeding After Implantation of the HeartWare HVAD Left Ventricular Assist Device; M. Stueber, D. Malehsa, M. Avsar, N. Jahn, C. Bara, A. Haverich. Hannover Medical School, Hannover, Germany.


455 Is Reduced Pump Speed Associated with Less Gastrointestinal Bleeding Among Patients on Non-Pulsatile Left Ventricular Assist Devices?: M. Sibbald, M. McDonald, D. Delgado, H. Ross, C. Alba, R. Cusimano, T. Yau, J. MacLver, V. Rao. Toronto General Hospital, University Health Network, Toronto, ON, Canada; Division of Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada.


457 Readmission Following Continuous Flow LVAD Implantation: Are We keeping Patients out of the Hospital Long Enough?; D. Goldstein, P. Edwards, S. Maybaum, J. Shin, G. Stevens, D. D’Alessandro. Cardiovascular and Thoracic Surgery, Mountefiore Medical Center, Bronx, NY; Cardiology, Mountefiore Medical Center, Bronx.


459 Impact of Continuous Flow Left Ventricular Assist Device (LVAD) on Carotid Artery Compliance and Distensibility; D.L. Templeton, D.R. Dengel, A.S. Kelly, P. Painter, P.M. Eckman, R. John, University of Minnesota, Minneapolis, MN; Division of Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN; Department of Veterans Affairs, Minneapolis VA Health Care System, Minneapolis, MN; Division of Cardiology, University of Minnesota, Minneapolis, MN.


(462) Cardiac Improvement with Combined Neurohormonal Blockade and Support with a Continuous Flow LVAD; S.R. Patel, S. Murthy, V. Bhatia, P. Edwards, D. Goldstein, S. Maybaum. Center for Advanced Cardiac Therapy, Division of Cardiology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY.

(463) Increased Levels of Retinol Binding Protein 4 in Patients with Severe Heart Failure Correct After Hemodynamic Improvement through Ventricular Assist Device Placement; N. Chavarria, F.H. Cheema, R. Khan, A. Chokshi, E. Collado, T. Kato, H. Takayama, Y. Naka, M. Farr, D.M. Mancini, P.C. Schulze. Cardiology/Medicine, Columbia University Medical Center, New York, NY; Cardiothoracic Surgery, Columbia University Medical Center, New York, NY.

(464) Systolic Augmentation of Continuous Aortic Regurgitation: A Novel Marker of Increased Fractional Shortening and Flow in HeartMate II Supported Patients; A. Agarwal, M. Padmalingam, R. Mohan, R. Banifatemi, J. Fontaine, S. Hankins, H. Eisen, J. Plehn. Division of Cardiology, Drexel University College of Medicine, Philadelphia, PA.

(465) Mechanical Unloading through Ventricular Assist Device Implantation Corrects Adiponectin Resistance in Patients with Advanced Heart Failure; R.S. Khan, A. Chokshi, M. Chew, S. Yu, P. Singh, F. Cheema, H. Takayama, Y. Naka, M.-J. Farr, D. Mancini, P.C. Schulze. Cardiology/Medicine, Columbia University Medical Center, New York, NY; Cardiothoracic Surgery, Columbia University Medical Center, New York, NY.

(466) Ventricular Assist Device Implantation Corrects Systemic and Peripheral Impairment of Growth Hormone/Insulin-Like Growth Factor-1 Signaling in Patients with Advanced Heart Failure; A. Chokshi, M. Chew, R.S. Khan, F. Cheema, M. Jones, H. Takayama, Y. Naka, D. Mancini, P.C. Schulze. Cardiology/Medicine, Columbia University Medical Center, New York, NY; Cardiothoracic Surgery, Columbia University Medical Center, New York, NY.

(467) Generally Accessible Echocardiographic Parameters of Left Heart Could Predict Right Heart Failure After Left Ventricular Assist Device Implantation; T.S. Kato, M. Farr, M. Maurer, H. Akashi, K. Shahzad, N. Gukasyan, M. Deng, S. Iwata, S. Homma, H. Takayama, Y. Naka, C.P. Schulze, U. Jorde, D. Mancini. Department of Medicine, Division of Cardiology, Columbia University Medical Center, New York, NY; Department of Surgery, Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY.


(474) Improvements in Neurocognitive Function are Delayed After LVAD Implantation; R.J. Petrucci, B.L. Carrow, A. Lagore, C. Cassano, E.J. Gracely, J.W. Entwistle. Psychiatry, Drexel University College of Medicine, Philadelphia, PA; Thoratec Corporation, Pleasanton, CA; LaSalle University, Philadelphia, PA; Cardiothoracic Surgery, Drexel University College of Medicine, Philadelphia, PA; Family, Community and Preventive Medicine, Drexel University College of Medicine, Philadelphia, PA.

(475) Ventricular Assist Device Related Infections Increase One-Year Mortality; S.V. Pamboukian, T. Saavedra, J.A. Tallaj, R.N. Brown, J.F. George, M. Patel, W.L. Holman, J.K. Kirklin, J. Baddley. Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL; Infectious Disease, University of Alabama at Birmingham, Birmingham, AL; Cardiothoracic Surgery, University of Alabama at Birmingham, Birmingham, AL.


(477) Temporal Trends in Body Mass Index After Implantation with Continuous Flow LVAD; M. Toma, M. Toma, A. Dorogi, G.V. Gonzalez-Stawinski, N.G. Smedira, R.C. Starling, M.M. Mounis. Department of Cardiology, St. Paul’s Hospital, Vancouver, BC, Canada; Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH; Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH.
(478) Ventricular Assist Device Implantation Provides Opportunity for Significant Weight Loss in Obese Patients with Advanced Heart Failure; R. Yanagida,1 L.S.C. Czer,2 A. Rusza,2 R. Vespignani,1 S.A. Simdir,1 E.R. Schwarz,2 M. De Robertis,1 J. Mirocha,1 B. Coleman,2 C. Runyon,1 R. Jocson,1 C. Olay,1 R.M. Kass,1 J. Kobashigawa,3 A. Trento,1 Division of Cardiothoracic Surgery, Cedars-Sinai Heart Institute, Los Angeles, CA; 2Division of Cardiology, Cedars-Sinai Heart Institute, Los Angeles, CA.

(479) Limited Correlation Between Cardiac Output and Displayed Device Flow in Patients with HeartMate II LVAS; F.M. McNeil,1 J.M. Gelow,1 J. Mudd,1 E. Adler,1 H. Song,1 A. Kim,1 Cardiovascular Medicine, Oregon Health and Science University, Portland, OR; Cardiothoracic Surgery, Oregon Health and Science University, Portland, OR.

(480) Bloodstream Infections in Pediatric Patients with Pulsatile Ventricular Assist Devices; C. Burton,1 S. Forgie,1 J. Rutledge,2 L. Lequier,3 A. Conradi,2 G. Garcia Guerra,3 D. Ross,4 I. Rebyk,4 H. Buchholz,4 Pediatrics, Division of Pediatric Infectious Diseases, Stollery Children's Hospital, Edmonton, AB, Canada; Pediatrics, Division of Pediatric Cardiology, Stollery Children's Hospital, Edmonton, AB, Canada; Pediatrics, Division of Pediatric Critical Care, Stollery Children's Hospital, Edmonton, AB, Canada; Surgery, Division of Cardiac Surgery, Stollery Children's Hospital, Edmonton, AB, Canada.

(481) Clinical Importance of Aortic Valve Deterioration During HeartMate II Support; R.M. Adamson,1 W.P. Dembitsky,1 S. Baradarian,1 J. Chammas,1 V. Norman,1 P. Hoagland,2 M. Stathovich,1 S. Chillcott,3 B. Jaski,1 Cardiothoracic Surgery, Sharp Memorial Hospital, San Diego, CA; Cardiology, Sharp Memorial Hospital, San Diego, CA; Nursing, Sharp Memorial Hospital, San Diego, CA.

(482) Consideration for Serial Surveillance of Aortic Valve Following Implantation of Continuous Flow Left Ventricular Assist Device; S. Emami,1 C.M. O'Keefe,1 Y. Ravi,1 R.S. Higgins,3 J.A. Crestanello,3 M.S. Firstenberg,7 J.H. Sirak,2 K. McBrair,2 A.K. Hasan,1 C.B. Sai-Sudhakar,2 Medicine, Ohio State University Medical Center, Columbus, OH; Comprehensive Transplant Center-Mechanical Circulatory Support, Ohio State University Medical Center, Columbus, OH; Surgery, Ohio State University Medical Center, Columbus, OH.

(483) Lower Socioeconomic Status Predicts Poor Waitlist and Post-Heart Transplant Survival in Children; R.R. Davies,1 M.J. Russo,2 O. Reinhartz,3 K. Maeda,1 R.C. Robbins,1 D.N. Rosenthal,1 C. Chin,2 D. Bernstein,1 H.S. Mallidi,2 Cardiothoracic Surgery, Stanford University, Palo Alto, CA; Surgery (Cardiothoracic), University of Chicago, Chicago, IL; Pediatrics (Cardiology), Stanford University, Palo Alto, CA.

(484) Depression Reduces Chance for Clinical Improvement in Heart Transplant Candidates Independent of Disease Severity; Physical Activity and Eating Habits; G. Weidner,1 H. Spaderna,2 D. Zahn,3 J.M.A. Smits,4 and the Waiting for a New Heart Study Group. Biology, San Francisco State University, San Francisco, CA; Psychology, Johannes Gutenberg University, Mainz, Germany; Psychosomatic Medicine, Ruhr University, Bochum, Germany; Eurotransplant International Foundation, Leiden, Netherlands.

(485) Hospital Charges for Pediatric Heart Transplant Hospitalizations in the United States from 1997 to 2006; J.W. Rossano,1 S.P. Law,1 J.A. Decker,1 J.F. Price,1 A.G. Cabrera,1 D.E. Graves,2 D.L.S. Morales,3 J.S. Heinle,3 S.W. Denfield,3 W.J. Dreyer,1 J.J. Kim,1 Pediatrics, Baylor College of Medicine/Texas Children's Hospital, Houston, TX; Physical Medicine and Rehabilitation, Baylor College of Medicine, Houston, TX; Michael E. DeBakey Department of Surgery, Baylor College of Medicine/Texas Children's Hospital, Houston, TX.

(486) Self-Care Agency and Its Predictors Among Lung Transplant Recipients; A. DeVito Dabbs,1 M.A. Dew,2 L. Terhorst,1 M.-K. Song,3 J. Aubrecht,1 R. Zomak,4 D. Zaldonis,4 M. Crespo,5 B.A. Johnson,5 J.M. Pilewski,5 J.K. Bhama,4 C.A. Bermudez,4 Y. Toyota,1 Nursing, University of Pittsburgh, Pittsburgh, PA; Psychiatry, Psychology, Epidemiology, University of Pittsburgh, Pittsburgh, PA; Nursing, UNC-Chapel Hill, Chapel Hill, NC; CT Surgery, University of Pittsburgh, Pittsburgh, PA; Pulmonary, Allergy, Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA.

(487) Trends in Health Disparities Among Left Ventricular Assist Device Recipients in the United States: An Analysis of the Centers for Medicare and Medicaid Services Database; A. Iribarne,1 K.N. Hong,1 M.J. Russo,2 R. Easterwood,1 K. Su,3 N. Egorova,3 A.A. Moskowitz,3 Y. Naka,1 D.D. Ascheim,3 A.C. Gelijns,1 Department of Surgery, Columbia University Medical Center, New York, NY; Section of Cardiac and Thoracic Surgery, The University of Chicago, Chicago, IL; Department of Health Evidence and Policy, Mount Sinai School of Medicine, New York, NY.

(488) Utilization of Checklists to Maintain Transplant Quality and Compliance; A. Berg,1 S. Hawthorne,1 A. Hauser. Transplant Services, Children's Healthcare of Atlanta, Atlanta, GA.

(489) A Nurse Initiated Clinical Audit to Evaluate a Change in Immunosuppression Regime Post Lung Transplantation; B. Lewey,1 L. Mitchell,1 S. Ivlich,1 G. Snell,1 Lung Transplant Service, The Alfred Hospital, Melbourne, VIC, Australia; Department of Pharmacy, The Alfred Hospital, Melbourne, VIC, Australia.

(490) Living with Mechanical Cardiac Support: Patients and Families in Crisis; J. Currey,2 P. Komesaroff,1 N. Hagan,1,3 Faculty Health, Medicine, Nursing and Behavioral Sciences, Deakin University, Burwood, VIC, Australia; Medicine, Monash University, Prahran, VIC, Australia; Alfred/Deakin Nursing Research Centre, The Alfred Hospital, Prahran, VIC, Australia.


(492) Children Transplanted for Single Ventricle Physiology Without Prior Surgery Have Better Graft Survival; S.R. Auerbach,1 J.K. Smith,1 M.B. Mitchell,2 D.N. Campbell,3 J. Jaggers,2 B.A. Pietra,1 S.D. Miyamoto,1 Pediatrics, Division of Cardiology, University of Colorado Denver Health Science Center, Aurora, CO; Pediatric Cardiovascular Surgery, University of Colorado Denver Health Science Center, Aurora, CO.

(494) HLA Desensitization in Pediatric Heart Transplant Candidates: Efficacy of Rituximab and IVlg; K.R. Schumacher,1 D. Schauss,2 C.A. Schall,2 M. Kamoun,1 D. Ramon,2 M.C.G. Zimmerlan,1 R.J. Gajarski.1 1Pediatrics and Communicable Diseases, Division of Pediatric Cardiology, University of Michigan Medical School, Ann Arbor, MI; 2Pathology, University of Michigan Medical School, Ann Arbor, MI.

(495) Thrombosis in Pediatric Heart Transplant Recipients During Their Waiting Period; Y.M. Law,1 S. Sharma,1 B. Feingold,2 W. Devine,4 B. Fuller,3 S.A. Webber.1 1Pediatrics, Seattle Children’s Hospital, Univ. of Washington, Seattle, WA; 2Pediatrics, Children’s Hospital of Pittsburgh, Pittsburgh, PA; 3Knoxville Pediatric Cardiology, Knoxville, TN; 4Public Health and Preventive Medicine, Oregon Health and Sciences University, Portland, OR.

(496) MRI Validated Echocardiographic Technique to Measure Total Cardiac Volume: A Tool for Donor Recipient Size Matching; J.A. Camarda,1 D. Sauder,1 M. Otto,1 P. Simpson,2 G. Stendahl,1 S. Berger,1 S. Zangwill.1 1Cardiology, Children’s Hospital of Wisconsin/Herma Heart Center/Medical College of Wisconsin, Milwaukee, WI; 2Children’s Research Institute, Medical College of Wisconsin, Milwaukee, WI.

(497) Cardiac MRI Improves Diagnostic Accuracy and Characterization in Children with Hypertrophic Cardiomyopathy; S.J. Kindel,1 R.A. DeFreitas,1 C.K. Rigsby,2 K.L. Matthews,1 E. Pahl.1 1Pediatric Cardiology, Children’s Memorial Hospital, Chicago, IL; 2Medical Imaging, Children’s Memorial Hospital, Chicago, IL.


(499) Improved Survival with Statin Use in Patients with Pulmonary Arterial Hypertension and Heart Failure with Normal Ejection Fraction; S. Shore,1 V. Aggarwal,1 M.F. Messinger,2 R. Zolty.3 1Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY; 2Albert Einstein College of Medicine, Bronx, NY; 3Division of Cardiology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.

(500) Outcomes of Pulmonary Arterial Hypertension Patients with Pericardial Effusion: A Single Center Experience; G.R. Honeycutt, Z. Safdar. Section of Pulmonary, Critical Care, and Sleep Medicine, Baylor College of Medicine, Houston, TX.


(502) Role of Perioperative Oral Sildenafil in Heart Transplant Recipients with Severe Pulmonary Artery Hypertension: Hospital Outcomes and 1-Year Functional Recovery; C. Amarelli,1 G. Romano,1 C. Maiello,1 C. Marra,1 M. Buonocore,1 M. Cefarelli,1 N. Galdieri,1 L.S. De Santo.2 2Cardiovascular Surgery and Transplant, V Monaldi Hospital, Naples, Italy; 1Cardiac Surgery, University of Foggia, Foggia, Italy.

(503) Anti-Inflammatory Drugs Improve Mortality in Pulmonary Hypertension; J.N. Salamon,1 M.R. Sardar,2 W. Saeed,3 R. Zolty.4 1Cardiology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY; 2Cardiology, Montefiore Medical Center, Bronx, NY.

(504) Improved Survival with Pioglitazone in Patients with Diabetes Mellitus, Pulmonary Arterial Hypertension and Heart Failure with Normal Ejection Fraction: A Comparative Effectiveness Analysis; S. Shore,1 V. Aggarwal,1 R. Zolty.2 1Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY; 2Division of Cardiology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.

(505) Pericardial Effusion in a Patient with Pulmonary Arterial Hypertension; E.R. Fenstad,1 G.C. Kane,1 R.P. Frantz.1 1Department of Internal Medicine, Mayo Clinic, Rochester, MN; 2Department of Medicine, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN; 3Department of Medicine, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN.

(506) Value of the First Biopsy for Predicting Cardiac Allograft Vasculopathy (CAV) in Heart Transplant Patients; C.A. Labarrere,1 J.R. Woods,1 J.W. Hardin,2 G.L. Campana,1 M.A. Ortiz,1 B.R. Jaeger,4 B. Reichart,4 L.A. Baldrige,5 J.M. Bonnin,6 A. Currin,6 S.K. Cosgrove,6 P.C. Kirlin,6 D.E. Pitts,6 J.A. O’Donnell,7 D.A. Hormuth,6 T.C. Wozniak.6 1Methodist Research Institute, Clarian Health Partners, Indianapolis, IN; 2Epidemiology and Biostatistics, University of South Carolina, Columbia, SC; 3Dr. Stein und Kollegen, München, Germany; 4Ludwig-Maximilians-Universität, München, Germany; 5Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN; 6Transplant Center, Clarian Health Partners, Indianapolis, IN; 7Kranert Institute of Cardiology, Indianapolis, IN.

(507) Value of Early Post-Transplant Biopsies for Predicting Long-Term Major Adverse Cardiac Events (MACE) in Heart Transplant Patients; C.A. Labarrere,1 J.R. Woods,1 J.W. Hardin,2 G.L. Campana,1 M.A. Ortiz,1 B.R. Jaeger,2 B. Reichart,4 L.A. Baldrige,5 J.M. Bonnin,6 A. Currin,6 S.K. Cosgrove,6 P.C. Kirlin,6 D.E. Pitts,6 J.A. O’Donnell,7 D.A. Hormuth,6 T.C. Wozniak.6 1Methodist Research Institute, Clarian Health Partners, Indianapolis, IN; 2Epidemiology and Biostatistics, University of South Carolina, Columbia, SC; 3Dr. Stein und Kollegen, München, Germany; 4Ludwig-Maximilians-Universität, München, Germany; 5Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN; 6Transplant Center, Clarian Health Partners, Indianapolis, IN; 7Kranert Institute of Cardiology, Indianapolis, IN.


(510) Human Lungs Declined for Transplantation: Clinical and Pathologic Correlation; C.F. Farver, H.B. Keshava, J.J. Yun, S.C. Murthy, G.B. Pettersson, D.P. Mason, Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH; Anatomic Pathology, Cleveland Clinic, Cleveland, OH.

(511) Analysis of Neural and Vascular Structures Across the Airway Anastomosis in Lung Transplant Recipients; A. Duarte, A. Myers, D.F. Dilling, R. Love, V.G. Valentine, G. Campbell, University of Texas Medical Branch, Galveston, TX; Johns Hopkins University, Baltimore, MD; Loyola University Medical Center, Maywood, IL.

(512) Alpha-1-Antichymotrypsin, A New Player in Remodeling of the Human Heart?; S.I. Lok, N. Bovenschen, R. Quadir, J. van Kuik, B. Winkens, M.E.I. Schipper, P.A.F. Doevendans, N. de Jonge, R. de Weger, Cardiology, University Medical Center Utrecht, Utrecht, Netherlands; Pathology, University Medical Center Utrecht, Utrecht, Netherlands; Department Methodology & Statistics, Academic Hospital Maastricht, Maastricht, Netherlands.

(513) WITHDRAWN

(514) Factors Influencing Early Onset of Coronary Allograft Vasculopathy After Orthotopic Heart Transplantation; V. Köse, H. Welp, J. Osterhues, J. Stypmann, H. Scheld, J. Sindermann, Thoracic and Cardiovascular Surgery, University Hospital, Muenster, Germany; Cardiology and Angiology, University Hospital, Muenster, Germany.


(516) Seasonal Variations in Cardiac Transplant Antibody-Mediated Rejection; L. Piponniau, A. Velleca, M. Kittleson, D. Lockhart, B. Kearney, T. Kao, M. Johnson, M. Kawano, Z. Goldstein, M. Rafiei, F. Esmailian, J. Kobashigawa, Cedars-Sinai Heart Institute, Los Angeles, CA.

(517) Pre-Transplant Strong Control of Circulating Antibody as Expressed in the Calculated Panel Reactive Antibody Score Predicts Antibody-Mediated Rejection After Heart Transplant; M. Kittleson, J. Patel, M. Kawano, Z. Goldstein, M. Rafiei, J. Moriguchi, N. Reinsmoen, E. Reed, A. Hage, A. Trento, J. Kobashigawa, Cedars-Sinai Heart Institute, Los Angeles, CA; University of California, Los Angeles, Los Angeles, CA.


(520) Improving Results of Adult Congenital Cardiac Transplantation in the Current Era; C. Irving, G. Parry, R. Kirk, M. Griselli, A. Hasan, Paediatric Cardiothoracic Transplantation, Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom; Paediatric Cardiac Intensive Care, Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom; Newcastle upon Tyne, United Kingdom.

(521) Rituximab Improves Survival in Cardiac Allograft Antibody Mediated Rejection: A Single Center Experience; A. Ravichandran, G. Ewald, J. Pfeifer, E. Novak, S. Joseph, Cardiovascular Division of Internal Medicine, Washington University Medical Center, Saint Louis, MO.


(523) Post-Transplant Diastolic Dysfunction Beyond the First Year: Incidence and Prognostic Significance; J. Iturriaga, S.V. Pamboukian, J. George, R.N. Brown, M. Cadeiras, M. Smallfield, R.C. Bourje, J.K. Kirklin, D.C. McGiffin, M. Hubbard, J.A. Tallaj, Medicine, University of Alabama at Birmingham, Birmingham, AL; Surgery, University of Alabama at Birmingham, Birmingham, AL; Medicine, Birmingham VA Medical Center, Birmingham, AL.

(524) Racial and Ethnic Differences in Initial Listing Status for Heart Transplantation; D.T. Majure, C. Hoopes, T. De Marco, K. Bibbins-Domingo, Medicine, University of California, San Francisco, San Francisco, CA; Surgery, University of California, San Francisco, San Francisco, CA.

(526) A Novel Surgical Technique in Heart Transplantation: Prophylactic Tricuspid Commissuro-Annuloplasty; Y. Toyota.
University of Pittsburgh Medical Center, Pittsburgh, PA.


(528) Does Gender Mismatch Increase the Risk of Antibody-Mediated Rejection (AMR) After Heart Transplantation?; J. Patel, M. Kittleston, M. Kawano, Z. Goldstein, M. Rafiei, O. Barry, M. Hamilton, E. Schwarz, F. Esmailian, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA; Los Angeles, CA; Los Angeles, CA.


1Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; 2Medicine, Mayo Clinic, Rochester, MN; 3Medicine, The Johns Hopkins Hospital, Baltimore, MD; 4Pathology, The Johns Hopkins Hospital, Baltimore, MD.

(532) Long-Term Outcome in Patients Treated with Combined Heart- and Liver Transplantation for Familial Amyloidotic Cardiomyopathy; L.M. Nelson, L. Penninga, K. Sander, P.B. Hansen, G. Villadsen, A. Rasmussen, F. Gustafsson. The Heart Centre, Rigshospitalet, Copenhagen, Denmark; Dept of Abdominal Surgery, Rigshospitalet, Copenhagen, Denmark; Department of Medicine, Aarhus University Hospital, Aarhus, Denmark.

(533) Analysis of Long-Term Outcome of Patients with Cardiac Sarcoidosis Undergoing Heart Transplantation; H. Akashi, T.S. Kato, M. Farr, K. Shahzad, M.C. Deng, H. Takayama, Y. Naka, P.C. Schulze, D. Mancini. Surgery, Columbia University Medical Center, New York, NY; Medicine, Columbia University Medical Center, New York, NY.


(535) Virtual Crossmatch Significantly Increases Sensitized Patients to Heart Transplantation; Q. Zhang, C.J. Michael, D.W. Gjersten, J. Kobashigawa, A. Abbas, A. Hickey, A.S. Baas, D. Cruz, E.F. Reed. Immunogenetics Center, Department of Pathology and Lab Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA; Cedars-Sinai Heart Institute, David Geffen School of Medicine, UCLA, Los Angeles, CA; Division of Cardiology, David Geffen School of Medicine, UCLA, Los Angeles, CA.

(536) NGAL Lacks Specificity for Acute Kidney Injury in Acute Heart Failure Syndrome; M. Rai, S. Statz, A. Ras, J. Rahn, L. O’Bara, F. Zaeem, R. Mulamalla, J. Hammond, D. Wenczer. Heart Failure and Transplant Center, Hartford Hospital, Hartford, CT; University of Connecticut, Farmington, CT.


FRIDAY, APRIL 15, 2011


(539) Conversion from Cellcept to Myfortic in Heart Transplant Recipients: Oh What a Relief It Is!; S. Kumar, M.W. Weston, D.A. Rinde-Hoffman, P.J. Berman. Heart Transplant, Tampa General Hospital, Tampa, FL.

(540) Decreased CMV Infection With Sirolimus Compared to Azathioprine After Lung Transplantation; B.J. Ghassemi, J. Charbeneau, V.N. Ahya, M.A. Baz, V.G. Valentine, S.M. Arca-soy, R.B. Love, H. Seetharamaju, C.G. Alex, R. Bag, N.C. DeOliveira, A. Husain, W.T. Vigneswaran, J.A. Krishnan, R. Durazo-Arvizu, L. Norwich, E. Garrity, S. Bhorade. 1University of Chicago, Chicago, IL; 2Hospital of the University of Pennsylvania, Philadelphia, PA; 3University of Florida School of Medicine, Gainesville, FL; 4University of Texas Medical Branch, Galveston, TX; 5Columbia University Medical Center, New York, NY; 6Loyola University Medical Center, Maywood, IL; 7Baylor College of Medicine, Houston, TX; 8INTEGRIS Baptist Medical Center, Oklahoma City, OK; 9University of Wisconsin School of Medicine, Madison, WI.

(541) Challenging the ISHLT Guideline Regarding Switch from Mycophenolate to Sirolimus with Standard Dose Calcineurin Inhibitor; M. Kittleston, J. Patel, M. Kawano, Z. Goldstein, M. Rafiei, A. Moradzadeh, J. Moriguchi, L. Czer, F. Esmailian, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.

(542) Incidence of Coronary Artery Vasculopathy Has Decreased with Modern Immunosuppression: Insights From Clinical Trials in Organ Transplantation; R.C. Starling.
J. Stehlik, 1 S. Nicholls, 1 D. Ilke, 4 A. Chandraker, 4 F. Teresa, 1 D. Baran, 9 K. Wolski, 1 B. Mfarraj, 4 U. Ahmad, 4 M. Sayegh, 4 P. Heeger, 2 Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH; 9 Nephrology, Mt Sinai School of Medicine, New York, NY; 3 Cardiology, University of Utah, Salt Lake City, UT; 1 Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH; 1 Rho Federal Systems Division, NIH, Chapel Hill, NC; 6 Nephrology, Brigham and Women’s Hospital, Boston, MA; 7 Nephrology, Brigham and Women’s Hospital, Boston, MA; 3 Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH; 8 Cardiology, New Jersey Medical School, Newark, NJ.

(543) Use of Bortezomib in the Management of Humoral Rejection in a Non-Compliant Teenage Heart Transplant Patient; T. Shah, D. Fixler, A. Barnes. Pediatrics, Division of Cardiology, University of Texas Southwestern Medical Center/Children’s Medical Center Dallas, Dallas, TX.

(544) Poor Stem Cell Mobilization in Patients with Advanced Chronic Heart Failure Is Associated with Increased Red Cell Distribution Width; G. Poglajen, 1 M. Sebestjen, 1 V. Androce, 1 F. Haddad, 2 B. Vrtovac, 1 Advanced Heart Failure and Transplantation Programme, UMC Ljubljana, Ljubljana, Slovenia; 2 Cardiovascular Medicine, Stanford University School of Medicine, Palo Alto.

(545) Immunogenicity and Immunomodulatory Properties of Umbilical Cord Lining Mesenchymal Stem Cells for Regenerative Therapies; M. Stubben, 1 T. Deuse, 1 X. Hua, 1 T. Gossler, 1 C. Paehmann, 1 K.R. Tang-Quan, 1 H. Reichenspurner, 1 R.C. Robbins, 3 Schrepfer, 1 TSI Lab, University Heart Center, Hamburg, Germany; 3 CT Surgery, Stanford University, Stanford, CA.

(546) Stem Cell Transplantation: HGF or VEGF Enhance Myocardial Function After Infarction; T. Deuse, 1, 14, 2 M. Adam, 2 P. Fedak, 3 R.C. Robbins, 4 H. Reichenspurner, 4 S. Schrepfer. 14 1 Cardiothoracic Surgery, Stanford University, Stanford; 2 Cardiology, University Heart Center Hamburg, Hamburg, Germany; 3 Cardiovascular Science, Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Canada; 4 Cardiothoracic Surgery, University Heart Center Hamburg, Hamburg, Germany.

(547) Hypoimmunogenic HLA I Knockdown Human Embryonic Stem Cells Induce Host Ignorance and Achieve Prolonged Xenogenic Survival: T. Deuse, 1 M. Seifert, 2 A. Fire, 2 N. Phillips, 3 X. Hua, 3 J. Velden, 3 M. Kay, 3 H.-D. Volk, 3 H. Reichenspurner, 1 R.C. Robbins, 3 Schrepfer, 3 University Heart Center, Hamburg, Germany; 3 Institute of Medical Immunology, Campus Charité, Berlin, Germany; 4 Stanford University, Stanford; 5 TSI Lab, University Hospital Hamburg-Eppendorf, Hamburg, Germany; 6 University Hospital Hamburg-Eppendorf, Hamburg, Germany.

(548) A Novel Multifunctional Bioreactor for Three-Dimensional Magnetically Guided Recellularization of Stented Decellularized Pericardium Derived Aortic Valves; V. Bordel, 1 A. Ghodsizad, 1 H. Takahashi, 1 T. Okada, 1 R. Arif, 1 M. Farag, 3 P. Pontek, 1 M. Ungere, 1 I. Roos, 1 H. Wiedensohler, 1 M. Loebe, 1 B. Bruckner, 2 M. Karck, 1 A. Ruhrwar. 1 Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Baden-Württemberg, Germany; 2 Department of Cardiothoracic Surgery, Baylor College, Houston, TX.

(549) Perfusion/Decellularization of Large Animal Lungs; G. Singh, 1 J. Javidfar, 1 J. Costa, 1 J.V. Guarrera, 1 J. Miller, 1 S. Henry, 1 Q. Jallerat, 2 O.O. Freytes, 4 G. Vunjak-Novakovic, 3 J.R. Sonett, 1 M.D. Bachetta, 1 Section of Thoracic Surgery, Division of Cardio Thoracic Surgery, Department of Surgery, Columbia University, College of Physicians and Surgeons, New York, NY; 1 Division of Transplant Surgery, Columbia University, College of Physicians and Surgeons, New York, NY; 2 Department of Biomedical Engineering, School of Engineering and Applied Science, Columbia University, New York, NY.

(550) The Reverse Remodelling Effect of Bone-Marrow-Derived Stem Cells Is Independent from the Site of Epimyocardial Cell Transplantation; J. Garbag, 1 M. Arsalan, 2 S. Dhein, 1 M.J. Barten, 1 A. Rasten, 1 I. H. Appelle, 3 H.B. Bittner, 1 F.-W. Mohr. 1 Cardiac Surgery, Heart Center, University of Leipzig, Leipzig, Germany; 2 Cardiac Surgery, Kerkhoff-Klinik, Bad Nauheim, Germany; 3 Dept. of Veterinary Pathology, Veterinary Medicine, University of Leipzig, Leipzig, Germany.

(551) Early Tolerance Induction with Hematopoietic Stem Cells and Myeloid Progenitor Cells; J. Domen, 1, 2 L. Sun, 2 K. Trapp, 2 Y. Li, 3 K.L. Gandy. 3 1 Surgery, Medical College of Wisconsin, Milwaukee, WI; 2 Surgery, Children’s Research Institute, Milwaukee, WI; 3 Surgery, Children’s Mercy Hospital, Kansas City, MO.

(552) Mechanism of Peripheral Tolerance in Porcine Lung Transplantation – Alloantigen-Primed Treg Control Alloreactivity Against MHC I Matched Bronchus Grafts; A.-K. Knöfel, 1 N. Madrahamov, 1 K. Dreckman, 1 M. Assar, 1 W. Sommer, 1 G. Büchler, 1 D. Jonigkeit, 1 A. Haverich, 1 M. Strüber, 1 G. Warnecke. 1 HTTG, MHH, Hannover, Germany; 2 Pathology, MHH, Hannover, Germany.

(553) The Epithelial Alarmin, Interleukin 1α(IL-1α), Is a Potential Fibrogenic Factor in Bronchiolitis Obliterans Syndrome (BOS); M.I. Suwara, 1 R. Mahiba, 1 L.A. Borthwick, 1 J. Mann, 1 P.A. Corris, 1 S.N. Farrow, 2 D.A. Mann, 1 A.J. Fisher. 1 Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom; 2 Inflammatory Biology Group, GSK R & D, Stevenage, United Kingdom.

(554) IL-17 Producing Cells Home to the Graft Early After Heart Transplantation; N.M. van Besouw, 1 A.M.A. Peeters, 1 M. Dieterich, 1 K. Caliskan, 2 L.P.W.M. Maat, 2 A.H.M.M. Balk, 2 W. Weimar, 1 C.C. Baan. 1 Internal Medicine- Transplantation, Erasmus MC, University Medical Center, Rotterdam, Netherlands; 2 Cardiology, Erasmus MC, University Medical Center, Rotterdam, Netherlands; 3 Thoracic Surgery, Erasmus MC, University Medical Center, Rotterdam, Netherlands.

(555) FoxP3 Positive Treg Correlate with Percent Predicted FEV1 Early After Lung Transplantation; W. Sommer, 1 A.-K. Knöfel, 1 C. Kuehn, 1 I. Tudorache, 1 T. Fuehner, 2 J. Gottlieb, 2 M. Strüber, 1 T. Welter, 2 A. Haverich, 1 G. Warnecke. 1 Department of Cardiothoracic Surgery, Hannover Medical School, Hannover, Germany; 2 Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany.
(556) Heart Transplants Are Genome Transplants: Universal Noninvasive Detection of Solid Organ Transplant Rejection; K.K. Khush,1 T.M. Snyder,2 S.R. Quake,2 H.A. Valantine,1 1Cardiovascular Medicine, Stanford University, Palo Alto, CA; 2Bioengineering, Stanford University, Palo Alto, CA.

(557) Clinical Relevance of Antibodies to Denatured HLA Antigens; J.D. Smith, A.J. Danskine, H. Newell, O. Umeh, V. Brunner, M.L. Rose. Transplant Immunology, Harefield Hospital, Harefield, Middx, United Kingdom.

(558) Alterations in Muscarinic Receptors in Human Heart Failure and Effects of LVAD Support; J.A. French,1,2 W.E. Sweet,1 C.S. Moravec,1 1Kauffman Center for Heart Failure, Department of Cardiovascular Medicine and Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH; 2Department of Biologic, Geological and Environmental Sciences, Cleveland State University, Cleveland, OH.


(560) Ivabradine Enhances the Sarcoplasmic Reticulum Calcium Content in Ventricular Myocytes During Mechanical Unloading in a Rodent Model of Heart Failure; M. Navaratnarajah,1 C. van Doorn,2 U. Siedlecka,1 M. Ibrahim,1 A. Gandhi,1 A. Shah,1 M.H. Yacoub,1 C. Terracciano.1 1Heart Science Centre and Cardiovascular Sciences, National Heart & Lung Institute, Imperial College, London, United Kingdom; 2Cardiothoracic Surgery, Aarhus University Hospital, Bredstrupgaard Svej 100, Denmark.

(561) Secretome of Apoptotic Peripheral Blood Cells (APOSEC) Confers Cytoprotection to Cardiomyocytes and Inhibits Tissue Remodeling After Acute Myocardial Infarction; M. Lichtenauer,1,2 M. Mildner,2 K. Hoetzenecker,1,2 S. Hacker,1,2 M. Zimmermann,1,2 B.K. Podesser,5 W. Sipos,6 E. Berényi,7 E. Tschachler,8 M. Gyöngyösi,8 W. Klepetko,8 H.J. Ankersmit.1,2 1Department of Thoracic Surgery, Medical University Vienna, Vienna, Austria; 2Christian Doppler Laboratory for Cardiac and Thoracic Diagnosis and Regeneration, Vienna, Austria; 3Department of Dermatology, Medical University Vienna, Vienna, Austria; 4Department of Plastic Surgery, Medical University Vienna, Vienna, Austria; 5Ludwig Boltzmann Cluster for Cardiovascular Research, Vienna, Austria; 6Clinical Department for Farm Animals and Herd Management, University of Veterinary Medicine, Vienna, Austria; 7Department of Biomedical Laboratory and Imaging Science, University of Debrecen, Debrecen, Hungary; 8Department of Cardiology, Medical University Vienna, Vienna, Austria.

(562) Fibrotic Differentiation of Resident Mesenchymal Stromal Cells in Bronchiolitis Obliterans Syndrome; A. Wadhwa, N. Walker, L. Badri, K. Chan, V. Lama. Internal Medicine, University of Michigan, Ann Arbor, MI.

(563) Identifying the Potassium Channel KCa3.1 as New Therapeutic Target to Prevent Airway Allograft Rejection;

(564) Desmosomal Protein Gene Mutations in Patients with Idiopathic Dilated Cardiomyopathy Undergoing Cardiac Transplantation: A Clinicopathological Study; P. García-Pavia,1 J. Segovia,1 P. Syrris,2 C. Salas,1 J.G. Mirelis,1 M. Gomez-Bueno,1 C. Vilches,1 M. Cobo-Marcos,1 M.D. García-Cosío Carmena,1 P. Avellana,1 B. Borinstein,1 P.M. Elliott,1 L.A. Alonso Pulpón.1 1Cardiomyopathy Unit, Heart Transplant Program, Hospital Universitario Puerta de Hierro, Madrid, Spain; 2Inherited cardiovascular Disease Unit, The Heart Hospital. University College London, London, United Kingdom.

(565) Characterization of the Failing Human Heart Via Diffusion Tensor Imaging: An Ex-Vivo Study; S.G. Drakos,1,2 D.R. Verma,3 O.M. Abdulla,2 A.G. Kfouri,4 J. Strehlik,5 C.H. Selzman,1 B.B. Reid,1 E.M. Gilbert,1 R. Alharethi,1 C. Myrick,1 D. Budge,1 G. Russel,2 S. Clayson,1 D. Bull,1 E.H. Hammond,1 E. Hsu,2 D.Y. Li,2 1UTAH Cardiac Transplant Program, Salt Lake City, UT; 2University of Utah Molecular Medicine/Small Animal Imaging Core Facility, Salt Lake City, UT; 3Intermountain Donor Services, Salt Lake City, UT.

(566) Serial Intravascular Ultrasound and Plaque Composition Analysis in Heart Transplant Recipients: A Single Center Experience; S.C. Rao,1,2 T.M. Khumri,1,2 J.A. House,2 L. Seifert,2 J. Murphy,2 A. Kao,1 A. Magalski,1,2 T.L. Stevens,1,2 M.P. Everley,1,2 K. St. Clair,2 M. Borkon,3 S.L. Lawhorn,1 S.P. Marso,1,2 Cardiovascular Diseases, University of Missouri Kansas City, Kansas City, MO; 2Cardiovascular Diseases, Saint Luke’s Mid America Heart and Vascular Institute, Kansas City, MO; 3Cardiothoracic Surgery, Saint Luke’s Mid America Heart and Vascular Institute, Kansas City, MO.


(569) Right Atrial Enlargement Is an Echocardiographic Marker for Cardiorenal Syndrome; M. Chahal,1 S. Bruhl,1 S. Khouri,1 Cardiovascular Medicine, University of Toledo Medical Center, Toledo, OH; 2Cardiovascular Medicine, University of Toledo Medical Center, Toledo, OH; 3Cardiovascular Medicine, University of Toledo Medical Center, Toledo, OH.

(570) Dobutamine Stress Echo (DSE) Used as Surveillance Test for Cardiac Allograft Vasculopathy (CAV) Eliminates the Early Use of Routine Angiography; A. Cordero-Reyes.1
(571) Clinical Utility of the Celyx Assay: Safe Conversion to Everolimus Based Immunosuppression in Heart Transplant Recipients; T. Ben Gal, 1 M. Israeli, 1 B. Medalion, 1 V. Yaari, 1 A. Valdman, 1 I. Matz, 2 A. Yusim, 4 T. Klein, 2 A. Battler. 1 Cardiology, Rabin Medical Center, Petah Tikva, Israel; 2 Tissue Typing Laboratory, Rabin Medical Center, Petah Tikva, Israel; 3 Cardiothoracic Surgery, Rabin Medical Center, Petah Tikva, Israel; 4 Transplantation, Rabin Medical Center, Petah Tikva, Italy.

(572) High-Sensitive Troponin T and I as Markers of Disease Severity and Mortality Patients with Left-Ventricular Dysfunction or Pulmonary Hypertension; M. Nygren, 1 K.M. Eggers, 2 P. Venge, 3 T. Jernberg, 1 G. Wikström, 2 Department of Cardiology, The Karolinska Institute, the Karolinska University Hospital, Huddinge, Stockholm, Sweden; 2 Dept. of Medical Sciences, Cardiology, Uppsala University Hospital, Uppsala, Sweden; 3 Dept. of Medical Sciences, Clinical Chemistry, Uppsala University Hospital, Uppsala, Sweden.

(573) Chronic Heart Failure (CHF) Patients with Cardiopulmonary Exercise Test (CPX) Result Suggesting Only Probable Indications for OHT are at High Risk of Death When Abnormalities in Spirometry (PFT) Occur; M.K. Lizak, 1 M. Zakliczynski, 2 A. Jarosz, 1 M. Zembala, 2 Z. Kalarus. 1 Department of Cardiology, Congenital Heart Disease and Electrotherapy, Silesian Centre for Heart Disease, Zabrze, Silesia, Poland; 2 Department of Cardiac Surgery and Transplantology, Silesian Centre for Heart Disease, Zabrze, Silesia, Poland; 3 Silesian Medical University, Zabrze, Silesia, Poland.


(575) Absence of Restrictive Pattern in Spirometry (PFT) Predicts Good Survival in Chronic Heart Failure (CHF) Patients with Peak Oxygen Consumption(PekVO2) Below the Cutoff Point for Heart Transplantation Listing; M.K. Lizak, 1 M. Zakliczynski, 2 A. Jarosz, 1 M. Zembala, 2 Z. Kalarus. 1 Department of Cardiology, Congenital Heart Disease and Electrotherapy, Silesian Centre for Heart Disease, Zabrze, Silesia, Poland; 2 Department of Cardiac Surgery and Transplantology, Silesian Centre for Heart Disease, Zabrze, Silesia, Poland; 3 Silesian Medical University, Zabrze, Silesia, Poland.

(576) Green Tea Reduces Left Ventricular Myocardial Mass in Patients with Transthyretin Amyloidosis; A.V. Kristen, 1 S. Lehrke, 1 D. Mereles, 1 P.A. Schnabel, 4 C. Röcken, 3 P. Ehlermann, 1 T.J. Dengler, 1 K. Altland, 2 H.A. Katus. 1 Department of Cardiology, University of Heidelberg, Heidelberg, Germany; 2 Human Genetics, University of Giessen, Giessen, Germany; 3 Department of Pathology, University of Kiel, Kiel, Germany; 4 Department of Pathology, University of Heidelberg, Heidelberg, Germany.

(577) “Let’s Twist Again”: Surgically Induced Renewal of Left Ventricular Torsion in Ischemic Cardiomyopathy; M. Cirillo, G. Troise. Heart Surgery Unit, Poliambulanza Foundation Hospital, Brescia, Italy.


(581) Functional Iron Deficiency and Anemia in Orthotopic Heart Transplantation Recipients Treated with mTOR; P. Przybylowski, 1 J. Małyszko, 2 J. Małyszko. 1 Cardiovascular Surgery and Transplantatology, Collegium Medicum, Jagiellonian University, John Paul II Hospital, Krakow, Poland; 2 Nephrology and Transplantology, Medical University, Bialystok, Poland.


(583) Cost Impact of Permanent Pacemaker Insertion in Orthotopic Heart Transplant Recipients: A Comparison of Bi-Atrial and Bi-Caval Techniques; M.J. Nelson, 1 K. Liao, 1 R. John, 1 S. Shumway, 1 H.A. Tetteh. 1 Department of Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN; 2 Department of Cardiothoracic Surgery, National Naval Medical Center, Bethesda, MD.

(584) Pneumonia in the First Year Post-Cardiac Transplant is Common and Associated with Reduced Long-Term Survival; N. Uriel, 1 S.W. Pak, 2 N. Gukasyan, 1 T. Carrillo, 2 S.W. Restaino, 1 D.B. Sims, 1 F. Latif, 1 R. Bijou, 1 M. Farr, 1 H. Takayama, 2 P.C. Colombo, 1 Y. Naka, 2 D. Mancini, 1 U.P. Jorde. 1 Medicine, Columbia University, New York, NY; 2 Surgery, Columbia University, New York, NY.

(585) Aspergillus Infection After Heart Transplantation: Risk Factors, Clinical Course and Outcomes; N. Uriel, 1 A. Kossar, 2 J. Gonzalez-Costello, 1 S.W. Pak, 2 S.W. Restaino, 1 D.B.
(586) Impact of the Number of Blood Pressure Medications on the Outcome of Heart Transplant Recipients; M. Kawano, M. Kittleson, J. Patel, Z. Goldstein, M. Rafiei, N. Moradzadeh, A. Moradzadeh, A. Hage, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.

(587) Long-Term Outcomes in Pediatric Heart Transplant Recipients Treated for Neoplasia: A Single-Institution Experience; A. Marcotty, A. Flagg, C. Nasman, J. Brubaker, G. Boyle. Center for Pediatric and Congenital Heart Disease, Children’s Hospital at Cleveland Clinic, Cleveland, OH; Case Western Reserve University School of Medicine, Cleveland, OH.


(589) Machine Perfusion Improves Metabolic Preservation of Heart Grafts from Non Heart Beating Donors; O. Van Caenegem, A. Poncelet, J. Vercruyssse, B. Theunis, C. Beauloey, G. Baurin, P.-Y. Adnet, S. Horman, L. Bertrand, L.M. Jacquet. Heart Transplant Unit, Cliniques Universitaires saint-Luc, Brussels, Belgium; Organ Recovery System, Zaventem, Belgium; Cardiotoracic Intensive Care, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium; Pole of Cardiovascular Research-Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium; Laboratoire de Chirurgie Expérimentale - Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium.


(592) Improved Lung Preservation by Increasing Flush Temperature in Rats; A.J. Munneke, G. Rakhorst, A.H. Petersen, J. Prop, W. van Oeveren, M.E. Erasmus. Department of Biomedical Engineering, University Medical Center Groningen, University of Groningen, Groningen, Netherlands; Thoraxcenter, University Medical Center Groningen, University of Groningen, Groningen, Netherlands; Department of Medical Biology Section Pathology and Laboratory Medicine, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.

(593) Continuous Crystalloid Microperfusion Provides Cardiac Preservation Superior to Cold Storage During Prolonged Donor Heart Preservation; J.W. Choong, Y.W. Lim, R. Ou, R.F. Salamonsen, F.W. Rosenfeldt. Cardiac Surgical Research Unit, Alfred Hospital, Melbourne, VIC, Australia.

(594) Intracellular Calcium Handling in the Donor Heart: Comparison Between DCD and Brainstem Dead (BSD) Donor Hearts; F.J. Taghavi, A.A. Ali, C. Woods, S.R. Large, E.A. Ashley. Cardiovascular Medicine, Stanford University, Stanford, CA; Papworth Hospital, Papworth Hospital, Cambridge, CAMBS, United Kingdom.

(595) Cardioprotective Effects of S-Nitroso Human Serum Albumin (S-NO-HSA) During Cardioplegic Arrest and Cold Storage in a Working Heart Heterotopic Transplant Model; A. Rungatscher, S. Hallström, D. Linardi, H. Suzuki, B. Podesser, H. Gasser, A. Mazzucco, G. Faggian. Department of Surgery, Division of Cardiac Surgery, University of Verona, Verona, Italy; Institute of Physiological Chemistry, Centre for Physiological Medicine, University of Graz, Graz, Austria; Department of Morphological and Biomedical Science, Division of Biochemistry, University of Verona, Verona, Italy; Ludwig Boltzmann Cluster for Cardiovascular Research, University of Vienna, Vienna, Austria.

(596) Interleukin 1 Receptor Antagonist and Donor Heart Function; V.B. Dronavalli, R.V. Venkateswaran, J. Mascaro, I.C. Wilson, R. Thompson, M. Mukadam, R.S. Bonser. Queen Elizabeth Hospital, University Hospital Birmingham, Birmingham, United Kingdom; Papworth Hospital, Papworth, United Kingdom.

(597) Impact of Infected Donors on Emergency Heart Transplantation; A. Forni, B. Chiomonti, A. Mazzucco, G. Faggian. Heart Transplantation, Division of Cardiac Surgery, University Hospital of Verona, Verona, Italy.

(598) Incidences of C. difficile Infections in Cardiothoracic Transplant Recipients; E. Ott, C. Fegbeutel, G. Warnecke, F. Mattner. Institute of Medical Microbiology and Hospital Epidemiology, Hannover Medical School, Hannover, Niedersachsen, Germany; Department of Cardiac, Thoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Niedersachsen, Germany; Department of Cardiac, Thoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Niedersachsen, Germany; Zentralbereich Hygiene, Kliniken der Stadt Köln, Universitätsklinikum Witten-Heerdecke, Campus Köln-Merheim, Cologne, Nordrheinwestfalen, Germany.

(599) Superior In Vitro Bactericidal Activity of Moxifloxacin Compared to Ciprofloxacin and Co-Trimoxazole Against Stenotrophomonas Maltophilia from Lung Transplant Patients; A. Nicholson, E. Marrs, S. Peart, K. Wilkinson, J.D. Perry, F.K. Gould. Microbiology, Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom.

(600) Bactericidal Combinations for Prevention of Sepsis in Lung Transplantation for Cystic Fibrosis Patients Colonised with Pan Resistant Pseudomonas Aeruginosa; A. Nicholson, E. Marrs, K. Wilkinson, S. Peart, J.D. Perry, H.N. Haja Mydin, F.K. Gould. Microbiology, Freeman Hospital, Newcastle upon Tyne, United Kingdom; Cardiopulmonary Transplan-
tation, Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom.

(601) Impact of Rhinovirus Infection After Lung Transplantation; R.F. Pearson,1 A. Fiene,2 B. McMullan,2 A. Havryk,1 M. Pilt,1 M.A. Malouf,1 A.R. Glanville.3 The Lung Transplant Unit, St Vincent’s Hospital, Sydney, NSW, Australia; 2Department of Microbiology, St Vincent’s Hospital, Sydney, NSW, Australia.

(602) Aerosolized Liposomal Cyclosporine (L-CsA) Shows Antimicrobial Activity to Different Opportunistic Microorganisms; J.M. Schierholz,1 D.M. Denk1 I. Fischer,2 A. Schwarzkopf3 PARI Pharma GmbH, Graefelfing, Germany; 2University of Tuebingen, Tuebingen, Germany; 3Labor L+S, Bad Bocklet, Germany.


(604) Optimizing Timing of Pretransplant Vaccination in Lung Transplant Recipients; J. Chu, D. Arslan, S. Worley, R. Avery, M. Budev, L. Danziger-Isakov. Cleveland Clinic, Cleveland, OH.

(605) Assessment of CMV Hybrid Preventative Strategy in Pediatric Heart Transplant Patients; A. Lin, J. Brubaker, S. Worley, C. Nasman, C. Sabella, G. Boyle, L. Danziger-Isakov. Pediatric Institute, Cleveland Clinic, Cleveland, OH.

(606) Preemptive Approach to CMV Treatment in Adult Cardiac Transplantation—Eight Years Single Centre Experience; C. Hamson,2 J. Samuel,1 G. Parry,1 K. Gould.1 Department of Microbiology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, Tyne and Wear, United Kingdom; 2Department of Cardiopulmonary Transplantation, Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom.

(607) Effectiveness of Oral Valganciclovir Prophylaxis for Cytomegalovirus Infection in Heart Transplant Patients; A.O. Doesch,1 J. Repp1 S. Celik1 J. Franke1 L. Frankenstein,1 A. Ruhparwar,2 P. Schnitzler,2 P. Ehlermann,1 C. Zuck,1 T.J. Dengler,1 H.A. Katus.1 Department of Cardiology, University of Heidelberg, Heidelberg, Germany; 2Department of Cardiothoracic Surgery, University of Heidelberg, Heidelberg, Germany; 3Institute of Virology, University of Heidelberg, Heidelberg, Germany.


(609) Outcomes in Scleroderma-Related Interstitial Lung Disease Following Lung Transplant; P.D. Sottile,1 D. Iturbe,2 J.A. Golden,3 T.R. Katsumoto,4 M.K. Connolly,5 H.R. Collard,2 C. Hoopes,4 J. Kukreja,4 L.E. Leard,3 J.P. Singer.3 Department of Internal Medicine, University of California San Francisco, San Francisco, CA; 4Hospital Universitario Marques de Valdecilla, Santander, Spain; 5Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, CA; 6Division of Rheumatology, University of California San Francisco, San Francisco, CA; 7Department of Dermatology and Medicine, University of California San Francisco, San Francisco, CA; 8Department of Cardiothoracic Surgery, University of California San Francisco, San Francisco, CA.


(611) Does Recurrence Influence the Outcome of Lung Transplantation for Sarcoidosis?; A. Bansal,1 J.K. Bhama,1 T. Ota,1 K. Fujimoto,1 K. Minakata,1 B. Sareyyupoglu,1 H. Shayan,1 N. Shigemura,1 J. Thacker,1 C. Bermudez,2 P. Bonde,1 S. Yousem,2 M. Crespo,3 Y. Toyoda.1 Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA; 2Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA; 3Pulmonary and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA.

(612) Prevalence and Natural History of Native Lung Hyperinflation After Single Lung Transplant for Emphysema; M.M. Crespo,1 Y. Toyoda,2 C. Bermudez,2 F.C. Sciarra,1 B.A. Johnson,1 Medicine, University of Pittsburgh, Pittsburgh, PA; 2Surgery, University of Pittsburgh, Pittsburgh, PA.

(613) An LC-MS Method for Quantifying Bile Acid Species in Bronchial Washings of Lung Transplant Patients; A. Sirici,1 T. Thomas,1 B. Aramin,2 S. Azad,2 J. Wilt,2 M.A. Pesce,3 S. Arcasioy,2 J. Sonett,1 S. Keshavjee,3 S. Cremers,1 F. D’Ovidio,2 Lung Transplant Program, Columbia University, New York; 2PhD Program in “Pneumo-Cardio-Thoracic Sciences of Medical and Surgical Interest,” University of Bologna, Bologna, Italy; 3Lung Transplant Program, University of Toronto, Toronto, Canada.

(614) Cadaveric Lobar Lung Transplantation—Technical Aspects; S. Marasco,1 S. Than,1 D. Keating,3 G. Westall,3 H. Whitford,2 G. Snell,3 A. Pick.1 Department of Cardiothoracic Surgery, Alfred Hospital, Melbourne, VIC, Australia; 2Department of Surgery, Monash University, Melbourne, VIC, Australia; 3Department of Respiratory Medicine, Alfred Hospital, Melbourne, VIC, Australia.

(615) Improvement of Post Operative Oxygenation and Clinical Outcome After Sequential Bilobular Lung Transplantation Using Cardiopulmonary Bypass During the Second Lung Implantation; H. Roze,1 M. Thumere,2 C. Dromer,2 L. Barandon,4 V. Perrier,1 J. Jougon,2 K. Nubret,2 L. Labrousse,4 J.-F. Velly,2 A. Ouatte.1 Département d’Anaesthésie et Réanimation, Coeur et Thorax, Bordeaux University Hospital, Bordeaux, France; 2Département de Thoracic Surgery, Bordeaux University Hospital, Bordeaux, France; 3Cardiopulmonary Transplantation Unit, Bordeaux University Hospital, Bordeaux, France; 4Département de Cardiac Surgery, Bordeaux University Hospital, Bordeaux, France.

(616) Are the Risk Factors and Underlying Mechanisms for Atrial Fibrillation and Atrial Flutter Post Lung Transplant the Same?; C.M. Orrego1 A. Cordero-Reyes,1 J.D. Estep,1 H.


(620) Revisit the Optimal Procedure of Lung Transplantation for Elderly Recipients with COPD; H.-Y. Fang, N. Shige-mura, J. Thacker, Y. Toyoda, P. Bonde. Cardiotoracic, University of Pittsburgh Medical Center, Pittsburgh, PA; Surgery, China Medical University Hospital, Taichung, Taiwan.

(621) Gastrointestinal Bleeding (GIB) Following Rotary Blood Pump Implantation; Are Arteriovenous Malformations (AVMs) the Culprit Lesions?; C. Brehm, K. Eleuteri, S. Wallace, B. Soleimani, E. Stephenson, J. Boehmer, W. Pae, A. El-Banayosy. Penn State Milton S. Hershey Medical Center, Hershey, PA.

(622) The Use of Intravenous Warfarin After Heartmate II Ventricular Assist Device Implantation Does Not Affect 30 Day Neurologic or Bleeding Outcomes; D. Acharya, J.A. Tallaj, W.L. Holman, J.K. Kirklin, J.F. George, R.M. Brown, M. Cadeiras, S.V. Pamboukian. Division of Cardiovascular Medicine, University of Alabama at Birmingham, Birmingham, AL; Division of Cardiovascular Surgery, University of Alabama at Birmingham, Birmingham, AL.


(625) Platelet Mapping Thromboelastography for Individualized Antiplatelet Treatment After Implantation of the HeartWare Ventricular Assist Device; B. Gordon, T. Biss, T. Butt, A. McDermid, F. Oezalp, T. Pillay, G. Parry, P. Kesteven, G. MacGowan, S. Schueler. Cardiology, Cardiac Surgery and Cardiac Transplantation, Freeman Hospital, Newcastle upon Tyne, United Kingdom; Haematology, Freeman Hospital, Newcastle upon Tyne, United Kingdom.


(627) Mechanical Blood Damage in an Axial VAD Compared to a Centrifugal VAD; K.H. Fraser, T. Zhang, E.N. Sorensen, J. Hu, K. Williams, E.D. Feller, J. Garcia, B.P. Griffith, S.J. Wu. Surgery, University of Maryland School of Medicine, Baltimore, MD; Cardiac Surgery, University of Maryland Medical Center, Baltimore, MD.

(628) Single Center Experience in the Use of Sildenafil for Right Ventricular Dysfunction After LVAD Implantation; A.R. Mahankali Srithar, V. Mukherjee, D.B. Patel, G. Ruiz, R. Chawla, S.W. Boyle, S.S. Najjar. Department of Medicine, Washington Hospital Center, Washington, DC; Department of Cardiothoracic Surgery, Washington Hospital Center, Washington, DC.


(632) Novel Quantification of Right Ventricular Pump Function To Estimate the Feasibility of Weaning from Inotropic Support After Implantation of Left Ventricular Assist System; Y. Murata, T. Shishido, O. Seguchi, M. Yanase, T. Fujita, K. Toda, K. Uemura, M. Sugimachi, T. Nakatani. Transplantation, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan; Cardiovascular Dynamics, National Cerebral and Cardiovascular Center Research Institute, Suita, Osaka, Japan; Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.

(633) Application of New Generation Rotary Pumps and Oxygenators for Veno-Arterial ExtraCorporeal Membrane Oxygenation (VA-ECMO) for Refractory Cardiogenic Shock
Correlation of Pre-Implant Norepinephrine Transporter Levels with Myocardial Recovery During Left Ventricular Assist Device Support; R.S. George, M. Yacoub, P. Facer, A. Khaghani, P. Anand, E.J. Birks, Imperial College London, London, United Kingdom; "Heart Science Centre, Magdi Yacoub Institute, London, United Kingdom; "Peripheral Neuropathy Unit, Hammersmith Hospital, London, United Kingdom.

Direct Comparison of the Performance Characteristics of the Thoratec HeartMate II, Heartware HVAD and Jarvik 2000 Left Ventricular Assist Devices; A. Schmidt, C.T. Bowles, M. Noor, N.R. Banner, K.H. Parker, A. Simon, Bioengineering, Imperial College London, London, United Kingdom; Transplant Unit, Harefield Hospital, Harefield, Middx., United Kingdom.


Severe Renal Dysfunction in Patients Receiving Continuous-Flow (CF) Left Ventricular Assist Devices Adversely Affects Survival; F. Kamdar, J. Rasmussen, P. Eckman, M. Colvin-Adams, K. Liao, R. John. Divisions of Cardiology and Cardiovascular Surgery, University of Minnesota, Minneapolis, MN.

Respiratory Failure While on Ventricular Assist Device (VAD) Support Has Persistent Consequences After Cardiac Transplantation; E.A. Genovese, M.A. Dew, J.J. Teuteberg, M.A. Simon, J.K. Bhama, P. Bonde, C. Bermudez, Y. Toyoda, D.M. McNamara, S. Winovich, K.L. Lockard, R.L. Kormos. School of Medicine, University of Pittsburgh, Pittsburgh, PA; Heart, Lung and Esophageal Surgery Institute, University of Pittsburgh Medical Center, Pittsburgh, PA; Departments of Psychiatry, Psychology and Epidemiology, University of Pittsburgh,

(647) Device Malfunction Reports Are Rarely Pump Related and Represent Controller and Peripheral Component Failure; R.D. Schaub, S. Winowich, B.C. Gulack, J.A. Zaldonis, G. O'Shea, D.A. Severyn, D.P. Lohmann, K.L. Lockard, P. Bonde, R.L. Kormos. Artificial Heart Program, University of Pittsburgh Medical Center, Pittsburgh, PA; Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA; Cardiovascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA.

(648) Midterm Outcomes of Patients Undergoing Durable VAD Support for Acute Myocardial Infarction Complicated with Cardiogenic Shock; C.A. Bermudez, A. Abarca, D. Zaldonis, Y. Toyoda, J.K. Bhama, P. Bonde, J.J. Teuteberg, D. McNamara, R.J. Alvarez, R. Kormos. Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA; Cardiovascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA.

(649) Preoperative Treatment with Levosimendan in Candidates for Mechanical Circulatory Support; S. Sponga, E. Ivanitskaia, E. Potapov, T. Krabatsch, R. Hetzer, H. Lehmkuhl. Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Quebec, Canada; German Heart Institute, Berlin, Germany.


(654) Outcome of Patients with Post Cardiotomy Shock Requiring Ventricular Assist Device Support Remains Poor; S. Melnitchouk, Y. Naka, U. Jorde, N. Uriel, J. Yang, M. Kocckert, et al. Department of Cardiac Surgery, Columbia University Medical Center, New York; Department of Cardiology, Columbia University Medical Center, New York.

(655) A New Bowel Management Strategy Reduces Gastrointestinal Complications and Improves Patient Outcomes After Ventricular Assist Device Implantation; E.A. Fehrenbach Prell, M.A. Murray, A.K. Proebstle, Y. Kotani, M.R. Johnson, L. Lozonschi, N.M. Edwards, T. Kohimoto. Department of Surgery-Cardiothoracic Surgery, University of Wisconsin-Madison Hospital and Clinics, Madison, WI; Department of Heart and Vascular Care, University of Wisconsin-Madison Hospital and Clinics, Madison, WI; Department of Medicine, University of Wisconsin-Madison Hospital and Clinics, Madison, WI.

(656) Lung Transplant Curriculum in Pulmonary/Critical Care Fellowship Training; D. Hayes, Jr., E. Diaz-Guzman, C.W. Hoopes, J.B. Zwischenberger. Departments of Pediatrics, Internal Medicine, and Surgery, University of Kentucky Medical Center, Lexington, KY; Department of Internal Medicine, University of Kentucky Medical Center, Lexington, KY; Department of Surgery, University of Kentucky Medical Center, Lexington, KY.

(657) To Be Immunosuppressed, Transplanted and Black: High Risk for Heart Transplantation; B. Coleman, L. Piponniu, P. Cornwell, M. McLennan, B. Gulack, D. McNamara, J. Woodard, W.R. Wagner, J.F. Antaki, H.S. Borovetz. Artificial Heart Program, University of Pittsburgh Medical Center, Pittsburgh, PA; Department of Cardiology, Columbia University Medical Center, New York.


(660) Rehospitalization and Resource Utilization Among Continuous Flow VAD Patients; M.J. Ruston, S. Akter, K. N. Hong, R. Malaya, J. Raman, A. Anderson, V. Jeevan. Department of Surgery, Section of Cardiac and Thoracic Surgery, University of Chicago, Chicago, IL; Department of Health Evidence and Policy, Mount Sinai School of Medicine, New York, NY.

(661) Determinants of Paid Employment After Lung Transplant; J.D. Hopper, P. Cornell, P. Hopkins, M. McLennan. Queensland Centre for Pulmonary Transplantation & Vascular Disease, The Prince Charles Hospital – Queensland Health, Brisbane, QLD, Australia; Occupational Therapy Department, The Prince Charles Hospital – Queensland Health, Brisbane, QLD, Australia; Allied Health Research Collaborative Metro North, The Prince Charles Hospital – Queensland Health, Brisbane, QLD, Australia.
(662) Transplant Education Program Improves Patient Medication Knowledge and Adherence; S. Reed, 1 S. Paridon, 1 H. Hanson, 2 J. Ellbacher, 2 D. Piccinini, 2 J. Kreindler, 3 S. Goldfarb. 3 1Division of Cardiology, Children’s Hospital of Philadelphia, Philadelphia, PA; 2Department of Physical Therapy, Children’s Hospital of Philadelphia, Philadelphia, PA; 3Division of Pulmonary Medicine, Children’s Hospital of Philadelphia, Philadelphia, PA.

(663) Is Patient Adherence to Immunosuppression Monitoring Associated with Improved Outcomes After Heart Transplantation?; H. Lyster, 1 M. Niespialowska-Steuden, 1 R. Prensaín, 1 J. Smith, 1 I. Hamour, 1 A. Firozu, 1 N. Leaver, 1 N.R. Banner, 2 1Dept of Cardiothoracic Transplantation, Harefield Hospital, London, United Kingdom; 2Imperial College, London, United Kingdom.

(664) Everolimus in Pediatric Heart Transplantation: A Spanish Center Experience; M.C. Vázquezálvarez, 1 M. Camino-López, 1 C. Medrano-López, 1 C. Fernández-Llamazares, 2 E. Panadero-Caravilla, 1 L. Echarri-Martínez, 2 F. Ballesteros-Tejerizo, 1 J.L. Zunzuneuigu-Martínez, 1 G.A. Brochet-Bayona, 2 E. Maroto-Álvaro. 1 Pediatric Cardiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain; 2Pharmacy, Hospital General Universitario Gregorio Marañón, Madrid, Spain; 3Pediatric Cardiac Surgery, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

(665) Outcome of Renal Function One-Year After Discontinuation of Everolimus; K. Behnke-Hall, J. Bauer, J. Thul, T. Logeswaran, M. Horn, D. Schranz. Pediatric Cardiology, Pediatric Heart Center of the University of Giessen, Giessen, Germany.

(666) Valganciclovir Pharmacokinetics and Determination of Optimal Dosing After Solid Organ Transplantation in Infants and Young Children; D. Villeneuve, 1 Y. Law, 2 S. Gantt, 3 T. Nemeth. 1 Pharmacy, Seattle Children’s Hospital, Seattle, WA; 2Transplant, Seattle Children’s Hospital, Seattle, WA; 3Infectious Disease, Seattle Children’s Hospital, Seattle, WA.

(667) Superior Vena Cava Obstruction in Pediatric Heart Transplant Recipients; O. Aldoss, 1 N. Arain, 1 L. Kochilas, 1 R. Amendt, 1 J. Menk, 2 R. Bryant, 2 D. Gruenstein, 1 Pediatric Cardiology, University of Minnesota Amplatz Children’s Hospital, Minneapolis, MN; 2Cardiac Surgery, University of Minnesota Amplatz Children’s Hospital, Minneapolis, MN; 3Biostatistical Design and Analysis Center, University of Minnesota, Minneapolis, MN.


(669) Development of Non-Cameral Coronary Artery Fistulae After Pediatric Cardiac Transplantation: A Multi-Center Study of a Vasculo-Neoegenic Phenomenon; K.Y. Allen, 1 B.H. Goldstein, 2 E. Pahl, 1 K.R. Schumacher, 2 R.J. Gajarski, 2 D. Wang, 2 Y. Zhou, 2 D.F. Wax, 2 S. Kaushal, 4 J.G. Gossett. 1Pediatrics, Children’s Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, IL; 2Pediatric Cardiology, C.S. Mott Children’s Hospital, University of Michigan Health System, Ann Arbor, MI; 3Biostatistics Research Core, Children’s Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, IL; 4Surgery, Children’s Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, IL.

(670) Factors Associated with Short-Term Exercise Capacity Following Lung Transplantation; M. McBride, 1 S. Paridon, 1 H. Hanson, 2 J. Ellbacher, 2 D. Piccinini, 2 J. Kreindler, 3 S. Goldfarb. 3 1Division of Cardiology, Children’s Hospital of Philadelphia, Philadelphia, PA; 2Department of Physical Therapy, Children’s Hospital of Philadelphia, Philadelphia, PA; 3Division of Pulmonary Medicine, Children’s Hospital of Philadelphia, Philadelphia, PA.

(671) Pediatric Heart Re-Transplantation: A 25-Year Single Center Experience; G. Tyagi, 1 L. Honoris, 1 J.J. Brand, 2 T. Shankel, 2 A. Gopal, 2 L.N. Stoletnyk. 3Department of Internal Medicine, Loma Linda University School of Medicine, Loma Linda, CA; 2Division of Cardiology, Loma Linda University School of Medicine, Loma Linda, CA.

(672) Evaluation of Renal Function Following Pediatric Lung Transplantation; C.A. Branch, 1 K. Balakas, 3 M. Shea, 4 M. Bultas, 2 P. Ercole. 2 Transplant Services, St Louis Children’s Hospital, St Louis, MO; 3Clinical Nursing Partnerships, Goldfarb School of Nursing, St Louis, MO; 4Pediatric Renal, Washington University School of Medicine, St Louis, MO.

(673) Impedance Cardiography Is Inaccurate in the Assessment of Cardiac Output in Pulmonary Arterial Hypertension in Comparison to Left Ventricular Heart Failure; P. Lesny, B. Liska, M. Luknar, E. Goncalvesova. Heart Failure and Transplantation, National Institute of Cardiovascular Diseases, Bratislava, Slovakia (Slovak Republic).


(675) Severity of Pulmonary Hypertension Predicts Short-Term Lung Transplantation Outcomes in Subjects with Chronic Obstructive Pulmonary Disease; J.P. Wrobel, 1,4 B. Thompson, 1,2 G.I. Snell, 1,2 T.J. Williams, 1,2 1Department of Medicine, Monash University, Melbourne, Australia; 2Allergy, Immunology & Respiratory Medicine, The Alfred, Melbourne, Australia.

(676) In Pre-Transplant (OHT) Pulmonary Hypertension (PH), Does Vascular Resistance (PVR) Tell the Story?; B.D. Hanna, 1 D.B. Frank, 1 H.L. Meluskey, 1 Z. Bshouty. 1Cardiology, Children’s Hospital of Philadelphia, Philadelphia, PA; 2Respiratory Investigation Unit, University of Manitoba, Winnipeg, MB, Canada.

(677) Estimation of Mean Pulmonary Artery Pressure in the Sickle Cell Population; I. Sharif, I. Sharif, I. Sharif, I. Sharif. Medicine, Newark Beth Israel Medical Center, Newark, NJ.

(678) Dose-Dependent Improvement in Survival with ACE Inhibitor Use in Patients with Pulmonary Arterial Hypertension and Heart Failure with Normal Ejection Fraction; S. Shore, 1 V. Aggarwal, 1 R. Zolty. 1Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY; 2Division of Cardiology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.
Patients with Idiopathic Pulmonary Arterial Hypertension Diagnosed Beyond the Age of 50th Year have Usually Less Survival Benefit from Transplantation than from Medical Treatment; M. Dandel, H.B. Lehmkühl, C. Knosalla, D. Kemper, R. Hetzer. Deutsches Herzzentrum Berlin, Berlin, Germany.

Long-Term Results with Bosentan Treatment in Pulmonary Hypertension; J. Segovia Cubero, P.M. Avellana Calvo, E. Sufrate Sorzano, M. Gomez Bueno, P. Garcia-Pavia, M.D. Gª Cosio Carmena, C. Gutierrez Landaluce, L.A. Alonso Pulpón. Cardiology, Hospital Universitario Puerta de Hierro, Madrid, Spain.

Cannula Neo-intima Growth and Thrombi: Impact on Cardiac Transplant Following Myocardial Infarction Is Heart Transplantation Contraindicated for a Young Cardiotropic Viruses Trigger Antibody Mediated Rejection in Heart Transplantation Recipients; J. Um, I. Dumitrut, T.R. Ryan, I. Darling, L. Jelinek, S. Michael, D. Zaldonos, T. Yoshiya, M. Morrell, K. Duncan, E. Raichlin. Cardiology, University of Nebraska Medical Center, Omaha, NE; Cardiothoracic Surgery, University of Nebraska Medical Center, Omaha, NE; Oncology and Hematology, University of Nebraska Medical Center, Omaha, NE; Surgery, University of Nebraska Medical Center, Omaha, NE.

Cardiac Transplant Following Myocardial Infarction in a Case of Takayasu’s Arteritis; A. McBrien, M. Griselli, M. Friswell, A. Hasan, R. Kirk. Department of Paediatric Cardiology, Freeman Hospital, Newcastle upon Tyne, United Kingdom; Department of Paediatric Rheumatology, Great North Childrens Hospital, Newcastle upon Tyne, United Kingdom.

Use of Percutaneous RVAD Support as a Bridge to Recovery in Type A Aortic Dissection Repair Patients with Evolving Right Coronary Artery Ischemia; S. Xydias, J.P. Slater, C.J. Magovern, J.M. Brown, G. Parr, F. Smart. Cardiovascular Medicine, Morristown Memorial Hospital, Morristown, NJ.

Recurrent Posterior Reversible Encephalopathy Syndrome (PRES) in a Heart Transplant Recipient: An Immunosuppression Dilemma; D.B. Sims, S.T. Martin, M.D. Suleski, U.P. Jorde, M.C. Deng, D.M. Mancini. Department of Medicine, Division of Cardiology, Columbia University Medical Center, New York, NY.

Is Heart Transplantation Contraindicated for a Young Patient in Acute Renal Failure, with Empyema, LVAD and Tracheostomy?; A.L. Haskins, A.J. Razzouk, L. Stoletniy. Cardiovascular & Thoracic Surgery, Loma Linda University Medical Center, Loma Linda, CA; Cardiology, Loma Linda University Medical Center, Loma Linda, CA.

Stress Induced Cardiomyopathy in a Transplanted Heart; Y. Selektor, L. Klein, W. Cotts. Medicine/Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL.

Rapidly Progressive Generalized Myopathy Following Ventricular Assist Device Placement; S.D. Clegg, Q. Gong, A.Y. Kim, H. Song, Z. Zhou. Cardiology, Oregon Health and Science University, Portland, OR.
(694) Spontaneous Endogenous Microbubbles in a Child with Ventricular Assist Device; S.S. Dhillon, N.S. Khoo, L. Quinonez, H. Buchholz. Pediatric Cardiology, Stollery Children’s Hospital, Edmonton, AB, Canada.

(695) The Rise of Rhizopus: A Rare Case of Mucormycosis Myocarditis Post Heart Transplant; R.R. Mulamalla, J. Gluck, M. Rai, J. Radojevic, D. Wencker. Heart Failure and Transplant, Hartford Hospital-University of Connecticut, Hartford, CT.


(698) Asymptomatic Pulmonary Allograft Kaposis’s Sarcoma: Case Report; B. Di Chiara, F. Lunardi, G. Marulli, M. Loy, M. Schiavon, C. Breda, S. Aversa, B. Calabrese, F. Rea. Cardio-Thoracic and Vascular Sciences, University of Padua, Padua, Italy; Medical Diagnostic Sciences and Special Therapies, Pathology CLOPD, Padua, Italy; Second Medical Oncology, Veneto Oncologic Institute, Padua, Italy.

(699) Ambulatory Venovenous Extracorporeal Membrane Oxygenation as a Bridge to Lung Transplantation; J. Lin, R.M. Reddy, K.M. Chan, J.M. Blum, J.W. Haft, A.C. Chang. Section of Thoracic Surgery, University of Michigan, Ann Arbor, MI; Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI; Department of Anesthesia, University of Michigan, Ann Arbor, MI; Section of Cardiac Surgery, University of Michigan, Ann Arbor, MI.

(700) Third Lung Transplantation After Treatment for Circulating Collagen Type V Antibodies; J.B. Price, L. Quittell, C.C. Marboe, D.S. Wilkes, D. Lederer, S.M. Arcasoy. Department of Pediatrics, Columbia University College of Physicians and Surgeons, New York, NY; Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY; Department of Pathology and Cell Biology, Columbia University College of Physicians and Surgeons, New York, NY; Department of Medicine, Center for Immunobiology, Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN.

(701) Persistent Hypoxemia After Left Lung-Transplant; J.A. Melendez, A. Mattewal, R. Kesavan, H. Seethamraju. Pulmonary and Critical Care-Lung Transplant, Baylor College of Medicine, Houston, TX.


(703) Mechanical Circulatory Support for the Pediatric Patient with an Unstable Social Situation: Unique Considerations; S.A. Hollander, O. Reinhartz, C. Chin, J. Yeh, K. Maeda, D. Bernstein, D.N. Rosenthal. Pediatric Cardiology, Stanford University, Stanford, CA; Pediatric Cardiology, Stanford University, Stanford, CA.

(704) Transitioning from Subcutaneous Treprostinil to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension; E.O. Chukwu, S. Shadrick, J. Coons, G. Sokos, R. Benza, S. Murali. Cardiology, Allegheny General Hospital, Pittsburgh, PA.

(705) Successful Lung Transplant in a Child with CF and Persistent Blastobotrys Lung Infection; A. Kapasi, C. Schellenberg, J. Fuller, A. Lacson, J. Mullen, D. Lien, A. Humar, J. Wong. Division of Pediatric Respiratory Medicine, Department of Pediatrics, University of Alberta, Edmonton, AB, Canada; Division of Pulmonary Medicine, Department of Medicine, University of Alberta, Edmonton, AB, Canada; Division of Infectious Disease, Faculty of Medicine, University of Alberta, Edmonton, AB, Canada; Division of Medical Microbiology, Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada; Division of Anatomical Pathology, Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada; Division of Cardiac Surgery, Department of Surgery, University of Alberta, Edmonton, AB, Canada.

(706) Chagas Reactivation in a Heart Transplant Recipient; M. Kittleson, J. Patel, B. Kubak, J. Kobashigawa. Cardiology, Cedars-Sinai Heart Institute, Los Angeles, CA; Internal Medicine/Infectious Disease, UCLA, Los Angeles, CA.
Hilton San Diego Bayfront
# Exhibiting Companies

<table>
<thead>
<tr>
<th>ALPHABETICAL LIST OF EXHIBITORS</th>
<th>BOOTH NUMBERS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abiomed, Inc.</td>
<td>410</td>
</tr>
<tr>
<td>Alere Home Monitoring</td>
<td>415</td>
</tr>
<tr>
<td>Argon Medical Devices</td>
<td>409</td>
</tr>
<tr>
<td>Astellas</td>
<td>103</td>
</tr>
<tr>
<td>Avalon Laboratories</td>
<td>418</td>
</tr>
<tr>
<td>Berlin Heart</td>
<td>100</td>
</tr>
<tr>
<td>Cardiac Assist, Inc.</td>
<td>404</td>
</tr>
<tr>
<td>CircuLite, Inc.</td>
<td>414</td>
</tr>
<tr>
<td>CSL Behring, L.L.C</td>
<td>315</td>
</tr>
<tr>
<td>Cylex, Inc.</td>
<td>201</td>
</tr>
<tr>
<td>Elsevier</td>
<td>403</td>
</tr>
<tr>
<td>Essential Pharmaceuticals</td>
<td>422</td>
</tr>
<tr>
<td>Evaheart Medical</td>
<td>417</td>
</tr>
<tr>
<td>Genentech <em>a Member of the Roche Group</em></td>
<td>105</td>
</tr>
<tr>
<td>Gilead Sciences, Inc.</td>
<td>303</td>
</tr>
<tr>
<td>HeartWare, Inc.</td>
<td>319</td>
</tr>
<tr>
<td>HKS Medical Information System</td>
<td>411</td>
</tr>
<tr>
<td>ISHLT Registry</td>
<td>421</td>
</tr>
<tr>
<td>Jarvik Heart, Inc.</td>
<td>412</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ALPHABETICAL LIST OF EXHIBITORS</th>
<th>BOOTH NUMBERS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levitronix</td>
<td>301</td>
</tr>
<tr>
<td>Lippincott Williams &amp; Wilkins</td>
<td>420</td>
</tr>
<tr>
<td>Methodist Transplant Center</td>
<td>401</td>
</tr>
<tr>
<td>Miller Pharmacal Group</td>
<td>416</td>
</tr>
<tr>
<td>Novartis Pharma AG</td>
<td>309</td>
</tr>
<tr>
<td>One Lambda, Inc.</td>
<td>107</td>
</tr>
<tr>
<td>Scanlan International, Inc.</td>
<td>313</td>
</tr>
<tr>
<td>Scholten Surgical Instruments, Inc.</td>
<td>405</td>
</tr>
<tr>
<td>SynCardia Systems, Inc.</td>
<td>408</td>
</tr>
<tr>
<td>Terumo Heart, Inc.</td>
<td>419</td>
</tr>
<tr>
<td>The Apothecary Shops</td>
<td>406</td>
</tr>
<tr>
<td>Thoratec Corp</td>
<td>101</td>
</tr>
<tr>
<td>TransMedics</td>
<td>207</td>
</tr>
<tr>
<td>United Network for Organ Sharing</td>
<td>407</td>
</tr>
<tr>
<td>United Therapeutics</td>
<td>203</td>
</tr>
<tr>
<td>Vital Engineering</td>
<td>402</td>
</tr>
<tr>
<td>Vivoline Medical AB</td>
<td>424</td>
</tr>
<tr>
<td>XDx</td>
<td>205</td>
</tr>
<tr>
<td>XVIVO Perfusion AB</td>
<td>413</td>
</tr>
</tbody>
</table>
Astellas Pharma US, Inc.
Three Parkway North
Deerfield, IL 60015
Web address: www.astellas.us

BOOTH NUMBER: 103

Astellas Pharma US, Inc., a U.S. affiliate of Tokyo-based Astellas Pharma Inc., is a pharmaceutical company dedicated to changing tomorrow by improving the health of people around the world through innovative and reliable pharmaceutical products. In the US, Astellas has an intense focus on six key therapeutic areas — Cardiology, Dermatology, Infectious Disease, Neuroscience, Transplant, and Urology. At all levels throughout the company our people are committed to the opportunity to positively affect and improve patient lives while remaining socially responsible to our community and those with whom we work and collaborate. For more information about Astellas Pharma US, Inc., please visit our Web site at www.astellas.us

Alere Home Monitoring (Formerly QAS)
30 S. Keller Road
Suite 100B
Orlando, FL 32810
Web address: www.alere.com

BOOTH NUMBER: 415

Alere Home Monitoring (formerly QAS) is a leading national service provider to outpatients supported by ventricular assist devices (VAD). Alere provides equipment, driveline supplies and devices for the patient self-testing of INR. Our pioneering development of VADWatch, the first wireless telehealth monitoring service designed exclusively for VAD patients, is completing its pilot program soon. VADWatch monitors daily measurements of medical and VAD-related metrics remotely and transmits this data for analysis on a 24/7 secure website. Monitoring is enhanced by Alere nurses who complete telehealth assessments. Immediate alerts are sent to hospital staff for any out of range results.

Argon Medical Devices
1445 Flat Creek Road
Athens, TX 75751
Web address: www.argonmedical.com

BOOTH NUMBER: 409

Argon Medical is a global manufacturer of specialty medical products headquartered in Athens, Texas. They offer a broad line of internationally accepted, single-use medical devices for Interventional Radiology, Interventional Cardiology, and Critical Care. Their products include JAWZ™ Endomyocardial Biopsy Forceps, OneStic™ Vascular Introducer Sheaths, MicroStic™ Micro-Access Kits, pressure transducers, thermo-dilution and pulmonary artery catheters, guidewires, in addition to other vascular products. The company’s products are sold through a combination of direct sales representatives and premier distributors in the United States and a network of leading distributors internationally.

Berlin Heart Inc.
200 Valleywood Rd., Suite A500
The Woodlands, TX 77380
Web address: www.berlinheart.com

BOOTH NUMBER: 100

Berlin Heart, the only company worldwide that manufactures and distributes implantable (INCOR®) and paracorporeal (EXCOR®) VAD’s for patients of every age and size with cardiovascular disease. EXCOR® Pediatric is approved for clinical investigation in the US.
Cardiac Assist, Inc.
240 Alpha Dr.
Pittsburgh, PA 15238
Web address: www.cardiacassist.com

BOOTH NUMBER: 404
CardiacAssist’s TandemHeart® System delivers extracorporeal circulatory support in minutes. The system can provide up to 5.0 L/min of circulatory support when deployed percutaneously and up to 8.0 L/min of support with direct surgical cannulation.

CircuLite, Inc.
Park 80 West, Ste 403
250 Pehle Ave
Saddle Brook, NJ 07663
Web address: www.circulite.net

BOOTH NUMBER: 414
CircuLite is a cardiovascular device company that is transforming heart failure treatment with the development of minimally-invasive devices for long term partial circulatory support (PCS). By enabling a proactive and lower-risk treatment approach by supplementing a patient’s native pumping capacity. CircuLite has the potential to improve the quality of life for millions of chronic heart failure patients and their families. CircuLite’s pipeline of PCS devices is lead by the Synergy® Pocket Micro-Pump, the world’s smallest implantable blood pump, currently in a CE Mark clinical trial. Next-generation Synergy micro-pumps include and endovascular system, a fully-implantable system and a pediatric system.

CSL Behring, L. L.C.
1020 First Ave.
King of Prussia, PA 19406
Web address: www.cslbehring.com

BOOTH NUMBER: 315
CSL Behring is a global leader in the plasma protein biotherapeutics industry. CSL Behring manufactures and markets a range of safe and effective plasma-derived and recombinant products and related services.

The company’s products are used for organ transplantation, inherited emphysema, in the prevention of hemolytic diseases in the newborn, in cardiac surgery, and in the treatment of burns and shock. Additional therapies are used in the treatment of hemophilia, von Willebrand disease, other bleeding disorders, and immune deficiency disorders.

CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company with headquarters in Melbourne, Australia.

For more information, visit www.cslbehring-us.com

Cylex Inc.
8980-I Old Annapolis Road
Columbia, MD 21045
Web address: www.cylex.net

BOOTH NUMBER: 201
Cylex™ is the global life sciences company leading the development and manufacture of in vitro diagnostic assays measuring cellular immune function. Its unique technology detects cell-mediated immunity, presenting an exciting opportunity for developing additional assays for diseases, and companion diagnostics for treatments, affecting the immune system. ImmuKnow®, its first commercial product, is the FDA-cleared, noninvasive biomarker of immune function utilized by clinicians to more effectively manage and optimize immunosuppression in organ transplant patients. Cylex is a Technology Fast 500™ award winner for 2009, Deolitte LLP’s ranking of 500 fast-growing technology companies in North America.

For more information, visit www.cylex.net.

Elsevier
1600 John F. Kennedy Blvd.
Suite 1800
Philadelphia, PA 19103
Web address: www.elsevierhealth.com

BOOTH NUMBER: 403
ELSEVIER presents the The Journal of Heart and Lung Transplantation, the official journal of the International Society for Heart and Lung Transplantation. Please stop by our booth to view the latest issue of the journal, and browse our other books and journals in the field of cardiology and transplantation.

Essential Pharmaceuticals
770 Newtown Yardley Road
Suite 212
Newtown, PA 18940
Web address: www.essentialpharma.com/www.custodiol.com

BOOTH NUMBER: 422
Essential Pharmaceuticals, LLC is a specialty pharmaceutical company devoted solely to the development and sales of branded pharmaceutical products in the transplant and cardiothoracic surgery fields including Custodiol® HTK organ preservation solution. Originally developed for cardiac surgery, Custodiol® HTK offers superior convenience due to its easy handling characteristics, water like viscosity and no need for additives or filters which makes it a preferred solution for many transplant centers.
HeartWare, Inc
205 Newbury Street
Framingham, MA 01701
Web address: www.heartware.com

BOOTH NUMBER: 319
HeartWare, Inc. is developing a family of implantable mechanical circulatory support systems for the treatment of advanced heart failure. HeartWare’s lead device, the HeartWare® Ventricular Assist System, incorporates state-of-the-art peripherals and features the only full-output pump designed to be implanted less invasively in the pericardial space. The HeartWare® System is commercially available in Europe and is the subject of a 150-patient US IDE trial.

HKS Medical Information Systems
2323 South 171st Street
Omaha, Nebraska 68130
Web address: www.hksys.com

BOOTH NUMBER: 411
HKS is a software developing company that has been involved with developing, installing and supporting software for Solid Organ Transplant and Bone Marrow Transplant for over 17 years. We are the largest supplier of medical software with over 68 hospitals. Within that number we have 42 hospitals with our heart and lung software. HKS has recently developed a VAD module that supports clinical care device and inventory and produces a report for INTERMACS.

ISHLT Registry
C/O UNOS
700 North 4th Street
Richmond, VA 23219
Web address: www.ishlt.org

BOOTH NUMBER: 421
Database Registry for ISHLT.

Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 944004
Web address: www.gilead.com

BOOTH NUMBER: 303
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet need, including serious cardiovascular disorders. With each new discovery we seek to improve the care of patients suffering from life-threatening diseases.
Levartonix
45 1st Avenue
Waltham, MA 02451
Web address: www.levitronix.com

BOOTH NUMBER: 301
Levartonix designed, developed, and produces the CentriMag, Ped-iMag and PediVAS circulatory support devices. In the United States, the CentriMag pump is approved for up to 30 days of use for patients requiring right ventricular support, and is undergoing clinical trials to treat patients in cardiogenic shock as a bridge to decision. The PediVAS is optimized to provide circulatory support for neonatal and pediatric patients, and is currently only available outside the United States. The PediMag pump is available in the United States for use in a cardiopulmonary circuit for up to 6 hours. CentriMag and PediVAS systems are both CE Mark approved for use for up to 30 days for use as a VAD or for ECMO.

Lippincott, Williams & Wilkins
4750 Matty Court
Le Mesa, CA 91941
Web address: www.lww.com

BOOTH NUMBER: 420
Methodist Transplant Center
6550 Fannin
Smith Tower 1201
Houston, TX 77030
Web address: www.facebook.com/MethodistHospital

BOOTH NUMBER: 401
Methodist. Leading Medicine. Recognized by U.S. News & World Report as one of America’s “Best Hospitals” in 13 specialties. Named to FORTUNE magazine’s “100 Best Companies to Work For” list five years in a row Designated as a Magnet hospital for excellence in nursing.

Visit us at methodisthealth.com
Follow us at twitter.com/MethodistHosp and www.facebook.com/MethodistHospital

Miller Pharmacal Group, Inc
350 Randy Road, Ste #2
Carol Stream, IL 60188
Web address: www.millerpharmacal.com

BOOTH NUMBER: 416
Miller Pharmacal’s magnesium supplement “MG Plus Protein” is used at many transplant centers for the treatment and prevention of the hypomagnesaemia caused by calcineurin inhibitors or diuretics, without the GI disturbances common with magnesium oxide. “MG Plus Protein” is: Effective, well-tolerated, inexpensive and easy for patients to swallow.

Novartis Pharma AG
Postfach
Basel, CH-4002 Switzerland
Web address: www.novartis.com

BOOTH NUMBER: 309
Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the only company with leading positions in these areas. In 2009, the Group’s continuing operations achieved net sales of USD 44.3 billion, while approximately USD 7.5 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 100,000 full-time-equivalent associates and operate in more than 140 countries around the world.

One Lambda, Inc.
21001 Kittridge St
Canoga Park, CA 91303
Web address: www.onelambda.com

BOOTH NUMBER: 107
One Lambda, Inc. is present at ISHLT to share advancements in transplant diagnostics. One Lambda’s legacy is built on the power of its antibody detection product lines, such as our LABScreen® Single Antigen assay. Our experts will also discuss One Lambda’s new research tool for donor specific antibody detection – C1qScreen™ – which distinguishes complement binding from non-complement binding antibodies. Gain new insights, review compelling data, and learn about diagnostic innovations at the One Lambda booth, Number 107.
Scanlan International, Inc.
One Scanlan Plaza
Saint Paul, MN 55107
Web address: www.scanlaninternational.com

BOOTH NUMBER: 313

Highest quality surgical products designed and manufactured by the Scanlan family since 1921. Over 3,000 titanium and stainless steel instrument designs including needle holders, forceps, scissors, clamps and specialty instruments. Featured instruments include the SCANLAN® LEGACY titanium needle holders and forceps, full line of VATS/MICS Thoracoscopic instruments including the Chitwood Clamp, Knot Pusher, and SUPER CUTC™ Suture Cutter, D’Amico and Wolf Suction instruments, D’Amico and Harkin Clamps; SUPER CUT™ Scissors and Rendina needle holder. Single-use products include: VASCU-STATT® bulldog clamps, Aorta/Vein Punch and A/C Locator® graft markers. Also offering custom instrument designs and modifications for your individual needs.

Scholten Surgical Instruments, Inc.
170 Commerce Street Suite 101
Lodi, CA 95240
Web address: www.bioptome.com

BOOTH NUMBER: 405

Scholten Surgical Instruments, Inc. has manufactured quality Endomyocardial Biopsy forceps for over thirty years. Our founder manufactured the original Stanford Bioptome which has been considered the “gold standard” by esteemed doctors throughout heart transplant history. Our forceps are known for having superior cutting force, ease of positioning, acquiring high quality samples, and locking finger ring actuation handle. Our single-use biopsy forceps are available in four french sizes, in lengths for carotid and femoral approaches. With three decades of successful clinical experience, we are confident that the quality and uncompromising reliability of Scholten products will continue to set standards worldwide.

SynCardia Systems, Inc.
1992 E. Silverlake Road
Tucson, AZ 85713
Web address: www.syncardia.com

BOOTH NUMBER: 408

The SynCardia temporary Total Artificial Heart (TAH-t) is the world’s only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the TAH-t is currently approved as a bridge to transplant for patients dying from end-stage biventricular failure. The 13.5 lb Freedom® portable driver has received CE approval in Europe and is undergoing an IDE clinical study in the U.S. The Freedom driver is designed to provide mobility for stable TAH-t patients both inside and outside the hospital. Visit our booth for updates on the clinical study and more.

Terumo Heart, Inc.
6190 Jackson Road
Ann Arbor, MI 48103
Web address: www.terumoheart.com

BOOTH NUMBER: 419

Terumo Heart, Inc. is dedicated to the innovation, introduction and advancement of products to improve the quality of healthcare for heart failure patients. Terumo Heart’s principal focus is the development, clinical evaluation and commercialization of the DuraHeart™ Left Ventricular Assist System (LVAS). Combining patented magnetic-levitation and centrifugal pump technologies, the DuraHeart LVAS is expected to decrease complications and improve the lives of patients with severe heart failure. The DuraHeart LVAS is limited to investigational use only in the United States and is CE marked in Europe. Terumo Heart, Inc. is a wholly owned subsidiary of Terumo Corporation (Japan) with headquarters and manufacturing facilities in Ann Arbor, Michigan.

The Apothecary Shops
23620 N. 20th Dr., Suite 12
Phoenix, AZ 85085
Web address: www.theapothecaryshop.com

BOOTH NUMBER: 406

Years of experience in the field of transplant pharmacy, coupled with a caring and compassionate staff make The Apothecary Shops your best referral source. All transplant medications including compounded medications, hard-to-find ones and limited distribution are stocked. We accept insurance, complete prior authorizations and offer free shipping. Patient co-pay assistance programs in place, access to transplant pharmacists 24 hours a day. Compounding for pediatric patients and those unable to swallow tablets/capsules. Monthly refill reminder and patient wellness check.

Ask about our New Patient Transplant Kit!

Thoratec Corporation
6035 Stoneridge Dr.
Pleasanton, CA 94588
Web address: www.thoratec.com

BOOTH NUMBER: 101

Thoratec Corporation is a world leader in therapies to address advanced-stage heart failure. The company’s products include the HeartMate® LVASs and Thoratec® VADs (Ventricular Assist Devices) with more than 15,000 devices implanted in patients suffering from heart failure.

For more information, visit the company’s web site at http://www.thoratec.com.
TransMedics
200 Minuteman Road, Suite 302
Andover, MA 01810
Web address: www.transmedics.com

BOOTH NUMBER: 207
TransMedics is dedicated to enabling increased utilization of donor organs for transplantation while enhancing patient outcomes and improving cost-effectiveness of transplant programs. The TransMedics® Organ Care System is a portable, advanced ex-vivo perfusion, monitoring and organ recruitment platform for heart and lung transplantation that is intended to maintain donor organs in a functioning state from donor to recipient.

The OCS™ HEART and LUNG systems are CE-marked and in clinical use in leading European transplant centers, and in a pivotal FDA clinical trial in leading US heart transplant centers comparing the OCS™ to cold storage.

United Network for Organ Sharing
700 N. 4th Street
Richmond, VA 23219
Web address: www.unos.org

BOOTH NUMBER: 407
UNOS is a 501 (c) 3 not-for-profit, scientific, educational and charitable Richmond-based Virginia membership corporation that manages the national Organ Procurement and Transplantation Network (OPTN). Its mission is to advance organ availability and transplantation by uniting and supporting its communities for the benefit of patients through education, technology and policy development. Tii Informatix Group (Tii), a subsidiary of UNOS, specializes in the design, development, operation and support of clinical registries specializing in transplantation, medical devices and immunosuppressive therapies (www.tii-informatix.com).

United Therapeutics
55 TW Alexander Dr.
Research Triangle Park, NC 27709
Web address: www.unither.com

BOOTH NUMBER: 203
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer.

Vital Engineering
330 Scaife Hall
200 Lothrop St.
Pittsburgh, PA 15213-2582
Web address: www.vitalengineering.com

BOOTH NUMBER: 402
Vital Engineering provides training and educational programs for physicians and other health care providers as well as on-site training and technical support prior to, during and following device implantation. Vital Engineering has the knowledge and resources to improve patient care from surgery through discharge planning and outpatient care. Our clinical experience equips the artificial organ industry with the ultimate product quality improvement from emerging to experienced companies. Vital Engineering offers many partnership benefits to patients, clinicians, hospitals and industry.

Vivoline Medical AB
Scheelevagen 17
SE-223 Lund, Sweden
Web address: www.vivoline.es

BOOTH NUMBER: 424
VivoLine® LS1…a new opportunity!

VivoLine® LS1 provides a simplified method that can perform an ex-vivo evaluation in a safe and controlled way, based on previous research for treating lungs ex-vivo. It is a compact system which can be set up quickly and easily; organs can be stored until next day for daytime surgery.

VivoLine® LS1 is intended for the reconditioning, evaluation and cold preservation of lungs ex-vivo, after lung donation and prior to transplantation.

The possibility to test marginal lungs provides the opportunity to increase the number of organs available for transplantation. Only for research purposes in the U.S.

XDx
3260 Bayshore Blvd.
Brisbane, CA 94005
Web address: www.allomap.com

BOOTH NUMBER: 205
XDx is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression testing in the areas of transplant medicine and autoimmunity. The company has developed a proprietary method of utilizing gene expression in blood that provides a new tool for physicians to aid in the management of heart transplant patients.
XVIVO Perfusion AB
(Part of the Vitrolife group)
Box 9080
SE – 400 92, Göteborg Sweden
Web address: www.xvivoperfusion.com

BOOTH NUMBER: 413
XVIVO Perfusion AB (Part of the Vitrolife Group) manufactures and markets solutions and equipment for transplantation and thoracic surgery, designed to preserve organs and tissues prior to transplantation. Our main two solutions are Perfadex® for hypothermic flushing and transportation of transplant lungs and STEEN Solution™ for normothermic ex-vivo evaluation (approved in US for research purposes only).

XVIVO aims to:
• minimize ischemic reperfusion injuries by improving the solutions used for extra corporeal preservation of organs and tissues.
• extend the safe extra corporeal preservation time for organs and tissues prior to transplantation.
• increase the organ availability and transplantation success rates by introduction of new transplantation concepts and techniques.
Join us for a FREE CME dinner event!

Thursday, April 14, 2011
7:00 PM – 9:00 PM
Hilton San Diego Bayfront (Aqua 306)

Featuring an engaging discussion among experts in the field:

- Lucie Clapp, PhD
  Professor of Vascular Physiology
  Deputy Post Graduate Tutor
  Department of Medicine
  University College, London, UK

- James R. Klinger, MD
  Associate Professor of Medicine
  Division of Pulmonary, Sleep and Critical Care Medicine
  Rhode Island Hospital
  Alpert Medical School of Brown University, Providence, RI

- Myung H. Park, MD
  Associate Professor of Medicine
  Director, Pulmonary Vascular Disease Program
  Division of Cardiology
  University of Maryland School of Medicine, Baltimore, MD

- Brendan J. R. Whittle, BPharm, PhD, DSc
  Professor of Applied Pharmacology
  William Harvey Research Institute
  Barts and the London School of Medicine
  Queen Mary, University of London, London, UK

LEARNING OBJECTIVES
Upon completion of this educational activity, the participant should be able to:

1. Identify some of the major challenges associated with guideline-driven care for patients with PAH.
2. Describe the evolution and role of prostanoids in the treatment of PAH.
3. Discuss the evolving science behind the role of prostanoids on antiproliferative effects, endothelial dysfunction and vascular remodeling.
4. Evaluate the evidence for combination drug therapy in patients with PAH.

CONTINUING MEDICAL EDUCATION
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Inc. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc. designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit is awarded to participants who attend the presentation and provide the requested roster information. There is no fee to participate and receive credit.

This activity is supported by an educational grant from United Therapeutics Corporation.
IN THE MANAGEMENT OF HEART TRANSPLANT RECIPIENTS

Reserve biopsy for those with signs of rejection.

Spare the rest.

APRIL 18-21 2012
32nd ISHLT Annual Meeting and Scientific Sessions
Convention Center
Prague, Czech Republic

APRIL 24-27 2013
33rd ISHLT Annual Meeting and Scientific Sessions
Palais des Congrès de Montréal, Canada

Future ISHLT Annual Meetings

INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION

14673 Midway Road
Suite 200
Addison, TX 75001
Phone: 972-490-9495
Fax: 972-490-9499
www.ishlt.org

Come see us at booth #205.

©2011 XDx, Inc. LK-10163 R1.0
It's a whole NEW Transplant Experience!
Help patients stay connected, inspired, and informed at every stage of their transplant journey

Join this FREE program and see what your patients will receive:

- Welcome kit: treatment journal, informational video (DVD), and medication organizer
- Regular updates: Inspire, the new Transplant Experience quarterly newsletter, monthly email newsletters, plus tools and advice for healthy living
- Visit the news www.TransplantExperience.com today, where you'll discover more program features—all designed to supplement your education programs and help your patients continue to play an active role in their long-term health.
  - NEW! Recipes for Success
  - NEW! Transplant Stories
  - NEW! Exclusive content for registered users
  - NEW! Fresh articles and frequent updates

To join, visit www.TransplantExperience.com or call toll-free: 1-800-466-9191